

# Regulation of System XC- and its Contribution to Cell Death

XiaoQian Liu  
*Marquette University*

---

## Recommended Citation

Liu, XiaoQian, "Regulation of System XC- and its Contribution to Cell Death" (2012). *Dissertations (2009 -)*. Paper 234.  
[http://epublications.marquette.edu/dissertations\\_mu/234](http://epublications.marquette.edu/dissertations_mu/234)

REGULATION OF SYSTEM XC- AND ITS CONTRIBUTION TO CELL DEATH

by

XiaoQian Liu, B.S.

A Dissertation submitted to the Faculty of the Graduate School,  
Marquette University,  
in Partial Fulfillment of the Requirements for  
the Degree of Doctor of Philosophy

Milwaukee, Wisconsin

December 2012

ABSTRACT  
REGULATION OF SYSTEM X<sub>C</sub>- AND ITS CONTRIBUTION TO CELL DEATH

XiaoQian Liu, B.S.

Marquette University, 2012

The main focus of the studies in this thesis involves examining the role of cystine/glutamate exchange (system X<sub>C</sub>-) in neuronal death in primary cortical cell culture, with an emphasis on how glial function affects neuronal cell death. System X<sub>C</sub>- is a sodium-independent transporter that mediates cystine uptake and glutamate release. It accounts for most of the cystine uptake in astrocytes in mature cultures, providing the rate limiting substrate for synthesis of the main endogenous antioxidant glutathione. The glutamate released by system X<sub>C</sub>- may lead to excessive extracellular glutamate and cause excitotoxicity.

β-N-methylamino-L-alanine (BMAA) is a non-protein amino acid that may be involved in neurodegenerative diseases. We found that BMAA induced oxidative stress by competing with cystine at system X<sub>C</sub>- leading to depletion of glutathione. BMAA also drives system X<sub>C</sub>- mediated glutamate release, which may contribute to its induction of excitotoxicity.

Fibroblast growth factor-2 (FGF-2) is involved in multiple processes in the central nervous system, including plasticity, neurogenesis, differentiation, and neuronal survival. Also, alterations in FGF-2 and its signaling have been implicated in neurodegenerative diseases and psychiatric disorders. We found that FGF-2 greatly increased cystine uptake through system X<sub>C</sub>- in astrocyte-enriched primary cultures, but not in neuronal or microglial cultures. Our data showed that FGF-2 increased cystine uptake by upregulating system X<sub>C</sub>- by acting on FGFR1, and signaling through the PI3K/Akt and MEK/ERK pathways.

FGF-2 treatment for 48 hours caused significant neuronal death only in mixed neuronal and glial cultures, but not in neuronal-enriched or astrocyte-enriched cultures. Blocking system X<sub>C</sub>-, or AMPA/kainate receptors, eliminated the neuronal death induced by FGF-2 treatment. Therefore, it is likely that 48 hour FGF-2 treatment induces AMPA receptor mediated toxicity through increased glutamate release from astrocytes due to increased system X<sub>C</sub>- function. However, we cannot exclude the possibility that FGF-2 treatment sensitizes the neurons to normal system X<sub>C</sub>- mediated glutamate release.

Together the results indicate that 1) competitive substrates of system X<sub>C</sub>-, such as BMAA, that do not lead to glutathione production are particularly toxic; and 2) upregulation of system X<sub>C</sub>- on astrocytes may be toxic to surrounding neurons.

## ACKNOWLEDGMENTS

XiaoQian Liu, B.S.

I would like to offer my sincere appreciation to those who helped me reach this important milestone. I would especially like to thank my family for their constant support, encouragement, and understanding. I want to thank my mentor Doug Lobner. I am extremely grateful for your generous support and patient guidance. Special thanks to my friends and fellow graduate students Jon Resch, Travis Rush, and Rebecca Albano, and our “pig-lady” Julie Hjelmhaug. Thank you all for the help throughout the years in and out of the lab. I would also like to thank all my committee members and the entire Marquette University Biological Sciences and Biomedical Sciences departments. Thank you all.

## TABLE OF CONTENTS

LIST OF FIGURES.....	vi
LIST OF ABBREVIATIONS .....	ix
CHAPTER I	
GENERAL INTRODUCTION.....	1
Glutamate Neurotransmission.....	4
Glutamate Receptors.....	4
AMPA/Kainate Receptors .....	5
NMDA Receptors .....	6
mGluRs .....	7
Excitotoxicity .....	7
Regulation of Extracellular Glutamate by Astrocytic Glutamate Transporters .....	8
Synaptic and Extrasynaptic Compartments .....	9
Neuron-Glia Interaction .....	10
Regulation of Astrocytes by Neurons.....	11
Regulation of Neurons by Astrocytes.....	12
Astrocyte and Neuron Metabolic Coupling .....	13
Oxidative Stress and Glutathione in the Brain.....	14
Oxidative Stress .....	14
GSH in the Brain.....	16
System $x_C^-$ .....	18
Structure of System $x_C^-$ .....	18

Function of System $x_C$ - .....	20
Regulation of System $x_C$ - .....	21
Nrf2-ARE Pathway .....	22
eIF2-ATF4-AARE Pathway .....	24
NF- $\kappa$ B .....	28
Activator protein 1 (AP-1) .....	29
Hypoxia inducible Factor (HIF).....	29
cAMP .....	29
Growth Factors.....	30
FGF-2 Receptors and Intracellular Signaling .....	30
FGF-2 Regulation, Function and Dysfunction in Diseases .....	33
FGF-2 in Ischemia/Stroke.....	33
FGF2 in Major Depression/Anxiety .....	34
FGF-2 and Schizophrenia .....	35
FGF-2 and Addiction .....	37
System $x_C$ - Contribution to Cell Death/Survival .....	37
Oxidative Glutamate Toxicity.....	37
Increased System $x_C$ - Activity: Protection Against Oxidative Stress.....	38
Increased System $x_C$ - Activity: Enhanced Excitotoxicity.....	39
Potential Role of System $x_C$ - in Neurological Disorders .....	39
Alzheimer's disease (AD).....	39
Parkinson's Disease (PD) .....	40
Amyotrophic Lateral Sclerosis–Parkinsonism Dementia Complex (ALS-PDC) .....	41

β-N-methylamino-L-alanine (BMAA) .....	42
Heavy Metals .....	44
Ischemia/Stroke.....	44
Glioma.....	45
Addiction.....	46
General Methods.....	48
Cortical Culture.....	49
Cell Death Assay.....	50
<sup>14</sup> C-cystine Uptake .....	51
 CHAPTER II	
B-N-METHYLAMINO-L-ALANINE INDUCES OXIDATIVE STRESS AND GLUTAMATE RELEASE THROUGH ACTION ON SYSTEM XC- .....	53
Abstract.....	54
Introduction.....	55
Materials and Methods.....	57
Results.....	61
BMAA Toxicity Involves the NMDA Receptor, mGluR5 Receptor, and Oxidative Stress .....	61
BMAA Induces Oxidative Stress Through Inhibition of System xc- Mediated Cystine Uptake.....	63
Discussion.....	67
 CHAPTER III	
FUNCTIONAL UPREGULATION OF SYSTEM XC- BY FIBROBLAST GROWTH FACTOR-2 .....	72

Abstract.....	73
Introduction.....	74
Materials and Methods.....	76
Results.....	79
Discussion.....	87
CHAPTER IV	
FGF-2 INDUCES NEURONAL DEATH.....	92
Abstract.....	93
Introduction.....	94
Materials and Methods.....	97
Results.....	100
Discussion.....	105
Conclusions.....	110
CHAPTER V	
GENERAL DISCUSSION.....	111
Interaction of FGF-2 and BMAA on Neuronal Death.....	112
Controversies Regarding BMAA.....	114
Is BMAA a Potent Neurotoxin?.....	115
Measurement of BMAA.....	120
BMAA in Animal Models.....	121
Is Action on System $x_C$ - an Important Mechanism of BMAA Toxicity?.....	122
Regulation of System $x_C$ - by FGF-2.....	122
FGF-2 in the Central Nervous System.....	123



FGF-2 and Oxidative Stress.....	124
FGF-2 and Glutamate .....	125
Toxicity of FGF-2 Mediated by System $x_C$ - .....	127
Is System $x_C$ - Activity Toxic to Neurons? .....	130
Questions Regarding System $x_C$ - Studies .....	131
Molecular Properties of System $x_C$ -.....	131
Relevance and Limitations of Translating in vitro Studies to in vivo: ...	133
CONCLUSION.....	135
BIBLIOGRAPHY.....	136

## LIST OF FIGURES

FIGURE 1.1. Schematic diagram illustrating the function of system $x_C^-$ and the interaction between neuron and astrocyte.....	3
FIGURE 1.2. Glutamate receptor subtypes .....	5
FIGURE 1.3. A typical glutamate synapse.....	11
FIGURE 1.4. Schematic representation of glutamate cycling and glucose metabolism coupling.....	14
FIGURE 1.5. Diagram illustrating the different pathways for handling $O_2^-$ .....	15
FIGURE 1.6. GSH synthesis and cycling in the central nervous system. ....	17
FIGURE 1.7. The structure of system $x_C^-$ .....	19
FIGURE 1.8. Nrf2-ARE pathway.....	23
FIGURE 1.9. Regulation of translation initiation by eIF2 phosphorylation.....	26
FIGURE 1.10. Regulation of translation initiation by eIF2B phosphorylation.....	27
FIGURE 1.11. Expression of mRNA for FGFR1 and FGFR2 in cerebral cortex, neuronal-enriched cultures, and glial-enriched cultures. ....	31
FIGURE 1.12. FGF-FGFR1 intracellular signaling pathways. ....	33
FIGURE 1.13. Structural similarities between the neurotransmitter L-glutamate and the neurotoxic carbonate adduct of BMAA.....	43
FIGURE 1.14. 24 hour FGF-2 treatment on 2 min and 20 min cystine uptake.....	52
FIGURE 2.1. BMAA induced toxicity occurs through multiple mechanisms. ....	62
FIGURE 2.2. BMAA inhibits system $x_C^-$ mediated cystine uptake. ....	63
FIGURE 2.3. BMAA decreases cellular glutathione levels. ....	64
FIGURE 2.4. BMAA induces oxidative stress.....	65
FIGURE 2.5. BMAA and cystine stimulate glutamate release. ....	66
FIGURE 2.6. Cystine-induced neuronal death is attenuated by MK-801 and MPEP. ....	67

FIGURE 3.1. Growth factor effects on cystine uptake in cortical cultures. ....	79
FIGURE 3.2. Growth factor effects on cystine uptake spinal cord glial cultures. ....	80
FIGURE 3.3. Effects of FGF-2 on cystine uptake in neuronal-enriched cultures (A), astrocyte-enriched cultures (B), and microglial cultures (C).....	82
FIGURE 3.4. FGF-2 induced increase in cystine uptake is mediated by system $x_C$ -. ....	83
FIGURE 3.4. Time and protein synthesis dependent changes in cystine uptake induced by FGF-2 treatment on astrocyte-enriched cultures.....	84
FIGURE 3.6. Kinetic analysis of FGF-2 effects on cystine uptake.....	85
FIGURE 3.7. Time course of changes in $xCT$ mRNA in astrocyte-enriched cultures assessed by RT-qPCR following different durations of FGF-2 (100 ng/ml) treatment. .....	85
FIGURE 3.8. FGF-2 stimulation of cystine uptake is mediated by activation of FGFR1 and both the MEK/ERK and PI3-kinase pathways.....	87
FIGURE 4.1. FGF-2 induced toxicity occurs in mixed neuronal and glial cultures after 48 hour treatment. ....	100
FIGURE 4.2. FGF-2 does not induce toxicity after 48 hour treatment on either neuronal- enriched cultures or astrocyte-enriched cultures.....	101
FIGURE 4.3. FGF-2 induced increase in cystine uptake is mediated by system $x_C$ -. ....	102
FIGURE 4.4. FGF-2 induced neuronal death is prevented by blocking system $x_C$ -. ....	103
FIGURE 4.5. Effects of the AMPA receptor antagonist NBQX and the NMDA receptor antagonist memantine on neuronal death induced by 48 hour exposure to FGF-2 or glutamate.....	104
FIGURE 4.6. FGF-2 induced toxicity is not mediated by calcium-permeable AMPA receptors.....	105
FIGURE 5.1. Concentration response of BMAA induced neuronal death after FGF-2 pretreatment. ....	113
FIGURE 5.2. Cholinergic, but not dopaminergic neurons are selectively sensitive to BMAA toxicity. ....	117

FIGURE 5.3. MK801 (10 $\mu$ M) and trolox (100 $\mu$ M) provide protection against BMAA toxicity to total septal neurons (A), while NBQX (20 $\mu$ M) provides protection of cholinergic neurons (B).....	118
FIGURE 5.4. FGF-2 induced increase in cystine uptake is not oxidative stress dependent. .....	125
FIGURE 5.5. Short-term synaptic glutamate release increases system $x_C$ - activity.....	126
FIGURE 5.7. 24 hour exposure to neuronal-conditioned media (NCM) increases system $x_C$ - mediated cystine uptake in astrocytes.....	134

## LIST OF ABBREVIATIONS

6-OHDA	6-hydroxydopamine
AAR	amino acid response
AARE	amino acid response element
AD	Alzheimer's disease
ALS-PDC	Amyotrophic lateral sclerosis–Parkinsonism dementia complex
AMPA	2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
APP	amyloid- $\beta$ precursor protein
ARE	antioxidant responsive element
ATF	activating transcription factor
A $\beta$	amyloid- $\beta$
BDNF	brain derived neurotrophic factor
BMAA	$\beta$ -N-methylamino-L-alanine
BMAA	$\beta$ -N-methylamino-L-alanine
BSO	buthionine sulphoximine
CHX	cycloheximide
CPG	S-4-carboxyphenyl glycine
CysGly	cysteinylglycine
DAG	diacyl glycerol
DAI	double-stranded RNA-activated inhibitor
dbcAMP	N(6),2'-O-dibutyryladenine 3':5' cyclic monophosphate
DCF	dichlorofluorescein
EAAT	excitatory amino acid transporter
eIF2	eukaryotic initiation factor 2
EpRE	electrophile response element
ER	endoplasmic-reticulum
ERK	extracellular signal-regulated kinase
FGF-2	fibroblast growth factor 2, basic fibroblast growth factor
FGFR	FGF receptor
FRS2	fibroblast growth factor receptor substrate 2
GCN2	general control nonderepressible protein 2
GEF	guanine nucleotide exchange factor
GSH	glutathione
GSK3 $\beta$	glycogen synthetase 3 $\beta$
GSSG	glutathione disulfide
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxide
HIF	hypoxia inducible factor
HRI	heme-regulated inhibitor
IGF-1	Insulin-like growth factor 1
IP3	inositol 1,4,5-trisphosphate
LPS	lipopolysaccharide
MeHg	methylmercury

MEK	mitogen-activated protein kinase kinase
MEM	memantine
mGluRs	metabotropic glutamate receptors
MK-801	[5R,10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
MPEP	6-methyl-2-[phenylethynyl]-pyridine
MPP+	1-methyl-4-phenylpyridinium ion
NASPM	1-naphthyl acetyl spermine
NBQX	2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione
NCM	neuronal-conditioned media
NMDA	N-methyl-D-Aspartate
Nrf2	erythroid 2-related factor 2
NRG	neuregulin
NT-4	neurotrophin-4
O <sub>2</sub> <sup>-</sup>	superoxide
ODAP	b-N-oxalyl-L-a,b-diaminopropionic acid
PD	Parkinson's disease
PERK	PKR-like endoplasmic-reticulum-localized eIF2 $\alpha$ kinase
PI3-kinase	phosphatidylinositol 3 kinase
PIP2	phosphatidylinositol 4,5-bisphosphate
PKA	protein kinase A
PKB, Akt	activate protein kinase B
PKC	protein kinase C
PKR	protein kinase R
PLC	phospholipase C
ROS	reactive oxygen species
RT-qPCR	reverse transcription quantitative real-time PCR
Slc7a11 18	solute carrier family 7, member 11
SOD	superoxide dismutase
system X <sub>AG</sub>	sodium-dependent glutamate/aspartate/cysteine transporter
system x <sub>C</sub> <sup>-</sup>	cystine/glutamate antiporter
TGF	transforming growth factor

## **CHAPTER I**


### **GENERAL INTRODUCTION**

## OVERVIEW

The brain is an extremely complex organ with complicated and specific interactions between multiple cell types and regions. However, neuroscience research has historically focused primarily on neurons. Glial cells have been traditionally considered as merely supporting cells. In the last couple of decades, as our knowledge of the glial cells has dramatically expanded, we now know that the function of glial cells extends far beyond just supporting neurons. Growing evidence suggests that neuronal and glial cells communicate through neurotransmitters, neuromodulators, and growth factors, and this bidirectional communication is critical for normal function of the brain.

The aim of this thesis is to explore the interaction between neurons and glia, and how that interaction regulates neuronal fate, with a particular emphasis on the involvement of the cystine/glutamate antiporter (system  $x_C^-$ ) (Fig. 1.1). System  $x_C^-$  is mainly expressed on astrocytes and it is the main route of cystine uptake in these cells. This cystine uptake is the critical step in synthesizing the major antioxidant glutathione. Astrocytes then release glutathione, and other cysteine containing molecules, to supply neurons with cysteine for them to produce glutathione. With every molecule of cystine uptake into the astrocytes, one molecule of glutamate is exchanged out of the cell. This extrasynaptic, nonvesicular, release of glutamate not only serves to regulate synaptic function, but also when excessive, can over-activate glutamatergic receptors on the neurons to cause excitotoxicity. Both oxidative stress and excitotoxicity have been implicated in various neurodegenerative diseases, as well as psychiatric disorders. Thus, it is possible that system  $x_C^-$  plays a role in these diseases.





**FIGURE 1.1. Schematic diagram illustrating the function of system  $x_{C^-}$  and the interaction between neuron and astrocyte.**

C: cysteine, CC: cystine, Glu: glutamate, GSH: glutathione, EAAT: excitatory amino acid transporter


Several pathways that are involved in system  $x_{C^-}$  regulation have been identified. However, the effects of changing system  $x_{C^-}$  function are not well understood. Since targeting system  $x_{C^-}$  as a treatment for various brain disorders is being considered, it is very important to achieve a full understanding of system  $x_{C^-}$  function and regulation, as well as the consequences of changing its activity.

## **GLUTAMATE NEUROTRANSMISSION**

Glutamate is the most important excitatory neurotransmitter in the brain (Fonnum, 1984). It is also a precursor for the most important inhibitory neurotransmitter GABA (Petroff, 2002; Schousboe and Waagepetersen, 2007), and is a component of glutathione, one of the major antioxidants in the brain (Meister and Anderson, 1983; Dringen et al., 2000). Glutathione can be synthesized de novo from glucose in astrocytes via the Krebs cycle, leading to the release of glutamine from astrocytes, which is taken up by neurons and hydrolyzed into glutamate by glutaminase (Erecińska and Silver, 1990). Glutamate can activate a large family of receptors existing on neurons and astrocytes leading to signal transmission.

### **Glutamate receptors**

Glutamate signal transmission is mediated by release of glutamate and activation of various glutamatergic receptors. Generally, as illustrated in Fig. 1.2, glutamatergic receptors can be divided into ionotropic receptors and metabotropic receptors. Ionotropic receptors include N-methyl-D-Aspartate (NMDA) receptors and 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid (AMPA)/kainate receptors, while metabotropic glutamate receptors (mGluRs) can be further divided into three subgroups. Specific receptors and their properties are briefly described below (for a detailed review see (Dingledine et al., 1999)).



**FIGURE 1.2. Glutamate receptor subtypes**  
(From (Niciu et al., 2012))

### *AMPA/Kainate receptors*

AMPA receptors are another family of glutamatergic receptors that are characterized by low affinity ( $EC_{50} \sim 500 \mu\text{M}$ ) (Lomeli et al., 1994; Mosbacher et al., 1994; Schoepfer et al., 1994). AMPA receptors are heterotetrameric receptors composed of four subunits (GluR1-4) (Alt et al., 2004). Unlike the other GluRs, GluR2 has a Q/R site (uncharged glutamine/positively charged arginine) located in the pore of the channel. Physiologically almost all of the GluR2 subunits are edited to the R form, which makes the receptor impermeable to calcium (Jonas et al., 1994; Petroff, 2002; Schousboe and Waagepetersen, 2007). Therefore, while all AMPA receptors are permeable to sodium and potassium, GluR2 lacking AMPA receptors are also calcium permeable (Meister and Anderson, 1983; Dringen et al., 2000; Clem and Barth, 2006), which awards these

receptors the important property of increasing intracellular calcium levels when they are activated (Erecińska and Silver, 1990; Schneggenburger et al., 1993).

Kainate receptors are tetramers of GluR5, GluR6, GluR7, KA1, and KA2 (Dingledine et al., 1999). Similar to AMPA receptors, they are ion channels that are permeable to sodium and potassium (Dingledine et al., 1999; Niciu et al., 2012). However, the functions of kainate receptors are not well defined.

### ***NMDA receptors***

NMDA receptors are another important ionotropic receptor subtype that are usually heteromers of GluN1 and GluN2 (GluN2A, GluN2B) subunits in mature brain (Béhé et al., 1995; Premkumar and Auerbach, 1997). Compared to AMPA receptors, NMDA receptors are characterized by a high affinity ( $EC_{50} \sim 1 \mu\text{M}$ ) for glutamate (Patneau and Mayer, 1990; Burnashev et al., 1995). However, under physiological conditions, they are normally blocked by magnesium at negative membrane potential (Nowak et al., 1984). During normal synaptic activity, AMPA receptors must be activated first to depolarize the cell membrane, which removes the magnesium block (Nowak et al., 1984; Dingledine et al., 1999). NMDA receptor activation also requires binding of a co-agonist, such as glycine or D-serine (Johnson and Ascher, 1987; Schell et al., 1995). NMDA receptors are nonspecific cation channels that are permeable to sodium, potassium, and calcium (Grienberger and Konnerth, 2012), with the permeability to calcium distinguishing them from most AMPA/Kainate receptors.

## ***mGluRs***

mGluRs are G-protein coupled receptors that exist on neurons and glial cells (Conn and Pin, 1997; Ferraguti and Shigemoto, 2006; Kim et al., 2008). Like all G-protein coupled receptors, mGluRs have 7 transmembrane spanning domains, an agonist binding domain (N-terminus), as well as an intracellular domain (C-terminus) that couples to different G-proteins (Niciu et al., 2012). To date, there are 8 known family members as illustrated in Fig. 1.2: mGluR1-8. They are divided into three subfamilies: Group I (mGluR1 and 5) that are coupled to  $G_q$ , Group II (mGluR2 and 3) and Group III (mGluR 4, 6, 7 and 8) that are coupled to  $G_i$ . Activation of  $G_q$  leads to activation of phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) to secondary messengers diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP<sub>3</sub>), which then lead to the increase in intracellular free calcium levels and activation of calcium dependent protein kinases such as protein kinase C (PKC) (Miller et al., 1995; Conn and Pin, 1997). On the other hand, activation of  $G_i$  leads to inhibition of adenylyl cyclase, decreased cAMP, and decreased activation of protein kinase A (PKA) (Winder and Conn, 1993; Niciu et al., 2012). Group I mGluRs are mainly localized to post synaptic and glial membranes, while the majority of Group II mGluRs are localized to presynaptic membranes and provide an autoinhibition mechanism for neurotransmitter release.

## **Excitotoxicity**

Although glutamate transmission is essential to normal brain function, excessive extracellular glutamate can cause excitotoxicity. Excitotoxicity is typically caused by

over-activation of glutamatergic receptors, especially NMDA receptors due to their permeability to calcium and slower inactivation, leading to excessive calcium influx into the cells to trigger cell death (Choi, 1987). This type of neuronal death can occur in conditions such as stroke, traumatic brain injury, and neurodegenerative diseases (Bains and Shaw, 1997; Choi, 1998).

In certain situations, over-activation of AMPA receptors can cause excitotoxicity as well. AMPA receptor over-activation by addition of AMPA, a direct agonist for AMPA receptors, has been shown to be toxic to oligodendrocytes (McDonald et al., 1998). The general AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) has been shown to be protective to oligodendrocytes in multiple sclerosis models (Pitt et al., 2000; Smith et al., 2000). Oligodendrocyte toxicity often appears to be mediated by calcium permeable GluR2 lacking AMPA receptors because it is prevented by the selective antagonist 1-naphthyl acetyl spermine (NASPM) (Yoshioka et al., 1996; Bannerman et al., 2007).

### ***Regulation of extracellular glutamate by astrocytic glutamate transporters***

Total glutamate concentration is extremely high in the brain (10 mM) (Erecińska and Silver, 1990), but the extracellular glutamate concentration is very low (below 10  $\mu$ M) (Ronne-Engström et al., 1995; Baker et al., 2003; Rodriguez et al., 2012). The extracellular glutamate is tightly regulated by the excitatory amino acid transporters (EAATs). EAATs mediate sodium-dependent high-affinity glutamate uptake, which is driven by the sodium concentration gradients: for every glutamate taken up, three molecules of sodium enter the cell while one molecule of potassium exits the cell

(Barbour et al., 1988; Zerangue and Kavanaugh, 1996a). Astrocytes with abundant glutamate transporters EAAT1/GLAST and EAAT2/GLT-1 activity-dependently ensheath glutamatergic synapses (Ventura and Harris, 1999; Witcher et al., 2010), where they are involved in clearing extracellular glutamate to avoid unwanted prolonged synaptic activation and excitotoxicity (Amara, 1992; Kanai and Hediger, 1992; Storck et al., 1992; Rothstein et al., 1994; 1996; Diamond and Jahr, 1997; Lehre and Danbolt, 1998). Glutamate taken up by astrocytes is converted into glutamine by glutamine synthetase. Glutamine, in turn, can be released and taken up by neurons to synthesize glutamate. This glutamate-glutamine cycle between neurons and astrocytes ensures signaling specificity and a fast turnover rate (Sibson et al., 1998).

### *Synaptic and extrasynaptic compartments*

Another important function of astrocytes ensheathing synapses is that they spatially separate synaptic and extrasynaptic compartments of the extracellular space. Astrocytic EAATs provide efficient buffering and clearance of glutamate to prevent spillover and cross-talk between different synapses and compartments (Rothstein et al., 1996; Asztely et al., 1997; Rusakov and Kullmann, 1998).


Synaptic and extrasynaptic receptors seem to have different functions; the most studied example are the synaptic and extrasynaptic NMDA receptors. It has become an increasingly accepted point of view that synaptic NMDA receptor activation is neuroprotective, while extrasynaptic NMDA receptor activation turns off the neuroprotective synaptic NMDA receptor activation and also activates intracellular pathways that lead to neuronal death (Hardingham et al., 2002; Riccio and Ginty, 2002;

Ivanov et al., 2006; Léveillé et al., 2008; Xu et al., 2009; Hardingham and Bading, 2010). Drugs that preferentially block extrasynaptic NMDA receptors have received particular attention as potential treatments for neurodisorders. For example, memantine (MEM), which is an FDA approved drug for late stage Alzheimer's disease, has been shown to have selectivity for extrasynaptic NMDA receptors (Lipton and Chen, 2004; Xia et al., 2010). MEM is an open channel blocker at NMDA receptors. At low doses, it does not accumulate in the synaptic cleft to interfere with synaptic NMDA receptor mediated signaling. However, it does antagonize extrasynaptic NMDA receptors that are hyperactive due to increased extrasynaptic glutamate levels in diseased brains (Lipton and Chen, 2004; Chen and Lipton, 2006; Xia et al., 2010).

### **NEURON-GLIA INTERACTION**

Bidirectional communication between astrocytes and neuronal cells is necessary for the normal functioning of the nervous system during signal processing. Some interactions between neurons and glia are discussed below with a focus on a typical glutamatergic synapse as shown in Fig. 1.3.





**FIGURE 1.3. A typical glutamate synapse.**

(Altered From (Niciu et al., 2012))

### Regulation of astrocytes by neurons

Physiologically, high levels of neuronal activation can cause elevated extracellular potassium levels, and in turn, slowly depolarize glial cells (Meeks and Mennerick, 2007; Sasaki et al., 2011). Under extreme conditions, depolarization can spread throughout the astrocyte network and cause cortical spreading depression (Unekawa et al., 2012; Bogdanov et al., 2013).

Similar to neurons, astrocytes also express a variety of receptors to respond to neurotransmitter release, such as mGluRs (Venance et al., 1997), nicotinic acetylcholine receptors (Oikawa et al., 2005), adrenoceptor, P2 receptors of the P2X (ligand-gated cationic channels) and P2Y (G-protein coupled receptors) types (Butt, 2011; Köles et al., 2011). Most of these astrocytic receptors are G<sub>q</sub>-protein coupled receptors. Unlike neurons, astrocytes do not generate action potentials. However, activation of these astrocytic G<sub>q</sub>-protein coupled receptors by neurotransmitters can lead to elevated intracellular calcium levels (Venance et al., 1997; Agulhon et al., 2008). Astrocytes also express some ionotropic glutamate receptors (Seifert and Steinhäuser, 2001), although their functional significance is largely unknown.

### **Regulation of neurons by astrocytes**


Each astrocyte is believed to have its own territory, and within that territory, it may interact with 140,000, or more, synapses and neuronal processes (Benarroch, 2009). Therefore, individual astrocytes are potentially capable of coordinating a large amount of neuronal activity (Poskanzer and Yuste, 2011). Astrocytes are also connected to each other through gap junctions, which allows fast chemical and electrical communication among astrocytes, enabling them to function as a network. Thus, activation of a single astrocyte can spread to an extended surrounding area and potentially regulate the function of multiple neighboring neurons (Cornell-Bell et al., 1990).

Astrocytes can also release gliotransmitters (such as glutamate, ATP, D-serine etc.) to regulate neuronal function and synaptic plasticity (Fellin et al., 2006; Butt, 2011; Parpura et al., 2012). It is known that increased calcium levels in astrocytes, like that in

neurons, can trigger the fusion of vesicles containing gliotransmitters with the plasma membrane (Bezzi et al., 1998; 2004; Kreft et al., 2004). Non-vesicular release of glutamate has also been suggested. A recent study describes a channel mediated release of gliotransmitter (<900 Da), such as glutamate (Duan et al., 2003). System  $x_C^-$  mediates a selective non-vesicular release of glutamate. It is believed that glutamate released from astrocytes mainly activates the extrasynaptic pool of glutamatergic receptors (Xi et al., 2002).

### **Astrocyte and neuron metabolic coupling**

As the largest population of cells in the nervous system, astrocytes are crucial in maintaining normal glutamate transmission (Ye and Sontheimer, 2002; Huang et al., 2004; López-Bayghen and Ortega, 2011). Glucose is the major substrate for brain energy production. Astrocytes take up glucose from their endfeet on capillaries (Magistretti and Pellerin, 1996; Edvinsson and Krause, 2002), metabolize it, and release L-lactate and pyruvate as energy sources for neurons (Dringen et al., 1993). Metabolites from glucose can also be further processed to produce essential neurotransmitters such as GABA and glutamate (Magistretti and Pellerin, 1996). Glutamate uptake and glucose utilization by astrocytes are tightly coupled as illustrated in Fig 1.4.



**FIGURE 1.4. Schematic representation of glutamate cycling and glucose metabolism coupling.**


At glutamatergic synapses, excessive extracellular glutamate is removed by a glutamate uptake system located primarily on astrocytes. Glutamate is cotransported with Na<sup>+</sup>, resulting in an increase in the intracellular concentration of Na<sup>+</sup> in astrocytes leading to activation of the Na<sup>+</sup>/K<sup>+</sup> ATPase pump. The pump utilizes ATP, which is provided by membrane-bound glycolytic enzymes. This demand for ATP activates glycolysis in astrocytes, resulting in the production of lactate. Lactate, once released can be taken up by neurons and serve as an energy substrate. From (Magistretti and Pellerin, 1996)

## OXIDATIVE STRESS AND GLUTATHIONE IN THE BRAIN

### **Oxidative stress**

Oxidative stress is an excessive accumulation of free radicals and other reactive oxygen species (ROS). It can be caused by either an overproduction of free radicals or a deficit in their clearance. ROS are normal products of cellular metabolism. While some levels of free radical generation is normal and necessary, overwhelming amounts of free radicals can lead to oxidative damage to proteins, lipids and DNA, causing dysfunction of these molecules (Freeman and Crapo, 1982; Simonian and Coyle, 1996). As illustrated in Fig. 1.5., ROS are mainly generated in the mitochondria: electrons along the electron

transport chain in mitochondria leak out and are accepted by oxygen resulting in superoxide ( $O_2^-$ ) production (Freeman and Crapo, 1982). There are various cellular defense mechanisms against ROS, such as superoxide dismutase (SOD), catalase, glutathione (GSH), vitamin C and vitamin E (Sies, 1997; Brigelius-Flohé and Traber, 1999). SOD can degrade superoxide generating hydrogen peroxide ( $H_2O_2$ ) (Fridovich, 1975).  $H_2O_2$  is not reactive. However, when there are metal ions present, highly reactive hydroxyl radical can be generated by Fenton reaction. In contrast, catalase can decompose  $H_2O_2$  into water and oxygen. The  $H_2O_2$  can also be eliminated by GSH in a process mediated by glutathione peroxidase, generating glutathione disulfide (GSSG). GSSG can be reduced back to GSH by NADPH via glutathione reductase (Fig.1.5). Besides reducing oxidative stress, GSH can also directly conjugate to toxins, and both GSH and GSH conjugates can be transported out of the cells by multi-drug resistance proteins (Rush et al., 2012b).



**FIGURE 1.5. Diagram illustrating the different pathways for handling  $O_2^-$ .**


$O_2^-$ : superoxide, SOD: superoxide dismutase, GSH: glutathione,  $H_2O_2$ : hydrogen peroxide, GSSG: glutathione disulfide.

The brain, while only 2% of the body weight, consumes about 20% of the total oxygen, generating high levels of ROS (Ballatori et al., 2009), and oxidative stress has been shown to be a possible contributor to the damage occurring in neurodegenerative diseases (Simonian and Coyle, 1996; Schulz et al., 2000; Ballatori et al., 2009).

### **GSH in the brain**

GSH is a tripeptide consisting of the amino acids glutamate, glycine, and cysteine (Dringen et al., 2000). It is the most prevalent cellular thiol in the brain, with an intracellular concentration of ~2.5 mM in neurons and ~ 3.8 mM in astrocytes (Bolaños et al., 1995; Rice and Russo-Menna, 1998). Normally, the intracellular GSSG/GSH ratio is tightly regulated, with over 99% of the total cellular GSH present as the reduced form (Deneke and Fanburg, 1989). The GSSG/GSH ratio is a sensitive indicator of oxidative stress (Rahman et al., 2005).

GSH is synthesized via a two-step reaction (Fig. 1.6) (Beutler, 1989; Deneke and Fanburg, 1989). First, glutamate and cysteine are catalyzed to  $\gamma$ -glutamylcysteine by glutamate cysteine ligase. Then glycine joins  $\gamma$ -glutamylcysteine mediated by glutathione synthetase. Both steps require ATP. Both glutamate and glycine are highly available in the cells, so the rate-limiting factor is cysteine. The rate of this reaction is based on intracellular cysteine levels and  $\gamma$ -glutamylcysteine synthetase that is feedback-regulated by GSH. Inhibiting cystine uptake inhibits GSH synthesis because the levels of intracellular cysteine are dependent on cystine uptake (Bannai and Kitamura, 1980).



**FIGURE 1.6. GSH synthesis and cycling in the central nervous system.**

In astrocytes: 1:  $\gamma$ -glutamylcystine synthetase; 2: glutathione synthetase; 3:  $\gamma$ -glutamyl transpeptidase. In Neurones: 4: dipeptidases. Glu: glutamate, CySS: cystine, Cys: cysteine, Gly: glycine, GSH: glutathione. From (McBean, 2002)

Sources for cysteine seem to depend on the developmental stage and cell type in the central nervous system (Kranich et al., 1996). It is believed that the sodium-independent system  $x_C$ - is the main mechanism of cysteine uptake in glial cells (Lobner, 2009), while the sodium-dependent glutamate/aspartate/cysteine transporter [System X<sub>AG</sub> (EAAT3/EAAC1)] is responsible for most of cysteine uptake in mature neurons (McBean, 2002). Cystine will immediately be broken down by thioredoxin reductase 1 into two cysteine molecules once it enters the cells (Arrick et al., 1985).

In the nervous system, glial cells are important in supplying neurons with cysteine containing molecules, such as cysteine itself, cysteinylglycine (CysGly), or GSH (Dringen et al., 1999). Extracellularly, GSH is metabolized by the ectoenzyme  $\gamma$ -glutamyl transferase, which transfers the  $\gamma$ -glutamyl residue of GSH to different acceptor

amino acids leading to the formation of a  $\gamma$ -glutamyl containing dipeptide and a dipeptide CysGly. CysGly is then either cleaved by extracellular dipeptidases to generate cysteine and glycine, or directly taken up by neurons. Knocking out EAAT3 greatly reduces neuronal cysteine uptake and intracellular GSH levels, resulting in decreased viability of hippocampal neurons against  $H_2O_2$  insults (Zerangue and Kavanaugh, 1996b; Chen and Swanson, 2003; Aoyama et al., 2006). This suggests that EAAT3 plays a critical role in the ability of neurons to obtain cysteine.

### **SYSTEM X<sub>C</sub>-**


System x<sub>C</sub>- is a sodium-independent, chloride-dependent amino acid transport system located on the plasma membrane. System x<sub>C</sub>- was first characterized by Bannai and Kitamura in 1980 when mutual inhibition of glutamate and cystine uptake was described (Bannai and Kitamura, 1980). It can transport one molecule of cystine into the cell in exchange for one molecule of intracellular glutamate, with  $K_m$  values of  $\sim 80 \mu M$  for cystine uptake and  $\sim 160 \mu M$  for glutamate uptake (Sato et al., 1999). The transport direction is determined by the high cytosolic glutamate levels and low cytosolic cystine levels.

### **Structure of system x<sub>C</sub>-**

System x<sub>C</sub>- is a heteromeric antiporter, composed of two subunits: a light-chain subunit xCT and a heavy chain 4F2hc, which are linked together by one disulfide bond (Torrents et al., 1998; Shih et al., 2006) (Fig. 1.7.). The 4F2hc subunit is a single transmembrane glycoprotein that is believed to be universally shared among the



heterodimer membrane transporter family: transporter systems L (Lewerenz et al., 2012; Bridges et al., 2012a). Although 4F2hc by itself does not have amino acid transport function, it is essential to system  $x_C^-$  function because it brings xCT to the membrane (Estévez et al., 1998; Sato et al., 1999; Bassi et al., 2001). xCT determines the substrate specificity and efficiency of system  $x_C^-$ . It is encoded by the solute carrier family 7, member 11 (Slc7a11) gene (Bassi et al., 2001), which produces a 502 amino acid short chain protein with a predicted molecular mass of about 55.5 kDa (Sato et al., 1999). The xCT subunit is highly hydrophobic and has a 12 transmembrane domain with a re-entrant loop and both N- and C-termini are located on the cytoplasmic side (Gasol et al., 2004).



**FIGURE 1.7. The structure of system  $x_C^-$**

System  $x_C^-$  is composed of a light chain xCT (shown in clear) and a heavy chain 4F2hc (shown in black), connected by a single disulfide bridge (shown in squares). From (Shih et al., 2006).

**Function of system x<sub>C</sub>-**

Because of the dual transport property of system x<sub>C</sub>-, it can regulate both intracellular GSH levels and extracellular glutamate levels. Cystine that enters cells through system x<sub>C</sub>- can be broken down to cysteine to synthesize GSH, which can reduce free radicals or be released to regulate the redox state of the extracellular milieu (Wang and Cynader, 2000; Banjac et al., 2008). System x<sub>C</sub>- has been shown to be responsible for 60% of extracellular glutamate in rat striatum (Baker et al., 2002). Deleting the xCT gene in *Drosophila* causes a 50% reduction in extracellular glutamate levels (Augustin et al., 2007). Extracellular glutamate released from system x<sub>C</sub>- can activate presynaptic mGluR2/3, which can regulate synaptic release of neurotransmitters, such as dopamine (Baker et al., 2002).

Sato et al. 2005, developed and characterized xCT null mice with a partial deletion of the xCT gene. These mutant mice appear healthy and fertile. However, in plasma, the cystine concentration is doubled compared to wild type, while GSH levels are half of the wild type (Sato et al., 2005). No difference in cysteine levels was reported. Microglial cells isolated from these mice showed normal levels of cystine uptake. However, the uptake was not blocked by glutamate and was not inducible by lipopolysaccharide (LPS) (Sato et al., 2005). Fibroblasts isolated from these xCT -/- mice die unless exogenous 2-mercaptoethanol or N-acetylcysteine, which reduces cystine to cysteine, is present (Sato et al., 2005). In xCT deficient mice, ischemia-reperfusion-induced acute renal failure is more severe compared to wild type animals (Shibasaki et al., 2009). No increased oxidative stress or brain atrophy were observed (De Bundel et al., 2011). This is probably because in xCT deficient animals other cystine/cysteine

uptake transporters are upregulated to maintain the normal activity. However, it is not possible to upregulate in these xCT deficient animals under oxidative stress to help increase GSH levels (Shibasaki et al., 2009). Therefore, it appears that some degree of compensation for the lack of system x<sub>C</sub>- occurs, but it is not entirely effective.

Another mutant mouse line involving altering system x<sub>C</sub>- function is the *sut/sut* mouse, which has a partial deletion of the xCT gene. These animals show changes in fur color due to a deficiency in the cysteine-dependent yellow/red pigment, pheomelanin (Chintala et al., 2005), and a large reduction in pheomelanin is also observed in cultured *sut/sut* melanocytes. Interestingly, *sut/sut* mice also exhibit prominent brain atrophy in the hippocampus (Shih et al., 2006). The mechanisms resulting in different phenotypes of these two different mutant mouse lines require further studies.


### **Regulation of system x<sub>C</sub>-**

Despite the involvement of system x<sub>C</sub>- in both excitotoxicity and oxidative stress, there is limited knowledge about its regulation. Because xCT is specific to system x<sub>C</sub>- and determines specificity of its transport function, the regulation studies have been mainly focused on xCT regulation (Sato et al., 1999). To date, the best-characterized pathways are nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant responsive element (ARE) and eukaryotic initiation factor-2 (eIF2) - activating transcription factor (ATF) 4- amino acid response element (AARE), which are discussed in detail below, along with other regulatory mechanisms.

### ***Nrf2-ARE pathway***

There are four ARE-like, also known as electrophile response element (EpRE)-like, sequences in the 5' flanking region of the mouse xCT gene (Sasaki et al., 2002), two of which are completely conserved in the 5'-flanking region of the human xCT gene (Sato et al., 2000; Sasaki et al., 2002).

The transcription factor Nrf2-ARE pathway was first proposed by Venugopal and Jaiswal (Venugopal and Jaiswal, 1996), as illustrated in (Fig. 1.8). Nrf2 is normally cytosolic because of keap-1 binding (Itoh et al., 1999). However, when under oxidative stress, Nrf2 is freed and translocates to the nucleus and binds to ARE to activate specific protein transcription (Itoh et al., 1999). ARE is a cis-acting regulatory element located in the promoter regions of multiple genes encoding phase II detoxification enzymes and antioxidant proteins (Lee and Johnson, 2004). These proteins include heme oxygenase,  $\gamma$ -glutamylcysteine synthetase, glutamate-cysteine ligase, glutathione synthetase, glutathione S-transferase, glutathione reductase, multidrug resistance protein 1, as well as xCT (Bannai, 1984; Erickson et al., 2002; Sasaki et al., 2002).



**FIGURE 1.8. Nrf2-ARE pathway**

Activation of Nrf2-ARE pathways that leads to expression of ARE-driven genes, including xCT. From (Lee and Johnson, 2004).

Nrf2-ARE has been shown to be necessary for increased cystine uptake through system  $x_C^-$  induced by various electrophiles, such as diethyl maleate, arsenite, cadmium and hydroquinone, in BHK21 kidney cells (Sasaki et al., 2002). Upregulating Nrf2 has been shown to increase xCT levels and protect both glial cells and neurons from oxidative stress insults in a phosphatidylinositol 3 kinase (PI3K)/ activate protein kinase B (PKB, aka, Akt) dependent manner (Shih et al., 2003; Wang et al., 2009).

However, knocking out Nrf2 failed to affect MeHg-induced upregulation of xCT, which suggests Nrf2-ARE is not always involved in xCT regulation (Wang et al., 2009).


### *eIF2-ATF4-AARE pathway*

There are two AARE-like sequences in the 5'-flanking region of the xCT gene (Sato et al., 2004; Lewerenz and Maher, 2009). Amino acid response (AAR) is usually triggered by limited uptake of any essential amino acid (Kilberg et al., 2005). It serves as a self-protective effect by globally slowing down protein production and cellular activity by limiting protein synthesis. However, transcription and translation of certain proteins, such as basic leucine zipper and ATF4 is enhanced (Wek et al., 2006). These proteins then regulate gene expression of membrane transporters and growth factors to cope with environmental stresses (Kilberg et al., 2005; Wek et al., 2006; Ameri and Harris, 2008; Kilberg et al., 2009). It is a protective mechanism against a harmful environment, such as changed pH, nutrient levels, and oxidative stress (Duncan and Hershey, 1985; 1987).

eIF2, a heterotrimer composed of eIF2 $\alpha$ , eIF2 $\beta$ , and eIF2 $\gamma$ , is an important component of the initiating complex for most of the protein synthesis (Fafournoux et al., 2000). The GDP in eIF2 has to be exchanged for GTP mediated by guanine nucleotide exchange factor eIF2B to successfully form the initiating complex (Matts and London, 1984; Dholakia and Wahba, 1989). Components of eIF2 can be phosphorylated, preventing the attached GDP from being replaced with GTP (Kilberg et al., 2009). Among the three, eIF2 $\alpha$  is the most easily phosphorylated (Costa-Mattioli et al., 2007). The two mechanisms of eIF2B inhibition are described below, both of which can lead to increased ATF4 production, and then activation of AARE regulated gene transcription.

When there are not enough available essential amino acids in the cell, the excessive free tRNAs activate the general control nonrepressible protein 2 (GCN2) kinase, which in turn phosphorylates eIF2 (Zhang et al., 2002). Phosphorylated eIF2 has

increased affinity for eIF2B, although it cannot be activated for initiating complex assembly. Therefore, phosphorylated eIF2 becomes a potent competitive inhibitor for eIF2B (Rowlands et al., 1988; Kimball, 1999). Normally, the intracellular eIF2 levels are significantly higher than eIF2B, therefore, phosphorylation of merely 30% of eIF2 $\alpha$  is enough to completely block eIF2B activity (Matts and London, 1984; Duncan and Hershey, 1987). Besides GCN2, there are other kinases that are sensitive to other stressors, and become activated leading to eIF2 phosphorylation. These kinases include heme-regulated inhibitor (HRI) activated by heme-deficiency (Han et al., 2001; Lu et al., 2001), double-stranded RNA-activated inhibitor (DAI) or dsRNA-dependent serine/threonine protein kinase R (PKR) activated by viral infection (Hershey, 1989; Proud, 2005) and PKR-like endoplasmic-reticulum (ER)-localized eIF2 $\alpha$  kinase (PERK) activated by ER stress (Lu et al., 2004) (Fig. 1.9.). All of these cellular stresses have the potential of activating the same pathways amino acid deprivation activate and inducing system  $x_C^-$  expression, but this theory has not yet been tested.




**FIGURE 1.9. Regulation of translation initiation by eIF2 phosphorylation.**

dsRNA-dependent serine/threonine protein kinase R (PKR), heme-regulated inhibitor (HRI), PKR-like endoplasmic-reticulum (ER)-localized eIF2  $\alpha$  kinase (PERK), general control nonrepressible protein 2 (GCN2) are activated in response to various environmental stresses, which leads to phosphorylation of eIF2. Phosphorylated eIF2 inhibits eIF2B mediated guanine nucleotide exchange, in turn, globally slows down translation initiation, but increases ATF4 levels. From (Wek et al., 2006)

Phosphorylation of eIF2B is another mechanism that leads to activation of AARE regulated gene transcription (Proud, 2005) (Fig. 1.10). Glycogen synthetase 3 $\beta$  (GSK3 $\beta$ ), a constitutively active kinase, can phosphorylate eIF2B, leading to the loss of its GEF property (Welsh and Proud, 1993) and prevents assembly of the initiation complex. Hormones, mitogens, and growth factors can activate phosphatidylinositol 3(PI3)-kinase (Welsh et al., 1998) and MEK/ERK (Kleijn and Proud, 2000; Quevedo et al., 2000), which can lead to phosphorylation of GSK3 $\beta$  to inactivate it, which removes the GSK3 $\beta$  inhibition effect on eIF2B.





**FIGURE 1.10. Regulation of translation initiation by eIF2B phosphorylation.**

Hormones, mitogens, and growth factors can phosphorylate glycogen synthetase 3 $\beta$  (GSK3 $\beta$ ) through phosphatidylinositol 3(P13)-kinase and mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways. Phosphorylation of GSK3 $\beta$  removes the inhibition of eIF2B, and ensures translation initiation.

Phosphorylation of either eIF2 or phosphorylation of eIF2B can lead to global shut down of protein translation, however, there is increased ATF4 production, in turn, activates expression of AARE regulated genes. Mutation studies showed that AARE like sequences in the 5'-flanking region of xCT are essential in both basal and amino acid deprivation induced increase in system x<sub>C</sub>- activity (Sato et al., 2004). Deprivation of cystine, an essential amino acid, activates the ATF4-AARE pathway, and induces an increase in cystine uptake in cultured human fibroblasts after 24 hours (Bannai, 1984). This suggests an involvement of ATF4-AARE in system x<sub>C</sub>- regulation. Further studies showed that 4F2hc is consistently induced under any amino acid deprivation, while xCT is only induced with certain amino acids missing (Sato et al., 2004). This suggests that

the two subunits of system  $x_C^-$  have different regulatory mechanisms. Decreasing intracellular eIF2 $\alpha$  levels increases HT22 cells resistance to oxidative glutamate toxicity, while increasing intracellular eIF2 $\alpha$  can render HT22 cells highly sensitive to glutamate toxicity by decreasing system  $x_C^-$ - mediated cystine uptake, depleting GSH, and increasing ROS (Tan et al., 2001; Lewerenz and Maher, 2009). This effect is mediated through ATF4 binding to AARE (Lewerenz and Maher, 2009). Therefore, it appears that the ATF4-AARE pathway is an important regulatory mechanism for system  $x_C^-$ .

### ***NF- $\kappa$ B (nuclear factor kappa-light-chain-enhancer of activated B cells)***

NF- $\kappa$ B may be another activator of xCT expression because there is a NF- $\kappa$ B binding site in the 5'-flanking region of xCT (Sato et al., 2001). NF- $\kappa$ B has long been known to play a role in rapid response to calcium influx and harmful cellular stimuli, especially in the immune response (Meffert et al., 2003). LPS is known to activate NF- $\kappa$ B (Sen and Smale, 2010). In mouse peritoneal macrophages, both xCT and 4F2hc mRNA increased in a time dependent manner within 12 hours of LPS treatment (Sato et al., 2001). However, this LPS induced increase in xCT levels is not likely to be mediated through NF- $\kappa$ B because there was no increased nuclear NF- $\kappa$ B caused by the LPS treatment (Sato et al., 2001). Since LPS still induces the activity of system  $x_C^-$  in macrophages prepared from Nrf2-deficient mice, it is not likely that an LPS induced increase in system  $x_C^-$  activity is mediated through the Nrf2-ARE pathway (Sato et al., 2001). Therefore, despite an NF- $\kappa$ B binding site in the 5'-flanking region of xCT, there is no direct evidence of its role in system  $x_C^-$  regulation. The mechanism of LPS inducing increased system  $x_C^-$  activity remains unclear.

### ***Activator protein 1 (AP-1)***

There are several putative AP-1 binding sites in the 5'-flanking region of xCT, one of them overlaps with the ARE sequence that is essential for response to electrophile reagent activated xCT transcription and translation (Sato et al., 2001). AP-1 transcription factor mediates gene regulation in response to cytokines, growth factors, stress, and infections (Hess et al., 2004). However, its role in xCT regulation has not yet been studied.

### ***Hypoxia inducible factor (HIF)***

Hypoxic preconditioning, the protection against a severe hypoxic insult by an earlier mild hypoxic insult, increases xCT levels both transcriptionally and translationally in hippocampus in vivo and in mouse neuronal stem cells (Ogunrinu and Sontheimer, 2010; Sims et al., 2012). This is mostly mediated through HIF-1 $\alpha$ , but since siHIF-1 $\alpha$  does not completely abolish xCT upregulation in B104 mouse neuronal stem cell cultures after hypoxic preconditioning, the possibility of other intracellular pathways being involved cannot be ruled out (Sims et al., 2012). Also, hypoxia did not induce system x<sub>C</sub>-function in mouse macrophage cultures (Sato et al., 2001). Determining the mechanism of system x<sub>C</sub>-regulation by preconditioning, and when it occurs, requires further study.

### ***cAMP***

In rat striatal punches, system x<sub>C</sub>- activity is decreased by 15 minutes of mGluR2/3 agonist treatment, and this effect is mimicked by inhibiting cAMP (Baker et

al., 2002). Also, a two-fold increase in xCT mRNA levels in rat cortical astrocytes was observed after a 10-day incubation with N(6),2'-O-dibutyryladenine 3':5' cyclic monophosphate (dbcAMP), a cAMP analog (Gochenauer and Robinson, 2001). One week dbcAMP treatment potentiates buthionine sulfoximine induced increase in system x<sub>C</sub>- activity in rat primary astrocytes (Seib et al., 2011). There are two consensus PKA phosphorylation sites on human xCT (Baker et al., 2002). However, the exact intracellular pathway by which cAMP is involved in system x<sub>C</sub>- regulation is yet to be investigated.

### ***Growth factors***


Our lab was the first to report growth factor effects on system x<sub>C</sub>- function. Insulin-like growth factor 1 (IGF-1) and transforming growth factor-β (TGF-β) can upregulate system x<sub>C</sub>- function in dental pulp cells (Pauly et al., 2011). We also showed that fibroblast growth factor-2 (FGF-2) upregulates system x<sub>C</sub>- function selectively in primary cortical astrocytes (Liu et al., 2011).

### **FGF-2 RECEPTORS AND INTRACELLULAR SIGNALING PATHWAYS**

FGF-2 was the first member isolated and cloned among the FGF family of growth factors in the 1980s. After decades of research, we now know FGF-2 is involved in many nervous system functions. During embryonic development, FGF-2 plays an important role in regulating proliferation, differentiation, and migration; while in adult, FGF-2 plays a critical role in neuronal death, neurogenesis, learning and memory, and lesion repair (Reuss and Bohlen und Halbach, 2003; Eswarakumar et al., 2005). FGF-2 expression is

found in both neuronal and glial cells, with glial cells as its main source (Eckenstein et al., 1991a; 1991b).


FGF-2 can activate all members of the FGF receptor (FGFR) family, with FGFR1 and FGFR2 the prominent forms present in the cerebral cortex (Reuss and Bohlen und Halbach, 2003). Like any typical tyrosine kinase receptor, FGFRs are composed of an extracellular ligand-binding domain composed of three immunoglobulin-like domains, a single transmembrane domain, and an intracellular domain with catalytic protein tyrosine kinase activity (Mohammadi et al., 1996a). Two molecules of FGF-2 bind to FGFRs, which triggers dimerization and activation of tyrosine kinase activity through autophosphorylation (Schlessinger et al., 1995; Mohammadi et al., 1996b). Previous studies from our lab showed that in primary mouse cortical culture, FGFR1 is the most prevalent receptor, followed by FGFR2, and both are mostly expressed in astrocytes (Fig. 1.11).



**FIGURE 1.11. Expression of mRNA for FGFR1 and FGFR2 in cerebral cortex, neuronal-enriched cultures, and glial-enriched cultures.**

Bps, base pairs; CTX, cerebral cortex; A, glia-enriched cortical cultures; N, neuronal-enriched cortical cultures. Three isoforms of both FGFR1 and FGFR2 were detected. From (Lobner and Ali, 2002).

Upon activation, at the carboxy terminal tail of the FGFR, autophosphorylation on a tyrosine residue (Tyr766) creates a specific binding site for PLC (Mohammadi et al., 1992; 1996a) and activates it to catalyze the hydrolysis of PIP<sub>2</sub> to generate two secondary messengers: IP<sub>3</sub> and DAG. Also, fibroblast growth factor receptor substrate 2 (FRS2) constitutively docks at the juxtamembrane domain of FGFRs (Reuss and Bohlen und Halbach, 2003; Eswarakumar et al., 2005). In response to FGFR activation, the docking proteins become tyrosine phosphorylated and recruit protein complexes and activate multiple intracellular signal transduction pathways, such as PI3K/Akt and mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways (Kouhara et al., 1997; Ojeda et al., 2011). The PLC activation mediated effects are independent from the FRS2 mediated effects (Fig. 1.12.).



**FIGURE 1.12. FGF-FGFR1 intracellular signaling pathways.**

Activation of fibroblast growth factor receptor 1 (FGFR1) requires binding of two fibroblast growth factor-2 (FGF-2) molecules, and two independent intracellular pathways are activated: phospholipase C (PLC), which leads to generation of two secondary messengers, inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacyl glycerol (DAG); fibroblast growth factor receptor substrate 2 (FRS2) mediated activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway.

### **FGF-2 regulation, function and dysfunction in diseases**

#### ***FGF-2 in ischemia/stroke***

FGF-2 expression is upregulated rapidly in the brain after lesioning or ischemic insult (Frautschy et al., 1991). Most of the FGF-2 expression is in astrocytes, with only some of the neurons close to the lesion core showing increased FGF-2 levels (Wei et al., 2000). Because of the success of FGF-2 in animal models of ischemia, it has been considered as a candidate for stroke treatment in humans (Ay et al., 1999; Ren and Finklestein, 2005). However, clinical trials of trafermin (recombinant human FGF-2) administration in human acute ischemic stroke were unsuccessful. Administration of

FGF-2 failed to produce any significant protection in the treated groups as compared with the control groups (Clark et al., 2000; Bogousslavsky et al., 2002). Instead, there was an increased mortality rate in the treated patients (Clark et al., 2000; Bogousslavsky et al., 2002). One hypothesis was that although FGF-2 is a cationic peptide that can be transported across the blood brain barrier at a higher rate than most other growth factors (Deguchi et al., 2000), due to the limited transportation efficiency, high doses were required to produce the central effect, which caused more peripheral side effects, such as vasodilatation (Cuevas et al., 1991; Rosenblatt et al., 1994). In light of our finding of FGF-2 induced increased system  $x_c$ - function, enhanced excitotoxicity must also be considered as a possibility.

### ***FGF2 in major depression/anxiety***

FGF-2 was recently suggested as a potential antidepressant (Turner et al., 2008c; Perez et al., 2009). Human postmortem studies indicate decreased FGF system function in the frontal cortex (Evans et al., 2004) and hippocampus (Gaughran et al., 2006) of patients who suffered from major depression. Patients with a history of antidepressant treatment showed attenuated FGF signaling dysregulation (Evans et al., 2004). In rodent studies, both FGF-2 and FGFR1 levels were decreased in hippocampus following social defeat (Turner et al., 2008a). Also, in a rodent model where rats were selectively bred to enhance different emotional behavior, lowered FGF-2 levels in the hippocampus were observed in the high anxiety group comparing to the low anxiety group (Perez et al., 2009). Exposure to an enriched environment effectively reduced anxiety behavior of the high anxiety group, and this was accompanied by increased FGF-2 levels in the



hippocampus (Perez et al., 2009). Chronic exogenous FGF-2 treatment produced the same behavioral effects (Perez et al., 2009). Furthermore, administration of FGF-2 during development prevented the low responders from exhibiting high anxiety-like behavior in adult (Turner et al., 2011). Administration of FGF-2 was also reported to reduce anxiety-like behaviors in the forced swim test model (Turner et al., 2008c). Antidepressants were shown to be able to increase FGF-2 levels in brain regions, such as prefrontal cortex, hippocampus, and striatum in rodents (Mallei et al., 2002; Maragnoli et al., 2004). Therefore, the evidence of FGF-2 dysregulation in depression is strong.

### ***FGF-2 and schizophrenia***

Schizophrenia is believed to be a result of interplay of both genetic predisposition and environmental risk factors (Tsuang, 2000). Prenatal stress has been suggested as an important environmental risk factor (Tsuang, 2000; Terwisscha van Scheltinga et al., 2010), and it has been shown to decrease FGF2 expression in rat entorhinal cortex and striatum, as well as FGF-2 levels in response to acute and chronic stresses in various brain regions in adult (Fumagalli et al., 2005). Social defeat is another risk factor for schizophrenia (Selten and Cantor-Graae, 2005; 2007). In adult rats, both FGF-2 and FGFR1 mRNA in hippocampus are downregulated after social defeat (Turner et al., 2008a). Smoking of cannabis is another environmental factor that is known to increase the risk of developing schizophrenia (Moore et al., 2007). Cannabinoid receptor type 1 antagonists have been shown to inhibit axonal growth responses stimulated by FGF-2 (Williams et al., 2003). Decreased FGFR1 mRNA levels in dentate gyrus were reported in a mouse knockout model of neuronal PAS domain protein 3, a familial mutation

involved in schizophrenia (Kamnasaran et al., 2003; Pieper et al., 2005), and two different FGFR1 knockout mice showed “schizophrenia-like characteristics” (Ohkubo et al., 2004; Shin et al., 2004; Klejbor et al., 2006).

Schizophrenia is also believed to involve impairments in connections between neurons, and between different brain regions, which could result from abnormal development (Foucher and Luck, 2006). FGF-2 has been shown to promote dendritic growth in the hippocampus (Rai et al., 2007), as well as promote embryogenesis and increase cerebral cortex volume (Vaccarino et al., 1999). FGF-2 knockout mice show decreased neuronal number in the cerebral cortex (Turner et al., 2006).

Several antipsychotic drugs have been shown to change FGF-2 mRNA levels in both human (Hashimoto et al., 2003) and rat hippocampus (Gómez-Pinilla et al., 2000; Ovalle et al., 2001; Fumagalli et al., 2004; Maragnoli et al., 2004). On the other hand, postmortem studies showed that FGF-2 mRNA in the hippocampus was decreased in clozapine treated schizophrenic patients compared with the nontreated (Gaughran et al., 2006).

Therefore, there is a strong association between FGF-2 dysregulation and schizophrenia. Schizophrenia is also associated with decreased glutathione and glutamate dysfunction in the brain (Pérez-Neri et al., 2006; Ballatori et al., 2009). These suggest the possibility of FGF-2 dysregulation mediated effects being due to its regulation of system  $x_C^-$ .

### ***FGF-2 and addiction***

FGF-2 has also been suggested to be involved in addiction. Agonists of dopaminergic D2 receptors increase FGF-2 gene expression in rat prefrontal cortex and hippocampus (Fumagalli et al., 2003). Both acute and chronic exposure to cocaine increases FGF-2 expression in rat striatum, prefrontal cortex, hippocampus, and frontal cortex (Fumagalli et al., 2006). Rats that were selectively bred for enhanced drug seeking behavior have higher FGF-2 expression levels (Turner et al., 2009). Postnatal administration of FGF-2 enhances acquisition of cocaine self-administration in adults (Turner et al., 2009). However, the functional involvement of FGF-2 in addiction has been little studied.

## **SYSTEM XC- CONTRIBUTION TO CELL DEATH/SURVIVAL**

### **Oxidative glutamate toxicity**

In vitro experiments demonstrated that immature neurons rely heavily on system  $x_C^-$  activity to take up cystine (Murphy et al., 1990). They lack glutamatergic receptors; so instead of causing excitotoxicity, high levels of extracellular glutamate cause toxicity in these cells by competitively inhibiting system  $x_C^-$ , causing oxidative glutamate toxicity (Murphy and Baraban, 1990; Schubert and Piasecki, 2001; Lewerenz et al., 2006). The oxidative glutamate toxicity is characterized by depletion of GSH (Miyamoto et al., 1989; Murphy et al., 1989; Murphy and Baraban, 1990; Murphy et al., 1990), and has characteristics of both apoptosis and necrosis (Tan et al., 1998). Similar oxidative glutamate toxicity is also observed in neuroblastoma-primary retina hybrid cells (N18-

RE105) (Miyamoto et al., 1989), primary rat hippocampal neurons (Murphy et al., 1989), a mouse hippocampal cell line (HT-22) (Tan et al., 2001), and primary oligodendrocytes (Oka et al., 1993).

### **Increased system $x_C^-$ activity: protection against oxidative stress**

Upregulation of system  $x_C^-$  has been shown to be protective against oxidative stress in multiple systems. Fast proliferating primary brain glial-derived tumor cells produce high levels of ROS. These cells rely primarily on system  $x_C^-$  to take up cystine to produce GSH, therefore, inhibiting system  $x_C^-$  decreases the growth of these tumor cells (Chung et al., 2005). High system  $x_C^-$  activity might contribute to the high tolerance of human ovarian cancer cells to anticancer treatments (Okuno et al., 2003). In mouse neural stem cells, hypoxic preconditioning increases system  $x_C^-$  function and strengthens the cell's resistance to oxidative glutamate toxicity (Sims et al., 2012). This preconditioning produced protection is absent when either system  $x_C^-$  is blocked by S-4-carboxyphenyl glycine (CPG), or GSH synthesis is blocked by buthionine sulphoximine (Sims et al., 2012). IGF-1 and TGF- $\beta$  increase cystine uptake through system  $x_C^-$  on dental pulp cells, which leads to protection against oxidative stress (Pauly et al., 2011). Retinoic acid increases SH-SY5Y cell (a human dopaminergic neuroblastoma cell line) tolerance for 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>) compared to untreated cells (Crockett et al., 2011). This is because retinoic acid increases system  $x_C^-$  activity, which increases GSH levels and protects the cells from these oxidative insults (Crockett et al., 2011). Upregulating Nrf2, one of the well-characterized pathways that regulate xCT expression, is also known to protect both glial

cells and neurons from oxidative stress insults in a PI3K/Akt dependent manner (Shih et al., 2003; Wang et al., 2009). Ceftriaxone protects fibroblasts and the hippocampal cell line HT22 from oxidative glutamate toxicity by upregulating system  $x_C^-$  through the Nrf2-ARE pathway (Lewerenz et al., 2009). All of this data suggests that increasing system  $x_C^-$  can increase cystine uptake, which can lead to increased glutathione production, and provide protection against oxidative stress.

### **Increased system $x_C^-$ activity: enhanced excitotoxicity**

Increasing system  $x_C^-$  activity is not always protective. Activated microglia have increased glutamate release via system  $x_C^-$ , which causes oligodendrocyte excitotoxicity through AMPA receptors (Domercq et al., 2007). Interleukin  $1\beta$  (IL- $1\beta$ ) upregulates system  $x_C^-$  activity selectively on astrocytes, but not neurons (Jackman et al., 2010). This increased system  $x_C^-$  activity is responsible for exacerbating neuronal cell death mediated by excitotoxicity when the cultures are exposed to hypoxia (Fogal et al., 2007) or glucose deprivation (Jackman et al., 2012). These studies demonstrate that when system  $x_C^-$  activity is increased, glutamate release is also increased, which can potentially exacerbate excitotoxicity.

## **POTENTIAL ROLE OF SYSTEM $x_C^-$ IN NEUROLOGICAL DISORDERS**

### **Alzheimer's disease (AD)**

AD is a common neurodegenerative disorder in elderly people. It is characterized by progressive memory loss and impaired cognitive function. Amyloid- $\beta$  ( $A\beta$ ) plaques and formation of neurofibrillary tangles are the characteristic hallmarks of this disease.

A $\beta$  is a normal product of the brain, therefore, the abnormal deposition must be due to an over production and/or impaired clearance. Astrocytes can degrade A $\beta$  (Koistinaho et al., 2004; Pihlaja et al., 2011). However, A $\beta$  can make astrocytes reactive, which can contribute to neuronal degeneration (Olabarria et al., 2010). There are increased levels of phosphorylated eIF2 $\alpha$  (Chang et al., 2002; Unterberger et al., 2006) and ATF4 (Lewerenz and Maher, 2009) in AD patient's brains, which are shown to be involved in xCT regulation (Lewerenz and Maher, 2009). In fact, in PC12 cells, induction of eIF2 $\alpha$  phosphorylation using the specific eIF2 $\alpha$  phosphatase inhibitor, salubrinal, increased ATF4 levels, system x<sub>C</sub><sup>-</sup> activity, and resistance to A $\beta$  toxicity (Lewerenz and Maher, 2009). Therefore, it is most likely that the increase of eIF2 $\alpha$  and ATF4 is an adaptation to the increased A $\beta$  accumulation. However, secreted A $\beta$  precursor protein (APP) can activate microglia and stimulate system x<sub>C</sub><sup>-</sup> mediated glutamate release from microglia, which leads to decreased synaptic density and neuronal viability (Barger and Basile, 2001). Therefore, it is not clear whether upregulation of system x<sub>C</sub><sup>-</sup> during AD is beneficial or harmful.

### **Parkinson's disease (PD)**

PD is a common nervous system disorder in the elderly that is characterized by degeneration of dopaminergic cells in the substantia nigra, resulting in symptoms such as difficulties in initiating and finishing voluntary movements, tremors, stiff movements, and eventually leads to muscle atrophy (Obeso et al., 2010). Extensive postmortem studies have reported that increased oxidative stress, decreased GSH, and increased oxidative damage to lipids, protein and DNA are observed in PD (Jenner and Olanow,

1996; Simonian and Coyle, 1996). Increased striatal glutamate (Massie et al., 2011) and decreased nigral glutathione (Schulz et al., 2000) have both been indicated to contribute to dopaminergic cell degeneration.

Involvement of system  $x_C$ - in animal models of PD has been studied.  $xCT$  is upregulated in the striatum three weeks after 6-OHDA lesion of the nigrostriatal area (Massie et al., 2008). Also, 24 hour 6-OHDA treatment increases system  $x_C$ - mediated cystine uptake in C6 glioma cells in a dose dependent manner (Massie et al., 2008). In  $xCT$  null mice, striatal glutamate levels are significantly lower compared to control suggesting that system  $x_C$ - is responsible for the majority of extracellular glutamate (Baker et al., 2002; De Bundel et al., 2011; Massie et al., 2011). The absence of  $xCT$  decreased the susceptibility of substantia nigra dopaminergic neurons to 6-OHDA toxicity (Massie et al., 2011). These data suggest that system  $x_C$ - function may have a net damaging effect in PD, but it must be kept in mind that the 6-OHDA lesion model is not an ideal model of PD.

### **Amyotrophic lateral sclerosis–Parkinsonism dementia complex (ALS-PDC)**

ALS-PDC is a neurological disease that is also known as lytico-bodig to the Chamorro people on the island of Guam (Reed and Brody, 1975). The disease has aspects of ALS, PD, and AD: muscular weakness, spasticity, flaccid paralysis and atrophy, and spinal-cord pathology similar to that are seen in ALS, tremors seen in PD, neurofibrillary tangles similar to these occurring in brain tissue in AD, and dementia that is seen both in PD and AD (Spencer et al., 1987; Liu et al., 2009). The disease has been known to be occurring on Guam for about 200 years (Kurland and Mulder, 1954).

However, an outbreak of ALS-PDC in the 1940s to 1960s gained attention because the incidence in the Chamorro population was 100 times higher than ALS elsewhere (Kurland and Mulder, 1954; Spencer et al., 1986). The etiology of ALS-PDC remains uncertain, dietetic, environmental and genetic factors have all been considered (Ince and Codd, 2005).

At first, genetic factors were considered as the cause since certain villages and families had higher rates of ALS-PDC. However, no genetic mutation that was found that could account for the disease, and later studies indicated that adopting the local life style and traditional diet had a significant association with the disease (Garruto et al., 1981).


### ***$\beta$ -N-methylamino-L-alanine (BMAA)***

BMAA is a non-protein amino acid that is one of the many potential toxins found in cycad plants (Spencer et al., 1987; Cox et al., 2003). It was proposed as a possible environmental trigger for ALS-PDC on Guam (Spencer et al., 1987). The local Chamorro people collect the cycad seeds for food and medicine (Bradley and Mash, 2009). The local flying foxes (fruit bats) also feed on cycad seeds and it was found that BMAA accumulates at high levels in these bats (Cox and Sacks, 2002; Cox et al., 2003; Monson et al., 2003). Flying fox stew was served as a local courtesy dish until its extinction in the 1960s, after which time the incidence of ALS-PDC declined.

BMAA was found to mimic glutamate and activate glutamatergic receptors when bicarbonate is present (Weiss and Choi, 1988; Richter and Mena, 1989) (Fig. 1.13), and BMAA was found to cause excitotoxicity when physiological concentration of



bicarbonate was present in the media (Weiss and Choi, 1988; Weiss et al., 1989b). The BMAA carbonate competes with glutamate at synapses (Richter and Mena, 1989) and was shown to have direct binding to the NMDA receptors (Weiss et al., 1989a).



Glutamate (neurotransmitter)    BMAA carbamate ion (neurotoxin)

**FIGURE 1.13. Structural similarities between the neurotransmitter L-glutamate and the neurotoxic carbonate adduct of BMAA.**

From (Erdner et al., 2008)

Oral bioavailability conducted in cynomolgous monkeys indicated that 80% of the administered BMAA was absorbed into the systemic circulation (Duncan et al., 1992). More specifically, BMAA crosses the blood-brain barrier, and is retained at high levels in the central nervous system (Kisby et al., 1988; Duncan et al., 1991; Smith et al., 1992).

BMAA bicarbonate mimicking glutamate is not the only mechanism of BMAA actions, since it also increases calcium levels in dissociated rat brain cells in bicarbonate-free media (Brownson et al., 2002). In previous studies, we found that BMAA can cause cell death of primary cultured cortical neurons by activating glutamatergic receptors such as NMDA and mGluR5 (Lobner et al., 2007). In this thesis we present evidence that BMAA also acts as a substrate for system  $x_C^-$  and by doing so both inhibits cystine uptake and stimulates glutamate release (Liu et al., 2009).

### ***Heavy metals***

Heavy metal toxicity was another hypothesis for ALS-PDC (Johnson and Atchison, 2009). However, no clear evidence of heavy metal toxicity was discovered. Since the outbreak of Minamata disease in Japan in 1956, due to an industrial release of methylmercury (MeHg) (Harada, 1995), MeHg has received attention for its neurotoxic actions both during development and in adults.

MeHg is an environmental neurotoxin that is most often consumed through contaminated seafood (Rush et al., 2012a). It is not directly associated with ALS-PDC, but has been implicated in neurodegenerative diseases (Wang et al., 2008). In vivo studies suggest that the major localization of MeHg is in glial cells (Charleston et al., 1995). Further studies showed that in glial cells MeHg decreases GSH levels (Aschner et al., 1994) and disrupts glutamatergic and GABAergic homeostasis (Schousboe et al., 1992). In astrocytes, MeHg exposure activates the Nrf2-ARE pathway to upregulate a series of antioxidative proteins and increases GSH levels (Wang et al., 2008; Niciu et al., 2012). We have shown that MeHg induces increased system  $x_C^-$  activity in primary mixed neuronal and glial cortical culture (Fonnum, 1984; Rush et al., 2012b). Interestingly, we also showed that MeHg and BMAA synergistically deplete cellular GSH levels and induced toxicity to neuronal cells in primary cultures (Petroff, 2002; Schousboe and Waagepetersen, 2007; Rush et al., 2012a).

### **Ischemia/Stroke**

Stroke is caused by disturbance in the blood supply to the brain, which leads to rapid loss of brain functions and often results in permanent neurological damage (Meister

and Anderson, 1983; Dringen et al., 2000; Kalra and Ratan, 2008). It is one of the leading causes for death and disability, especially in the elderly population (Erecińska and Silver, 1990; Choi, 1998). Injury induced increases in IL-1 $\beta$  from microglia may exacerbate ischemic injury, because IL-1 receptor type I deficient mice show smaller infarcts compared to wild type animals following 90 minute reversible middle cerebral artery occlusion (Dingledine et al., 1999; Fogal et al., 2007). In vitro data shows that IL-1 $\beta$  selectively upregulates system  $x_C^-$  levels on astrocytes but not neurons, and that glutamate released from system  $x_C^-$  enhances hypoxic neuronal death (Jackman et al., 2010; Niciu et al., 2012). Therefore, IL-1 $\beta$  mediated ischemic damage may be mediated by its upregulation of system  $x_C^-$ . In contrast, erythropoietin has been shown to be protective against ischemic neuronal injury (Noguchi et al., 2007; Niciu et al., 2012). Interestingly, erythropoietin increases  $xCT$  expression in B104 cells, and this upregulation can protect the cells from oxidative glutamate toxicity (Dingledine et al., 1999; Sims et al., 2010). Ischemic preconditioning, which protects cells from further ischemic stress, has also been shown to upregulate system  $x_C^-$  (Jonas et al., 1994; Sims et al., 2012). It is possible that the net effect of upregulation of system  $x_C^-$  on ischemia induced cell death is dependent on the cell type on which it is upregulated.

## **Glioma**

Gliomas are a type of tumor that arise from glial cells and are the most common type of brain tumor (Sontheimer, 2003; Clem and Barth, 2006). Glioma cells have increased need for GSH because of their fast dividing rate. When glioma cells experience oxidative stress, system  $x_C^-$  is rapidly upregulated to maintain the GSH levels

(Schneggenburger et al., 1993; Kim et al., 2001). Glioma cells release a large amounts of glutamate into the extracellular space because of the high system  $x_C^-$  activity (Dingledine et al., 1999; Ye and Sontheimer, 1999), but they also lack sodium-dependent glutamate transporters that clear glutamate from extracellular space (Dingledine et al., 1999; Ye et al., 1999). The combination of these actions cause excitotoxicity to surrounding neuronal cells and promotes glioma growth at the same time (Béhé et al., 1995; Premkumar and Auerbach, 1997; Takano et al., 2001). Therefore, glioma cells utilize system  $x_C^-$  to kill surrounding neuronal cells by releasing glutamate to cause excitotoxicity to make room for additional growth, and take up sufficient amounts of cystine through system  $x_C^-$  to make GSH to reduce oxidative stress (Patneau and Mayer, 1990; Burnashev et al., 1995; Sontheimer, 2003; 2008). The high system  $x_C^-$  activity also makes the tumor cells more resistant to drugs (Nowak et al., 1984; Lo et al., 2008). In mouse models of glioma tumors, the increased glutamate release can cause epileptic activity, which is a common symptom in the majority of glioma patients (Nowak et al., 1984; Dingledine et al., 1999; Buckingham et al., 2011). Because inhibiting system  $x_C^-$  suppresses glioma growth by depleting GSH (Johnson and Ascher, 1987; Schell et al., 1995; Chung and Sontheimer, 2009; Guan et al., 2009), it has been suggested as a treatment for gliomas (Chung and Sontheimer, 2009; Grienberger and Konnerth, 2012).

## **Addiction**

According to the American Society of Addiction Medicine, “addiction is a primary, chronic disease of brain reward, motivation, memory and related circuitry.” Decreased levels of basal extracellular glutamate resulting from disrupted system  $x_C^-$

function following chronic cocaine administration has been implicated in the pathophysiology of drug addiction (Conn and Pin, 1997; Baker et al., 2003; Ferraguti and Shigemoto, 2006; Kim et al., 2008; Lewerenz et al., 2012). System  $x_C^-$  provides most of the extrasynaptic glutamate in nucleus accumbens, which can activate group II mGluRs that are autoreceptors localized on presynaptic terminals (Baker et al., 2002; Niciu et al., 2012). Intracellularly, group II mGluRs couple to  $G_{i/o}$  to cause decreased cAMP levels and eventually lead to decreased neurotransmitter release from the presynaptic terminal (Kilbride et al., 2001; Niciu et al., 2012). Decreased group II mGluRs function has been reported after chronic cocaine administration (Xi et al., 2002; Niciu et al., 2012). Interestingly, before reinstatement of cocaine seeking, infusing cystine into the nucleus accumbens of chronic cocaine administrated animals not only eliminated the decreased extracellular glutamate levels, but also prevented acute cocaine induced increase in synaptic glutamate release (Choi, 1987; Baker et al., 2003). Administration of N-acetylcysteine, a cysteine pro drug, prevented cocaine induced reinstatement (Bains and Shaw, 1997; Choi, 1998; Baker et al., 2003; Moussawi et al., 2009). A logical explanation for these results is that chronic cocaine administration decreases glutamate release from system  $x_C^-$ , as well as decreases presynaptic group II mGluRs functions, which leads to decreased presynaptic inhibition of neurotransmitter release. After extinction, following acute cocaine administration, increased neurotransmitter release elicits reinstatement. However, when extrasynaptic glutamate levels are restored through increasing glutamate release by driving system  $x_C^-$  with cystine, presynaptic inhibition is restored, which prevents excessive synaptic glutamate release.

The exact mechanism by which cocaine decreases system  $x_C$ - activity is unknown. However, injections of N-acetylcysteine before each self-administration prevented chronic cocaine intake escalation (McDonald et al., 1998; Madayag et al., 2007), as well as blunted reinstatement (Pitt et al., 2000; Smith et al., 2000; Madayag et al., 2007; Kau et al., 2008). These studies showed that promotion of system  $x_C$ - function can prevent cocaine induced synaptic plasticity to a certain extent. The beneficial effect of N-acetylcysteine does not seem to be limited to preventing the synaptic plasticity caused by cocaine administration, but also involves the ability to reverse some plasticity caused by cocaine administration. Infusion of N-acetylcysteine after drug administration also restores basal extracellular glutamate levels (Yoshioka et al., 1996; Bannerman et al., 2007; Moussawi et al., 2009), and blunts reinstatement (Erecińska and Silver, 1990; Amen et al., 2011). Ceftriaxone, which induces  $xCT$  expression and increases system  $x_C$ - function (Barbour et al., 1988; Zerangue and Kavanaugh, 1996a; Lewerenz et al., 2009), was also shown to be able to restore cocaine administration induced decrease in extracellular glutamate back to normal and prevent relapse to cocaine seeking (Ventura and Harris, 1999; Knackstedt et al., 2010; Witcher et al., 2010).

## **GENERAL METHODS**

In this dissertation all of the studies utilize primary cell cultures. Following is an overview of the essential methods used in the studies, with a brief assessment of the advantages and limitations of these procedures.

## Cortical Culture

Cortical cell culture is a well-established system for modelling aspects of in vivo systems. For these studies, the cortex is dissected from mice on gestational day 15. Cortices from the same litter are dissociated, then trypsinized before plating in Eagle's minimum essential media containing 5% heat-inactivated horse serum and 5% fetal bovine serum on poly-D-lysine and laminin coated 24 well plates. Cultures are then incubated in a 5% CO<sub>2</sub> incubator at 37°C for two weeks before being used for experiments. Every six to eight embryos yield one plate. In a mature mixed plate the neurons (~200,000) extend out axons and dendrites to form complicated networks, below the neurons, glial cells (~100,000) form a confluent layer. Similarly, we can also make neuronal-enriched and glia-enriched cultures. By adding cytosine arabinocide, a mitotic inhibitor, 2-3 days after plating, glial replication is eliminated producing neuronal-enriched cultures. By delaying the dissection until postnatal day one, neurons do not survive producing glia-enriched cultures. These procedures provide a complex, but easily reproducible, in vitro system in which to perform studies.

However, there are some limitations of this culture system. The cells can only be maintained in vitro for a maximum of about 3 weeks, and even during that time cells are continually dying, this limits the ability to mimic low-dose, long-term insults. Most of our experiments are performed on cultures DIV 13-15, with insults lasting 24-48 hours. Also, as a common limitation of all cell culture studies, the cells are maintained in a media that is optimized for cell health, and is not exactly the same as that in vivo. These limitations should always be kept in mind when interpreting cell culture studies.

## Cell death assay

To quantify the cell death/survival, plate reader based assays are used. Lactate dehydrogenase (LDH) is a large cytosolic enzyme that is normally retained in the cells. However, in the event of cell damage/death, the cell membrane is compromised and the cellular contents, including LDH, leak out into the extracellular culture media. The amount of LDH being released is proportional to the amount of dead cells. The assay for LDH involves the fact that it catalyzes the conversion of pyruvate to lactic acid using NADH. By sampling the extracellular media, then adding pyruvate and NADH, the amount of LDH present can be determined by measuring the rate of NADH loss using an absorbance based plate reader. By comparing experimental groups to the control group and full kill (neuronal full kill is achieved by adding 500  $\mu$ M NMDA to induce excitotoxicity; glial full kill is achieved by adding 20  $\mu$ M A23187, a calcium ionophore, to cause calcium overload to induce cell death), the relative percentage of cell death can be obtained. Another assay we use to measure neuronal injury is the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. MTT can be reduced by mitochondrial reductase enzymes forming a dark purple formazan compound. By measuring the formazan levels, an indirect measure of cell viability is obtained. The results of these automated assays are confirmed for key experiments by trypan blue staining, which is a blue dye that only stains the cells whose membrane is compromised.

The automated assays provide a fast and accurate way of assessing cell death. However, one should keep in mind that reagents that can potentially alter the function of the enzymes that are used for the assays may alter the results. For example, LDH function can be altered by hypoxia (Soñanez-Organis et al., 2012), anoxia (Xiong and




Storey, 2012), and growth factors (Matrisian et al., 1985). Also, these assays utilize changes in absorbance to detect color changes to measure enzyme activity. Therefore, reagents that interfere with absorbance detection may dramatically change the results. Because of these confounding factors visual examination and estimation of cell death is always performed.

### **<sup>14</sup>C-cystine uptake**

Under physiological conditions, system x<sub>C</sub><sup>-</sup> transports cystine into cells in exchange for glutamate being transported out. To assess system x<sub>C</sub><sup>-</sup> activity, we take advantage of the amino acid transport function of system x<sub>C</sub><sup>-</sup> and measure the uptake of <sup>14</sup>C-cystine. The advantage of measuring cystine uptake, as opposed to glutamate uptake or release, is that, in our primary cortical cultures, cystine does not directly interact with receptors on the cell membrane. In contrast, there are a large amount of glutamatergic receptors and transporters present on the membrane. However, there are some drawbacks to using <sup>14</sup>C-cystine uptake as measure of system x<sub>C</sub><sup>-</sup> function. Cystine taken up by cells is quickly broken down into cysteine, and this can happen extracellularly as well. Therefore, the uptake data may be a mixture of cystine/cysteine uptake. Since system x<sub>C</sub><sup>-</sup> only transports cystine, not cysteine, this problem can be addressed by blocking system x<sub>C</sub><sup>-</sup> to dissect out the system x<sub>C</sub><sup>-</sup> mediated uptake activity. Intracellularly, cysteine can be used to synthesize glutathione, and other cysteine containing molecules, which can be exported. Therefore, with long-term treatment times the uptake data may be a compromised by changes in the efflux rate. To address this concern we compared <sup>14</sup>C-cystine uptake for 2 and 20 minutes with or without 24 hour FGF-2 treatment (Fig. 1.14).

The two time points gave similar results, suggesting that 20 minutes is not too long of a period to measure uptake under these conditions.



**FIGURE 1.14. 24 hour FGF-2 treatment on 2 min and 20 min cystine uptake**

Following 24 hour exposure to FGF-2 (100 ng/ml), <sup>14</sup>C-cystine uptake was measured for 2 min and 20 min in astrocyte-enriched cultures. Data are expressed as <sup>14</sup>C-cystine uptake in CPM per microgram protein normalized to control (mean±s.e.m., n=4) (A). \* indicates significantly different from control uptake.

## CHAPTER II

**$\beta$ -N-methylamino-L-alanine induces oxidative stress and glutamate  
release through action on system  $x_C^-$**

**ABSTRACT**

$\beta$ -N-methylamino-L-alanine (BMAA) is a non-protein amino acid implicated in the neurodegenerative disease amyotrophic lateral sclerosis and Parkinson-dementia complex (ALS-PDC) on Guam. BMAA has recently been discovered in the brains of Alzheimer's and ALS patients in North America and is produced by various species of cyanobacteria around the world. These findings suggest the possibility that BMAA may be of concern not only for specific groups of Pacific Islanders, but for a much larger population. Previous studies have indicated that BMAA can act as an excitotoxin by acting on the NMDA receptor. We have shown that the mechanism of neurotoxicity is actually three-fold; it involves not only direct action on the NMDA receptor, but also activation of metabotropic glutamate receptor 5 (mGluR5) and induction of oxidative stress. We now explore the mechanism by which BMAA activates the mGluR5 receptor and induces oxidative stress. We found that BMAA inhibits the cystine/glutamate antiporter (system  $x_C^-$ ) mediated cystine uptake, which in turn leads to glutathione depletion and increased oxidative stress. BMAA also appears to drive glutamate release via system  $x_C^-$  and this glutamate induces toxicity through activation of the mGluR5 receptor. Therefore, the oxidative stress and mGluR5 activation induced by BMAA are both mediated through action at system  $x_C^-$ . The multiple mechanisms of BMAA toxicity, particularly the depletion of glutathione and enhanced oxidative stress, may account for its ability to induce complex neurodegenerative diseases.

## **INTRODUCTION**

In the 1950s it was observed that a substantial number of Chamorros, the native people of Guam, began developing a disease that showed combined symptoms of amyotrophic lateral sclerosis and Parkinson's dementia complex (ALS-PDC). The idea that BMAA may be involved in this disease began in the 1980s when it was found that BMAA was present in cycad seeds which were consumed by the Chamorros (Nunn et al., 1987; Amara, 1992; Kanai and Hediger, 1992; Storck et al., 1992; Rothstein et al., 1994; 1996; Diamond and Jahr, 1997; Lehre and Danbolt, 1998) and that injection of BMAA into monkey brains induced a Parkinson-like disease (Spencer et al., 1987; Sibson et al., 1998). Since its initial proposal, the BMAA hypothesis for the development of ALS-PDC on Guam has been controversial (Rothstein et al., 1996; Asztely et al., 1997; Rusakov and Kullmann, 1998; Cox and Sacks, 2002; Papapetropoulos, 2007). It was challenged by findings that the levels of BMAA in cycad seeds are too low to cause damage to the brain or the spinal cord, particularly because the Chamorros thoroughly wash the cycad seeds, leading to very low levels of BMAA being consumed (Duncan et al., 1990; Hardingham et al., 2002; Riccio and Ginty, 2002; Ivanov et al., 2006; Léveillé et al., 2008; Xu et al., 2009; Hardingham and Bading, 2010). The BMAA hypothesis was largely abandoned until the last few years.

A number of recent studies have brought the BMAA hypothesis back into prominence. First, it was shown that BMAA is biomagnified. BMAA is produced by cyanobacteria that live on cycad plants; it accumulates in the cycad seeds, which are eaten by fruit bats, which are in turn eaten by the Chamorros (Cox et al., 2003; Lipton and Chen, 2004; Xia et al., 2010). This system provides a new mechanism by which

BMAA can be accumulated to high levels in humans. Second, it was shown that BMAA could become protein-associated. This property allows for BMAA to build up in tissue and provides a mechanism for slow release (Lipton and Chen, 2004; Murch et al., 2004b; Chen and Lipton, 2006; Xia et al., 2010). This slow release may provide a possible explanation for the delayed onset of ALS-PDC following the time of BMAA consumption (Ince and Codd, 2005; Niciu et al., 2012). Third, cyanobacteria present throughout the world have been shown to produce BMAA (Futamachi and Pedley, 1976; Roitbak and Fanardjian, 1981; Cox et al., 2005; Banack et al., 2007; Esterhuizen and Downing, 2008; Johnson et al., 2008; Metcalf et al., 2008). Also, BMAA was found not only in brain samples of ALS-PDC patients from Guam, but also in the brains of ALS and Alzheimer's disease patients from North America, but not in patients who died of other causes (Venance et al., 1997; Murch et al., 2004a; Pablo et al., 2009). These results suggest that BMAA may be of concern not only for people on select Pacific islands, but for a much larger population. Fourth, BMAA at lower concentrations than previously believed is neurotoxic. The original studies in cortical cell culture found that very high BMAA concentrations (1-3 mM) were required to induce neuronal death (Ross et al., 1987; Weiss and Choi, 1988; Weiss et al., 1989a; Oikawa et al., 2005). A more recent study found that BMAA concentrations as low as 30  $\mu$ M can cause selective death of motor neurons (Rao et al., 2006; Butt, 2011; Köles et al., 2011) and cholinergic neurons (Venance et al., 1997; Agulhon et al., 2008; Liu et al., 2010), and we found that BMAA concentrations as low as 10  $\mu$ M can enhance neuronal death induced by amyloid- $\beta$  or 1-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>) (Seifert and Steinhäuser, 2001; Lobner et al., 2007).

Given the potential relevance of BMAA consumption to neurodegenerative diseases it is important to determine the mechanism of BMAA induced neuronal death. We have previously shown that BMAA induces neuronal death through three distinct mechanisms: activation of the NMDA and mGluR5 receptors, and induction of oxidative stress (Lobner et al., 2007; Benarroch, 2009). Through electrophysiological recording it has been shown that BMAA directly acts on NMDA receptors (Ross et al., 1987; Weiss and Choi, 1988; Brownson et al., 2002; Lobner et al., 2007; Poskanzer and Yuste, 2011). The current studies were designed to determine how BMAA activates mGluR5 receptors and induces oxidative stress. Evidence is presented that the cystine/glutamate antiporter (system  $x_C^-$ ) plays an important role in these effects. System  $x_C^-$  involves the transport of cystine into the cell in exchange for glutamate being transported out of the cell. Given the functions of system  $x_C^-$  it seems likely that it plays an important role in neuronal survival and death. By releasing glutamate it can increase extracellular glutamate levels and potentially cause excitotoxicity. Through providing cystine uptake, it can regulate cellular glutathione levels and in this way determine whether oxidative stress induced neuronal death will occur. We find that the effects of BMAA on neuronal death involve actions on system  $x_C^-$  to both inhibit cystine uptake and increase glutamate release.

## **MATERIALS AND METHODS**

### **Materials**

Timed pregnant Swiss Webster mice were obtained from Charles River Laboratories (Wilmington, DE).  $^{35}\text{S}$ -cystine was from Perkin Elmer Life and Analytical Sciences (Boston, MA). 5-(and -6)-carboxy-2'7'-dichlorodihydrofluorescein diacetate

(carboxy-H<sub>2</sub>DCFDA) was from Molecular Probes (Eugene, OR).

### **Cortical cell cultures**

Mixed cortical cell cultures containing neuronal cells were prepared from fetal (15-16 day gestation) mice as previously described (Cornell-Bell et al., 1990; Lobner, 2000). Dissociated cortical cells were plated on 24 well plates coated with poly-D-lysine and laminin in Eagles's Minimal Essential Medium (MEM, Earle's salts, supplied glutamine-free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2 mM glutamine and glucose (total 21 mM). Cultures were maintained in humidified 5% CO<sub>2</sub> incubators at 37°C. Mice were handled in accordance with a protocol approved by our Institutional Animal Care Committee.

### **Induction of neuronal death**

All experiments were performed on mixed cultures 13-15 days in vitro (DIV). Toxicity was induced by exposure to the toxic agents for 24 hours in media as described for plating except without serum. All exposure media contained 26 mM NaHCO<sub>3</sub>, as it has been shown previously that HCO<sub>3</sub><sup>-</sup> is required for expression of NMDA receptor mediated BMAA toxicity (Weiss and Choi, 1988; Fellin et al., 2006; Butt, 2011; Parpura et al., 2012).

### **Assay of neuronal death (LDH release)**

Cell death was assessed in mixed cultures by the measurement of lactate dehydrogenase (LDH) release from damaged or destroyed cells, in the extracellular fluid



24 hours after the beginning of the insult. Blank LDH levels were subtracted from insult LDH values and results normalized to 100% neuronal death caused by 500  $\mu$ M NMDA. Control experiments have shown previously that the efflux of LDH occurring from either necrotic or apoptotic cells is proportional to the number of cells damaged or destroyed (Koh and Choi, 1987; Bezzi et al., 1998; Lobner, 2000; Bezzi et al., 2004; Kreft et al., 2004). Glial cell death (assessed by trypan blue staining) was not observed in any of the current studies. Therefore results are presented as percent neuronal death.

### **<sup>35</sup>S-cystine uptake**

Uptake of cystine was measured by exposure of cultures to <sup>35</sup>S-cystine (2  $\mu$ Ci/ml) for 20 min in the presence or absence of 3 mM BMAA and/or 1 mM S-4-carboxyphenyl glycine (CPG). Following the exposure to <sup>35</sup>S-cystine, the cultures were washed three times and dissolved in 1% SDS (250  $\mu$ l). An aliquot (200  $\mu$ l) was removed and added to scintillation fluid for counting. Values were normalized to control <sup>35</sup>S-cystine uptake (20 min exposure to <sup>35</sup>S-cystine without BMAA or CPG).

### **Glutathione assay**

Total glutathione was assayed using a modification of a previous method (Baker et al., 1990; Duan et al., 2003; Lobner et al., 2003). Briefly, following exposure to BMAA for three hours, cells were washed with a HEPES buffered saline solution, dissolved in 200  $\mu$ l of 1% salicylic acid, and centrifuged. A 25  $\mu$ l aliquot of the supernatant was combined with 150  $\mu$ l of 0.1 M phosphate/5 mM EDTA buffer, 10  $\mu$ l of 20 mM dithiobis-2-nitrobenzoic acid, 100  $\mu$ l of 5 mM NADPH, and 0.2 U of glutathione

reductase. Total glutathione was determined by kinetic analysis of absorbance changes at 402 nm for 1.5 min, with concentrations determined by comparison to a standard curve.

### **Assay of intracellular oxidative stress**

Oxidative stress was assayed by measuring dichlorofluorescein oxidation using a fluorescent plate reader following a modification of a previous method (Wang and Joseph, 1999; Bridges et al., 2004; Lobner et al., 2007). Cultures were exposed to 3 mM BMAA for 3 hours in the presence of 5- (and -6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H<sub>2</sub>DFDA) (10  $\mu$ M). The carboxy-H<sub>2</sub>DFDA is de-esterified within cells to form a free acid that can then be oxidized to the fluorescent 2',7'-dichlorofluorescein (DCF). After the exposure to carboxy-H<sub>2</sub>DCFDA, cultures were washed three times with culture media lacking serum. Fluorescence was then measured using a Fluoroskan Ascent fluorescence plate reader (Thermo lab systems). The excitation filter was set at 485 nm and emission filter at 538 nm. Background fluorescence (no carboxy-H<sub>2</sub>DCFDA added) was subtracted and the results normalized to control conditions (carboxy-H<sub>2</sub>DCFDA added, but no BMAA exposure).

### **Analysis of glutamate release**

Glutamate release was measured following exposure to 3 mM BMAA or cystine for 1 hour. Experiments were performed in the presence of 10  $\mu$ M MK-801 to block potential injury induced by glutamate release. Samples of the bathing media from the cell cultures were assayed for glutamate by using phenylisothiocyanate (PITC) derivatization, HPLC (Agilent 1100) separation using a Hypersil-ODS reverse phase

column, and ultraviolet detection at a wavelength of 254 nm (Cohen et al., 1986; Lobner and Choi, 1996; Magistretti and Pellerin, 1996; Edvinsson and Krause, 2002). 200 µl of the bathing media was derivatized with 100 µl of PITC, methanol, triethylamine (2,7,4) and dried under vacuum. These samples were then reconstituted in solvent consisting of 0.14 M sodium acetate, 0.05% TEA, 6% acetonitrile and brought to pH 6.4 with glacial acetic acid. The above solvent was used as the mobile phase with the column being washed between each sample run in 60% acetonitrile, 40% water. Media glutamate concentrations were calculated by normalizing to glutamate standards. Glutamate measurements were found to be linear over the range 0.1-10 µM.

### **Statistical analysis**


Differences between test groups were examined for statistical significance by means of one-way ANOVA followed by the Bonferroni t-test, with  $p < 0.05$  being considered significant.

## **RESULTS**

### **BMAA toxicity involves the NMDA receptor, mGluR5 receptor, and oxidative stress**

As has been shown before we found that blockade of NMDA receptors with MK-801 provided significant protection against high concentration BMAA toxicity (Ross et al., 1987; Weiss et al., 1989a; Dringen et al., 1993). As we have shown previously (Magistretti and Pellerin, 1996; Lobner et al., 2007) that the mGluR5 antagonist 6-methyl-2-[phenylethynyl]-pyridine (MPEP), and the free radical scavenger, trolox, were not protective by themselves, but provided additional protection against BMAA toxicity

beyond that provided by MK-801 (Fig. 2.1.). Furthermore, the combination of these agents provided the greatest protection, suggesting that they were acting through distinct mechanisms. The MPEP and trolox were not protective against BMAA toxicity with the MK-801 present likely because of the overwhelming toxic effects of BMAA on NMDA receptor in the absence of MK-801 (Lobner et al., 2007). Activation of AMPA/kainate receptors does not appear to be involved as we have shown previously that blocking AMPA/kainate receptors with CNQX is not protective even in the presence of MK-801 (Freeman and Crapo, 1982; Simonian and Coyle, 1996; Lobner et al., 2007). A high concentration of BMAA (3 mM) was used so that complete neuronal death was induced and the different mechanisms of toxicity could be studied.




**FIGURE 2.1. BMAA induced toxicity occurs through multiple mechanisms.**

MK: 10  $\mu$ M MK-801; MPEP: 50  $\mu$ M 6-methyl-2-[phenylethynyl]-pyridine (MPEP); trolox: 100  $\mu$ M trolox. Bars show % neuronal cell death (mean  $\pm$  s.e.m., n = 16-20) quantified by measuring release of LDH, 24 hours after the beginning of the insult.

\* indicates significant difference.

## BMAA induces oxidative stress through inhibition of system $x_C$ - mediated cystine uptake

One possibility for induction of oxidative stress by BMAA is that it inhibits cystine uptake. Cystine is the precursor for production of the endogenous free radical scavenger, glutathione. We found that BMAA did in fact greatly attenuate cystine uptake (Fig. 2.2.). Also, the cystine uptake was largely blocked by the cystine/glutamate antiporter (system  $x_C$ -) inhibitor (s)-4-carboxyphenylglycine (CPG), suggesting that the majority of the cystine uptake is system  $x_C$ - mediated. BMAA did not cause inhibition of uptake in the presence of CPG (Fig. 2.2.). Therefore, it is likely that BMAA attenuates the uptake of cystine by inhibition of system  $x_C$ -.




**FIGURE 2.2. BMAA inhibits system  $x_C$ - mediated cystine uptake.**

BMAA: 3 mM BMAA; CPG: 1 mM S-4-carboxyphenyl glycine (CPG). Bars show  $^{35}\text{S}$ -cystine uptake during a 20 minute exposure presented as % control (mean  $\pm$  s.e.m., n = 16). \* indicates significant difference from control.


Since cystine uptake is rate-limiting step for glutathione synthesis, glutathione levels in response to BMAA treatment was measured. After a three hour treatment with BMAA, glutathione levels were decreased by about 50% (Fig. 2.3.). Three hour exposure was chosen because at this time point there was no significant neuronal death observed (less than 10% by the LDH release assay).

Since BMAA causes a decrease in the levels of the endogenous free radical scavenger glutathione, the total oxidative stress of the cells should be increased. We measured cellular oxidative stress with the fluorescent dye dichlorofluorescein (DCF). Treatment with BMAA for 3 hours caused a significant increase in oxidative stress, which was blocked by the free radical scavenger trolox (Fig. 2.4.).



**FIGURE 2.3. BMAA decreases cellular glutathione levels.**


BMAA: 3 mM BMAA. Bars show glutathione levels following three hour BMAA exposure presented as % control (mean  $\pm$  s.e.m, n = 16). \* indicates significant difference from control.



**FIGURE 2.4. BMAA induces oxidative stress.**

BMAA: 3 mM BMAA; trolox: 100  $\mu$ M trolox. 5-(and -6)-carboxy-2'7'-dichlorodihydrofluorescein diacetate (10  $\mu$ M) was added to the cultures during a three hour exposure to BMAA. Bars show % control fluorescence (mean  $\pm$  s.e.m., n = 12). \* indicates significant difference from control.

The inhibition by BMAA of system  $x_C$ - mediated cystine uptake suggests that BMAA competes with cystine; if like cystine, it is transported, the high levels of BMAA used in these studies should lead to increased glutamate release. We did in fact find that 3 mM BMAA increased extracellular glutamate. A similar increase was also caused by 3 mM cystine (Fig. 2.5.).




**FIGURE 2.5. BMAA and cystine stimulate glutamate release.**

BMAA: 3 mM BMAA; cystine: 3 mM cystine. Bars show extracellular glutamate levels following a 1 hour BMAA or cystine exposure (mean  $\pm$  s.e.m., n = 8). \* indicates significant difference from control.

Since BMAA appears to induce glutamate release via system  $x_C^-$ , it is possible that this glutamate is responsible for at least part of the glutamate receptor mediated neuronal death. Because BMAA is also a direct agonist for glutamate receptors (Lobner et al., 2007; Cucchiaroni et al., 2010), and 3 mM cystine caused a similar increase in extracellular glutamate compared with 3 mM BMAA, we used 3 mM cystine to study the effect of glutamate released by system  $x_C^-$ . We found that 3 mM cystine did induce neuronal death (Fig. 2.6.). However, the death was less than that caused by 3 mM BMAA, likely due to the fact that cystine is not a direct NMDA receptor agonist like BMAA. However, the cystine toxicity was partially blocked by either MPEP or MK-801. No protection was afforded by trolox, as would be expected since a high concentration of cystine should not induce oxidative stress.





**FIGURE 2.6. Cystine-induced neuronal death is attenuated by MK-801 and MPEP.**

MK: 10 μM MK-801; MPEP: 50 μM MPEP; trolox: 100 μM trolox. Bars show % neuronal cell death (mean ± s.e.m, n = 24) quantified by measuring release of LDH, 24 hours after the beginning of the insult. \* indicates significant difference from control (cystine alone).

## DISCUSSION

We found that BMAA inhibits system  $x_c^-$ - mediated cystine uptake leading to decreased cellular glutathione. The process of glutathione production in neurons involves a complex series of steps in which cystine is taken up primarily into astrocytes (Freeman and Crapo, 1982; Sagara et al., 1993). The glutathione produced by astrocytes is released and converted extracellularly into cysteine, which is taken up by neurons and used by them to produce glutathione (Fridovich, 1975; Wang and Cynader, 2000). Whether the action of BMAA to inhibit cystine uptake was primarily on neurons or astrocytes was not determined in this study. Therefore, it is not known if BMAA is initially acting to inhibit cystine uptake into neurons, or if it inhibits the uptake of cystine into astrocytes and prevents their release of glutathione and therefore restricts the supply of cysteine to neurons. Complicating this simple analysis of BMAA effects of glutathione levels is the

finding that blocking system  $x_c^-$  with CPG for as long as 24 hours does not cause a decrease in cellular glutathione levels (data not shown). The fact that BMAA does cause a decrease in cellular glutathione indicates that it has actions beyond its effect on system  $x_c^-$  mediated cystine uptake. Other known actions of BMAA that may play a role in its effect on glutathione levels include inhibition of the enzymes involved in glutathione synthesis (Esterhuizen-Londt et al., 2011), activation of NMDA and mGluR5 receptors (Lobner et al., 2007), and results presented in the current study indicating that it can cause glutamate release.

The data presented here strongly suggests that BMAA not only inhibits cystine uptake, but also drives system  $x_c^-$  to release glutamate and that this glutamate induces neuronal death by acting on mGluR5 receptors and NMDA receptors. The evidence for this is that BMAA and cystine at the same concentration (3 mM) increase extracellular glutamate and they both induce NMDA receptor and mGluR5 mediated neuronal death. There is no evidence that either of these compounds directly activates mGluR5. Unfortunately, CPG could not be used to block the glutamate release because while it is a fairly poor substrate for system  $x_c^-$  (Patel et al., 2004; Rush et al., 2012b), at the high concentrations needed to compete with the high concentrations of BMAA and cystine used in these studies it stimulated glutamate release by itself (data not shown). Why in our studies there was some protection against cystine induced toxicity by MK-801 is not clear. There is no published data indicating that cystine is a direct NMDA receptor agonist. However, we can not exclude the possibility that some of the cystine may be converted into cysteine, which is an NMDA receptor agonist (Pullan et al., 1987; Ballatori et al., 2009). Alternatively, the glutamate release stimulated by cystine via

system  $x_C^-$  may act to stimulate NMDA receptors. Furthermore, it has been shown activation of mGluR5 and NMDA receptor positively enhances each other's activity (Alagarsamy et al., 1999; Benquet et al., 2002; Chen et al., 2011), which could potentially add to the BMAA toxicity.

Both oxidative stress and excitotoxicity have been suggested to be regulated by system  $x_C^-$  in various cell types. It has been known for many years that inhibition of cystine uptake mediated by system  $x_C^-$  can induce neuronal death by decreasing glutathione levels (Murphy et al., 1989; Murphy and Baraban, 1990; Dringen et al., 2000). In contrast, astrocytes activated by IL-beta were shown to kill cortical neurons by release glutamate via system  $x_C^-$  (Bolaños et al., 1995; Rice and Russo-Menna, 1998; Fogal et al., 2007). Also, microglia can release glutamate via system  $x_C^-$  that can kill cerebellar granule cells (Deneke and Fanburg, 1989; Piani and Fontana, 1994), oligodendrocytes (Rahman et al., 2005; Domercq et al., 2007), and enhance amyloid- $\beta$  induced neuronal death in cortical cultures (Beutler, 1989; Deneke and Fanburg, 1989; Qin et al., 2006a). Finally, glutamate release from kidney dendritic cells via system  $x_C^-$  can inhibit T cell activation through actions on mGluR5 receptors (McBean, 2002; Pacheco et al., 2006). In the current study we find evidence that oxidative stress induced by the inhibition of cystine uptake and excitotoxicity induced by system  $x_C^-$  mediated glutamate release both play a role in BMAA induced neuronal death.

Interestingly, another amino acid implicated in neurological diseases,  $\beta$ -N-oxalyl-L- $\alpha,\beta$ -diaminopropionic acid (ODAP), also shares some properties with BMAA: it directly activates glutamatergic receptors and is transported by system  $x_C^-$  (Kranich et al., 1996; Chase et al., 2007). It is likely that ODAP acts similar to BMAA and causes

cytotoxicity through at least some of the same mechanisms.

The finding that BMAA not only inhibited cystine uptake by system  $x_C^-$ , but also stimulated glutamate release, suggests that it was transported by system  $x_C^-$ . This transport provides a mechanism by which BMAA can accumulate in cells. There is evidence that BMAA may be incorporated into proteins (Murch et al., 2004b; Lobner, 2009) and could therefore potentially play a role in the protein misfolding found in neurodegenerative diseases (McBean, 2002; Uversky, 2008). Whether BMAA can be incorporated into GSH is unknown. If BMAA does become incorporated into GSH this would provide another potential mechanism for its ability to cause depletion of GSH and oxidative stress.

The importance of BMAA acting on system  $x_C^-$  to induce oxidative stress and excitotoxicity at the same time is that this may be partially account for the different types of neurological diseases that have been associated with BMAA consumption. It is possible that the different actions of BMAA, in association with varying underlining conditions, may lead to the multiple disorders. Most neurodegenerative diseases appear to involve NMDA receptor mediated excitotoxicity (Arrick et al., 1985; Lipton and Chen, 2004) and oxidative stress (Dringen et al., 1999; Cui et al., 2004), and mGluR5 receptor activation has been implicated in Parkinson's disease as well (Zerangue and Kavanaugh, 1996b; Chen and Swanson, 2003; Marino et al., 2003; Aoyama et al., 2006). All of these mechanisms of neuronal injury may be enhanced by BMAA. The finding that BMAA causes a depletion of cellular glutathione is of particular importance. There is evidence that glutathione depletion plays a role in Alzheimer's disease, Parkinson's disease, and ALS (Bannai and Kitamura, 1980; Bains and Shaw, 1997; Liu et al., 2004; Zeevalk et al.,

2008). This type of low level, long-term, depletion of glutathione that may be caused by the inhibition of cystine uptake could cause the long-term oxidative stress that may underlie aspects of neurodegenerative diseases.

From these results and previous studies, it is obvious that system  $x_C^-$  plays an important role in neuronal fate. We next want to examine if system  $x_C^-$  can be regulated by neurotrophic factors, which are naturally occurring molecules, which also regulate neuronal fate in multiple ways. Neurotrophic factors have wide ranging effects in the central nervous system, including altering excitotoxicity (Koh et al., 1995; Sato et al., 1999), oxidative stress (Zhang et al., 1993).

## **CHAPTER III**

**FUNCTIONAL UPREGULATION OF SYSTEM XC- BY**

**FIBROBLAST GROWTH FACTOR-2**

## **ABSTRACT**

The cystine/glutamate antiporter (system  $x_C^-$ ) is a sodium-independent amino acid transport system. Disruption of this system may lead to multiple effects in the central nervous system including decreased cellular glutathione. Since multiple neurological diseases involve glutathione depletion, and disruption of growth factor signaling has also been implicated in these diseases, it is possible that some growth factors effects are mediated by regulation of system  $x_C^-$ . We tested the growth factors fibroblast growth factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1), neuregulin-1 (NRG), neurotrophin-4 (NT-4), and brain derived neurotrophic factor (BDNF) on system  $x_C^-$ -mediated  $^{14}\text{C}$ -cystine uptake in mixed neuronal and glial cortical cultures. Only FGF-2 significantly increased cystine uptake. The effect was observed in astrocyte-enriched cultures, but not in cultures of neurons or microglia. The increase was blocked by the system  $x_C^-$  inhibitor (s)-4-carboxyphenylglycine (CPG), required at least 12 hour FGF-2 treatment, and was prevented by the protein synthesis inhibitor cycloheximide. Kinetic analysis indicated FGF-2 treatment increased the  $V_{\max}$  for cystine uptake while the  $K_m$  remained the same. Quantitative PCR showed an increase in mRNA for xCT, the functional subunit of system  $x_C^-$ , beginning at 3 hours of FGF-2 treatment, with a dramatic increase after 12 hours. Blocking FGFR1 with PD 166866 blocked the FGF-2 effect. Treatment with both a PI3-kinase inhibitor (LY-294002) or a MEK/ERK inhibitor (U0126) for 1 hour prior to and during the FGF-2 treatment blocked the increased cystine uptake. The upregulation of system  $x_C^-$  by FGF-2 may be responsible for some of the known physiological actions of FGF-2.

## **INTRODUCTION**

The function of system  $x_C^-$  makes it likely to play an important role in regulating many processes in the central nervous system. By releasing glutamate, it can increase extracellular glutamate levels, which may alter neuronal plasticity and potentially cause excitotoxicity; Through providing cystine uptake, it supplies the substrate for cellular glutathione synthesis, and in this way may determine whether oxidative stress induced neuronal death will occur.

There is considerable evidence that glutamate released from system  $x_C^-$  is involved in both physiological and pathological processes. Physiologically glutamate release from system  $x_C^-$  plays a role at the photoreceptor synapse (Hu et al., 2008) and in regulating immune cell function (Xue and Field, 2011). It is known that glutamate release from system  $x_C^-$  can cause toxicity, and this is observed in many pathological processes. Activated astrocytes release glutamate via system  $x_C^-$  that can kill cortical neurons (Fogal et al., 2007). Also activated microglia release glutamate via system  $x_C^-$  that can kill cerebellar granule cells (Piani and Fontana, 1994) and enhance amyloid-beta induced neuronal death in cortical cultures (Qin et al., 2006b).

Glutathione is known to detoxify superoxide in a reaction catalyzed by glutathione peroxidase forming disulfide/oxidized glutathione. This reaction is accomplished by redox changes at the sulfhydryl group of the cysteine residue of glutathione (Dringen and Hirrlinger, 2003). The cystine uptake mediated by system  $x_C^-$  appears to play a critical role in regulating cellular glutathione levels, because de novo synthesis of glutathione in the brain is rate-limited by the uptake of cystine (Sagara et al., 1993). Specifically, astrocytes express high levels of system  $x_C^-$  and have high levels of



cystine uptake (Dringen et al., 2000; Lewerenz et al., 2006), while neurons of the central nervous system have limited capacity for cystine uptake, and are reliant primarily on astrocytes for the provision of cysteine and cysteinylglycine for neuronal glutathione production (Dringen et al., 1999). The first evidence that system  $x_C^-$  could play a role in neuronal death was provided when it was shown that high concentrations of glutamate could competitively inhibit cystine uptake leading to an oxidative stress mediated neuronal death (Murphy et al., 1990). This type of toxicity was shown to occur before glutamate receptors developed (Murphy and Baraban, 1990) and to involve depletion of glutathione (Ratan et al., 1994). In contrast to the enhancement of neurotoxicity caused by releasing glutamate, system  $x_C^-$  activity on non-neuronal cells can be protective to neurons by generating and releasing glutathione. Overexpression of xCT, the functional subunit of system  $x_C^-$ , in astrocytes has been shown to enhance glutathione release and protect neurons from oxidative stress (Shih et al., 2006). Since neurological diseases including schizophrenia, depression, Alzheimer's disease, and Parkinson's disease have all been associated with depletion of cellular glutathione (Ballatori et al., 2009; Dean et al., 2009; Shibasaki et al., 2009; Maes et al., 2011), it is possible that altered system  $x_C^-$  function plays a role in these diseases.

Neurotrophic factors have wide ranging effects in the central nervous system including altering excitotoxicity (Koh et al., 1995; Chintala et al., 2005), oxidative stress (Zhang et al., 1993; Shih et al., 2006), and cellular glutathione levels (Pan and Perez-Polo, 1993; Sato et al., 1999). The overlapping actions of growth factors and system  $x_C^-$  suggest the possibility that some neurotrophic factor effects may be mediated by

regulation of system  $x_C$ -. Therefore we tested the effects of a number of well-established neurotrophic factors on system  $x_C$ - function.

## **MATERIALS AND METHODS**

### **Materials**

Timed pregnant Swiss Webster mice were obtained from Charles River Laboratories (Wilmington, DE). Serum was from Atlanta Biologicals (Lawrenceville, GA). Growth factors were from Alomone Labs (Jerusalem, Israel).  $^{14}\text{C}$ -cystine was from Perkin Elmer (Waltham, MA). All other chemicals were obtained from Sigma (St. Louis, MO).

### **Cortical cell cultures**

Mixed cortical cell cultures containing glial and neuronal cells were prepared from fetal (15-16 day gestation) mice as previously described (Lobner, 2000; Sasaki et al., 2002). Dissociated cortical cells were plated on 24-well plates coated with poly-D-lysine and laminin in Eagles' Minimal Essential Medium (MEM, Earle's salts, supplied glutamine-free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2 mM glutamine and glucose (total 21 mM). Neuron-enriched cultures were prepared exactly as above with the addition of 10  $\mu\text{M}$  cytosine arabinoside 48 hours after plating to inhibit glial replication. In these cultures <1% of cells are astrocytes (Dugan et al., 1995; Sato et al., 2000; Sasaki et al., 2002; Rush et al., 2010). Astrocyte-enriched cultures were prepared as described for mixed cultures except they are from cortical tissue taken from post-natal day 1-3 mice (Choi et al., 1987; Schwartz and Wilson, 1992;

Venugopal and Jaiswal, 1996; Rush et al., 2010). Microglia cultures were prepared by first growing astrocyte-enriched cultures, then shaking the microglia free and plating them in media containing 10 ng/ml colony stimulating factor (CSF) (Itoh et al., 1999; Barger and Basile, 2001). Cultures were maintained in humidified 5% CO<sub>2</sub> incubators at 37°C. Mice were handled in accordance with a protocol approved by our institutional animal care committee and in compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and reduce the number of animals used.

### **<sup>14</sup>C-cystine uptake**

System x<sub>C</sub>- mediated uptake of radiolabeled cystine was assayed as previously described with modifications (Itoh et al., 1999; Liu et al., 2009). Growth factors were added to the serum containing media for the indicated durations. Cultures were then washed into HEPES buffered saline solution and immediately exposed to <sup>14</sup>C-cystine (0.025μCi/ml) for 20 min. Following <sup>14</sup>C-cystine exposure, cultures were washed with ice cold HEPES buffered saline solution and dissolved in 250 μl sodium dodecyl sulfate (0.1%). An aliquot (200 μl) was removed and added to scintillation fluid for counting. In some experiments an aliquot was also used to measure cellular protein levels by the BCA assay. Values were normalized to <sup>14</sup>C-cystine uptake in untreated control on the same experimental plate. Kinetic analysis of cystine uptake was performed as previously described (Lee and Johnson, 2004; Fogal et al., 2007). Uptake of <sup>14</sup>C-cystine was measured over a range of cystine concentrations: 0.1 μM, 0.3 μM, 1μM, 3 μM, 10 μM, and 30 μM. Kinetic analysis was performed using the Hanes-Woolf plot where

[substrate]/velocity is plotted against [substrate]. The slope corresponds to  $1/V_{\max}$ , while the X-intercept corresponds to the  $K_m$ .

### **Reverse transcription quantitative real-time PCR (RT-qPCR)**


Transcriptional expression of xCT in astrocyte-enriched cultures after stimulation with FGF-2 was examined using RT-qPCR. Briefly, after various durations of treatment with FGF-2 cells were washed 3 times with cold PBS. Total RNA was isolated with TRIzol extraction (Invitrogen; Carlsbad, CA) according to manufacturer's protocol, cDNA was synthesized using the Reverse Transcription System (Promega; Madison, WI) from 1  $\mu$ g of total RNA following the manufacturer's protocol. All products were amplified on a StepOne real-time PCR system (Applied Biosystems; Carlsbad, CA) using 100 ng of cDNA, PerfeCTa SYBR Green FastMix with ROX (Quanta Biosciences; Gaithersburg, MD), and the following primers: gapdh mouse forward-AAG GGC TCA TGA CCA CAG TC; gapdh mouse reverse-GGA TAC AGG GAT GAT GTT CT; xCT mouse forward-AGG GCA TAC TCC AGA ACA CG; xCT mouse reverse-GAC AGG GCT CCA AAA AGT GA. xCT expression was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (gapdh). Quantitative PCR was used to determine fold increase of xCT mRNA using the  $2^{-\Delta\Delta C_T}$  method.

### **Statistical analysis**

Differences between test groups were examined for statistical significance by means of one-way ANOVA followed by the Bonferroni correction post-hoc test, with  $p < 0.05$  being considered significant.

## RESULTS


The effects of FGF-2, IGF-1, NRG, NT-4, and BDNF, each of which have been shown to have actions on cortical cells (Bannai, 1984; Koh et al., 1995; Anton et al., 1997; Erickson et al., 2002; Sasaki et al., 2002; Lobner et al., 2003), were tested on  $^{14}\text{C}$ -cystine uptake in mixed neuronal and glial cortical cultures. In these cultures approximately 90% of cystine uptake is mediated by system  $x_{\text{C}}$ - (Lee and Johnson, 2004; Liu et al., 2009; Lobner, 2009). Following 24 hour growth factor treatment, only FGF-2 caused a significant increase in cystine uptake (Fig. 3.1). Importantly, the growth factors were added to the cultures on DIV 13-14, a time point at which there was already a confluent layer of astrocytes. None of the growth factors had a significant effect on total cellular protein levels (data not shown).



**FIGURE 3.1. Growth factor effects on cystine uptake in cortical cultures.**

Treatment for 24 hours with 100 ng/ml of the growth factors on mixed neuronal and glial cultures. FGF-2: fibroblast growth factor-2; IGF-1: insulin-like growth factor-1; NRG: neuregulin; NT-4: neurotrophin-4; BDNF: brain derived neurotrophic factor. Cultures were exposed to growth factors for 24 hours, washed into a growth factor free media, and  $^{14}\text{C}$ -cystine uptake measured for 20 min. Bars show % control (mean  $\pm$  s.e.m., n = 12-16). \* indicates significantly different from control uptake.

This effect of FGF-2 on cystine uptake does not appear to be limited to cortical astrocytes. We also examined some growth factors that are known to have effects on spinal cord, and found a similar regulatory effect of FGF-2 on cystine uptake in spinal cord glial cultures (Fig. 3.2.).




**FIGURE 3.2. Growth factor effects on cystine uptake spinal cord glial cultures.**

24 hour treatment with growth factors (100 ng/ml) on primary mouse spinal cord glial cultures. FGF-2: fibroblast growth factor-2; NT-4: neurotrophin-4; IGF-1: insulin-like growth factor-1; NRG: neuregulin; BMP-2: Bone morphogenetic protein 2; BDNF: brain derived neurotrophic factor. Cultures were exposed to growth factors for 24 hours, washed into a growth factor free media, and <sup>14</sup>C-cystine uptake measured for 20 min. Spinal cord glia cultures were prepared as cortical glial cultures except they were prepared from whole spinal cords from postnatal day one mice. Bars show % control (mean±s.e.m., n=12-16). \* indicates significantly different from control uptake.

We also examined FGF-2 actions on neuronal-enriched, astrocyte-enriched, and microglial cultures to see which cell type mediates the FGF-2 effect. We found that the FGF-2 effect only occurred in astrocyte-enriched cultures (Fig. 3.3.). We have shown previously that the majority of cystine uptake in cortical cultures is into the glial cells (Lobner, 2009). Astrocyte-enriched cultures prepared by the current method are known to also contain microglial cells (Shih et al., 2003; Hamby et al., 2006; Wang et al., 2009).


However, since there was no effect of FGF-2 in the microglial cultures, we believe that the effect occurs on astrocytes. Therefore, all of the following experiments were performed using the astrocyte-enriched cultures. We next tested whether the effect of FGF-2 was on system  $x_C$ - mediated cystine uptake. More than 90% of cystine uptake was blocked by the system  $x_C$ - antagonist (s)-4-carboxyphenylglycine (CPG), and the increase caused by 24 hour treatment with FGF-2 was completely blocked by CPG (Fig. 3.4.).



**FIGURE 3.3. Effects of FGF-2 on cystine uptake in neuronal-enriched cultures (A), astrocyte-enriched cultures (B), and microglial cultures (C).**

Cultures were exposed to FGF-2 (100 ng/ml) for 24 hours, washed into a growth factor free media, and <sup>14</sup>C-cystine uptake measured for 20 min. Bar show % control (mean±s.e.m., n=8). \* indicates significantly different from control uptake.






**FIGURE 3.4. FGF-2 induced increase in cystine uptake is mediated by system  $x_{c-}$ .**

Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 24 hours, washed into a growth factor free media, and <sup>14</sup>C-cystine uptake measured for 20 min with or without the system  $x_{c-}$  antagonist (s)-4-carboxyphenylglycine (200  $\mu$ M CPG). Bars show % control (mean $\pm$ s.e.m., n=8). \* indicates significantly different from control uptake.

The previous studies were all performed using a 24 hour growth factor treatment.


We next performed a time course of FGF-2 treatment. A significant effect of FGF-2 treatment was first observed after a 12 hour exposure (Fig. 3.5A.). None of the growth factors tested in Fig. 3.1., including FGF-2, had an effect with acute treatment (20 min prior to and during the cystine uptake-data not shown). Treatment with the protein synthesis inhibitor cycloheximide during the 24 hour FGF-2 treatment blocked the FGF-2 induced increase in cystine uptake (Fig. 3.5B.). These results suggest an upregulation of the number of transporters.



**FIGURE 3.4. Time and protein synthesis dependent changes in cystine uptake induced by FGF-2 treatment on astrocyte-enriched cultures.**

(A) Cultures were exposed to FGF-2 (100 ng/ml) for the indicated period of time, washed into a growth factor free media and <sup>14</sup>C-cystine uptake measured for 20 min. Bars show % control (mean±s.e.m., n=32). (B) Cultures were exposed to FGF-2 (100 ng/ml) for 24 hours with or without the protein synthesis inhibitor cycloheximide (CHX, 200 ng/ml), washed into a growth factor and inhibitor free media, and <sup>14</sup>C-cystine uptake measured for 20 min. Bars show % control (mean±s.e.m., n=8). \* indicates significantly different from control uptake.


We also assessed the kinetic changes of the transporter. Treatment with FGF-2 for 24 hours caused a significant increase in the  $V_{max}$  of the transporter activity, but no change in the  $K_m$  (Fig. 3.6.).



**FIGURE 3.6. Kinetic analysis of FGF-2 effects on cystine uptake.**

Following 24 hour exposure to FGF-2 (100 ng/ml),  $^{14}\text{C}$ -cystine uptake was measured for 20 min in astrocyte-enriched cultures in the presence of varying concentrations of cystine. Data are expressed as  $^{14}\text{C}$ -cystine uptake in CPM per microgram protein (mean  $\pm$  s.e.m., n=4) (A).  $V_{\max}$  (1/slope) and  $K_m$  (-X-intercept) were determined using the Hanes-Woolf plot (B). \* indicates significantly different from control uptake.


Finally, a time course of mRNA levels of xCT, the functional subunit of system  $x_{\text{C}}^{-}$ , measured with RT-qPCR, showed an increase starting after 3 hours of FGF-2 treatment, with a large increase after 12 hours (Fig. 3.7).



**FIGURE 3.7. Time course of changes in xCT mRNA in astrocyte-enriched cultures assessed by RT-qPCR following different durations of FGF-2 (100 ng/ml) treatment.**

Bars show % control (mean  $\pm$  s.e.m.), data is from 4 independent experiments run in duplicate for n=8. \* indicates significantly different from control.

FGF-2 can act on a number of FGF receptors. FGFR1 is highly expressed in the brain (Gonzalez et al., 1995; Wang et al., 2009) and it is found at high levels in astrocytes in the current culture system (Lobner and Ali, 2002; Sato et al., 2004; Lewerenz and Maher, 2009). Therefore we tested the effects of an antagonist of this receptor on the FGF-2 treatment induced increase in system  $x_C$ - function. The FGFR1 antagonist PD 166866 caused a concentration dependent inhibition of FGF-2 stimulated cystine uptake (Fig. 3.8A.). We next attempted to determine the signaling pathway of the FGF-2 effect. We tested the effects of selective inhibitors of the MEK/ERK (U0126) (Favata et al., 1998; Kilberg et al., 2005) and PI3-kinase (Vlahos et al., 1994) pathways on the FGF-2 stimulated cystine uptake. Inhibition of either the MEK/ERK or PI3-kinase pathway partially blocked the FGF-2 stimulated cystine uptake, while the combination of the inhibitors completely blocked the increase (Fig. 3.8B.).



**FIGURE 3.8. FGF-2 stimulation of cystine uptake is mediated by activation of FGFR1 and both the MEK/ERK and PI3-kinase pathways.**

(A) Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 24 hours with or without the FGFR1 inhibitor (PD 166866), washed into a growth factor and inhibitor free media, and <sup>14</sup>C-cystine uptake measured for 20 min. Bars show % control (mean±s.e.m., n=12). (B) Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 24 hours with or without the MEK/ERK inhibitor (10 μM U0126) or the PI3-kinase inhibitor (45 μM LY-294002) added 1 hour prior to and during the FGF-2 exposure, washed into a growth factor and inhibitor free media, and <sup>14</sup>C-cystine uptake measured for 20 min. Bars show % control (mean ± s.e.m., n = 18). \* indicates significantly different from control uptake. # indicates significantly different from FGF-2 stimulated uptake.

## DISCUSSION

The upregulation of system x<sub>c</sub><sup>-</sup> induced by the FGF-2 treatment has multiple implications for understanding the biological effects of FGF-2 and its potential use as a therapeutic agent. Both dysregulation of FGF-2 signaling and system x<sub>c</sub><sup>-</sup> function have

been implicated in psychiatric disorders such as schizophrenia, depression, and addiction. As FGF-2 and regulators for system  $x_C$ - have been suggested for therapeutic use, it is important to understand the mechanism of regulation of system  $x_C$ -. Also, upregulation of system  $x_C$ - must be taken into account when considering the use of FGF-2 for the treatment of neurological conditions, particularly those that involve excitotoxicity.

The evidence suggesting the involvement of dysregulation of the FGF-2 system in schizophrenia is substantial (Terwisscha van Scheltinga et al., 2010). FGF-2 is involved in neurogenesis and normal brain development (Zechel et al., 2010). FGFR1 is widely expressed in the brain (Gonzalez et al., 1995) and is required for proliferation of hippocampal stem cells (Ohkubo et al., 2004). Therefore FGF-2 system signaling dysregulation may be involved in altered development in schizophrenia. Supporting this idea, in post-mortem brains from schizophrenia patients there was found to be increased FGFR1 expression in the CA4 region of the hippocampus (Gaughran et al., 2006) and there is increased expression of FGF-2 in the serum of schizophrenia patients (Hashimoto et al., 2003). It is interesting to note that disruption of MEK/ERK and PI3-kinase signaling have also been implicated in developmental diseases, such as schizophrenia (Waite and Eickholt, 2010; Yuan et al., 2010). We found that the action of FGF-2 to upregulate system  $x_C$ - function was partially dependent on both MEK/ERK and PI3-kinase signaling. The results presented in the current study of FGF-2 effects on system  $x_C$ - that are mediated by FGFR1 provide a potential mechanism by which defects in FGF-2 signaling leads to developmental disorders.

There are decreased levels of glutathione in schizophrenics (Raffa et al., 2011) and an animal model of schizophrenia involves the post-natal treatment with buthionine

sulfoximine, an inhibitor of a glutathione synthesis (Cabungcal et al., 2007). In one study it was found that in an animal model of schizophrenia there was decreased system  $x_C$ -activity, although in the brain of human schizophrenics there was a slight increase in xCT expression (Baker et al., 2008). Therefore, it is possible that increased FGF-2 signaling is a compensatory mechanism in schizophrenia to increase xCT expression to increase system  $x_C$ - activity. However, a great deal more work determining the time course of changes in FGF-2 system signaling, system  $x_C$ - function, glutathione levels, development changes, and development of the disease is necessary.

Disruption of FGF-2 signaling may also be involved in depression. In the post-mortem brains of depressed patients there is reduced mRNA for FGF-2, but increased mRNA for FGFR1 (Gaughran et al., 2006). Treatment with FGF-2 has antidepressant effects in mouse models of depression and reversed the decrease in neurogenesis in the hippocampus of these mice (Zechel et al., 2010).

Alterations in both system  $x_C$ - and FGF-2 have been implicated in cocaine addiction. In adult rats, following withdrawal from repeated cocaine, there is decreased function of system  $x_C$ - in the nucleus accumbens (Baker et al., 2003). Repeated cocaine administration increases FGF-2 mRNA in the striatum and prefrontal cortex (Fumagalli et al., 2006), while it decreases FGFR1 mRNA in the hippocampus but increases it in the prefrontal cortex (Turner et al., 2008b). Due to differences in the areas of the brain assessed, it is at this time not possible to draw conclusions regarding the interaction between system  $x_C$ - and FGF-2 during addiction. However, it is clear that both are changed.

We showed that 24 hour treatment with FGF-2 increases cystine uptake through system  $x_C^-$  selectively on primary cortical astrocytes, but not neurons or microglia. This effect does not appear to be limited to cortical astrocytes. We found a similar regulatory effect of FGF-2 on cystine uptake through system  $x_C^-$  in spinal cord glial cultures. The result that FGF-2 also increases cystine uptake in spinal cord glial cultures is especially interesting because of a recent study showing that knocking out FGF-2 can delay disease progression in the SOD1 ALS mouse model (Thau et al., 2012). One possible explanation for this result is that the lack of FGF-2 signaling leads to decreased system  $x_C^-$  activity in the ALS mice, and the protection would then be due to decreased glutamate release from system  $x_C^-$  and decreased excitotoxicity. However, what role FGF-2 plays in ALS is unclear. Post mortem studies revealed that there was no change in FGF-2 or FGFR1 mRNA in ALS patients compared to control (Petri et al., 2009). Preliminary data from our laboratory on mutant SOD1 mice showed a significant increase in system  $x_C^-$  function in spinal cord slices even before the animals showed any symptoms (unpublished data). Future studies on FGF-2 signaling and regulation of system  $x_C^-$  in the SOD1 model can potentially help clarify the involvement of FGF-2 and system  $x_C^-$  in ALS.

The function of system  $x_C^-$  makes it likely to play an important role in regulating neuronal survival and death; by releasing glutamate it can increase extracellular glutamate levels and potentially cause excitotoxicity, through providing cystine to the cell it regulates cellular glutathione levels and in this way may protect cells against oxidative stress. Both excitotoxicity and oxidative stress play a role in neurodegenerative diseases (ALS) (Bains and Shaw, 1997; Lau and Tymianski, 2010). The dual nature of system  $x_C^-$



means that it may either protect against or enhance neuronal death depending on the relative importance of excitotoxicity and oxidative stress in each disease.

FGF-2 was tested in clinical trials for the treatment of stroke. It was found that FGF-2 treatment caused roughly a doubling of the mortality rate (Clark et al., 2000; Bogousslavsky et al., 2002). While there are many possible reasons for a lack of protective effects of FGF-2, the increase in mortality indicates that, in this situation, it was having injury potentiating effects. Could an increase in system  $x_C$ - be responsible for the increased mortality following FGF-2 treatment? Certainly excitotoxicity plays a role in cerebral ischemia (Choi, 1998) and system  $x_C$ - activity can enhance excitotoxicity (Fogal et al., 2007). However, FGF-2 has multiple effects on systems that can alter neuronal death. For example, in the central nervous system, it increases AMPA receptor expression (Cheng et al., 1995), and decreases NMDA receptor expression (Mattson et al., 1993). Therefore, the net effect of FGF-2 on neuronal death in various conditions will depend on many factors. We began to explore the net effect of FGF-2 by testing whether long-term upregulation of system  $x_C$ - by FGF-2 directly induces neuronal death.

## **CHAPTER IV**

### **FGF-2 INDUCES NEURONAL DEATH**

## **ABSTRACT**

FGF-2 upregulates system  $x_C$ - selectively on astrocytes, which will lead to both increased cystine uptake, with increased glutathione production, and increased extracellular glutamate. While the increased intracellular glutathione can contribute to decreased oxidative stress, the increased glutamate release can potentially lead to excitotoxicity to neurons. To test this hypothesis, we performed a long-term treatment (48 hours) of FGF-2 in mature mixed neuronal and glial cultures. Treatment with FGF-2 for 48 hours caused a significant neuronal death in these cultures. This cell death was not observed in neuronal-enriched cultures, or astrocyte-enriched cultures, suggesting the toxicity is a result of neuron-glia interaction. Blocking system  $x_C$ - eliminated the neuronal death. Since increasing cystine uptake is unlikely to induce toxicity, we examined the involvement of glutamate release. The general AMPA/kainate receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) abolished the neuronal toxicity induced by FGF-2 treatment, and surprisingly, the NMDA receptor antagonist memantine did not. When cultures were exposed directly to glutamate, either NBQX or memantine blocked the neuronal toxicity. The mechanism of this altered profile of glutamate receptor mediated toxicity by FGF-2 is unclear. The selective calcium permeable AMPA receptor antagonist 1-naphthyl acetyl spermine (NASPM) failed to offer protection. FGF-2 has been suggested to be able to decrease NMDA receptor mediated toxicity by both reducing NMDA receptor expression and causing a faster inactivation. FGF-2 has also been shown to increase GluR1 expression, as well as increased calcium influx. Therefore, the most logical explanation for the results is that 48 hour FGF-2 treatment induces AMPA receptor toxicity through

increased system  $x_C^-$  function resulting in increased release of glutamate. At the same time, FGF-2 decreases neuronal sensitivity to NMDA receptor mediated toxicity, and possibly enhances sensitivity to AMPA receptor mediated toxicity, although we cannot exclude the possibility that FGF-2 treatment sensitizes the neurons to normal system  $x_C^-$  mediated glutamate release.

## **INTRODUCTION**

Fibroblast growth factor 2 (FGF-2), despite its discovery in fibroblasts, is widely expressed throughout the brain (Eckenstein, 1994; Dono, 2003). FGF-2 can activate members of the FGF receptor family leading to activation of several intracellular pathways, including PI3K/Akt and MEK/ERK pathways (Reuss and Bohlen und Halbach, 2003). It has been demonstrated to be involved in development (Ohkubo et al., 2004), adult neurogenesis (Mudò et al., 2009), and tissue repair (Reuss and Bohlen und Halbach, 2003). Dysregulation of FGF-2 signaling has been implicated in acute and chronic neurodegenerative diseases, such as stroke (Alzheimer and Werner, 2002), traumatic brain injury (Mellergård et al., 2012), and Alzheimer's disease (Mark et al., 1997), as well as psychiatric disorders such as schizophrenia (Terwisscha van Scheltinga et al., 2010), stress (Molteni et al., 2001; Frank et al., 2007), addiction (Flores and Stewart, 2000), and major depression (Evans et al., 2004). The use of FGF-2 for treatment for stroke in clinical trials has been attempted but without success (Clark et al., 2000; Bogousslavsky et al., 2002).

System  $x_C^-$  is a cystine/glutamate antiporter on the cell membrane (Sato et al., 1995b; Liu et al., 2011). Physiologically, system  $x_C^-$  takes up cystine and releases

glutamate in exchange at a 1:1 ratio (Sato et al., 1999). The direction of transport is determined by the high glutamate levels and low cystine levels intracellularly. Once cystine is taken up it is rapidly reduced to cysteine, which can then be used to synthesize protein, or glutathione (GSH), an important endogenous antioxidant in the brain (Meister and Anderson, 1983). GSH and cysteine can both be released into the extracellular space, typically by astrocytes, to regulate the redox state of the brain (Wang and Cynader, 2000; Dringen and Hirrlinger, 2003). Also, the extracellular cysteine is taken up by neurons to synthesize GSH (Wang and Cynader, 2000; Lewerenz et al., 2006; Escartin et al., 2011). The glutamate released by system  $x_C^-$  can have multiple effects. Glutamate is the most important excitatory neurotransmitter in the central nervous system. Along with mediating excitatory neurotransmission at synapses, glutamate released from astrocytes is also believed to regulate synaptic activity and plasticity through activating parasynaptic and extrasynaptic receptors (Asztely et al., 1997; Hardingham et al., 2002). However, high extracellular glutamate levels can cause neuronal death through excitotoxicity, typically resulting from high NMDA receptor activation leading to excess calcium influx triggering cell death (Choi et al., 1987).

System  $x_C^-$  has been shown to be widely expressed, especially in the central nervous system (Sato et al., 2002; Burdo et al., 2006). In vitro cell culture studies have shown that immature neuronal cells rely on system  $x_C^-$  to take up cystine (Murphy et al., 1990). When immature neuronal cell cultures are incubated with high levels of glutamate, glutamate competitively inhibits cystine uptake through system  $x_C^-$  and the cells die from oxidative stress (Murphy et al., 1989). This mechanism of neuronal death is called oxidative glutamate toxicity (Schubert and Piasecki, 2001). This type of

glutamate toxicity is distinct from glutamate toxicity in mature neuronal cells, which results from over-stimulation of NMDA receptors leading to excessive calcium influx, and it is called excitotoxicity (Choi, 1987). Also, in mature cell cultures, neurons show low levels of system  $x_C^-$  activity, while astrocytes exhibit high levels of system  $x_C^-$  activity (Lobner, 2009). This shift of function indicates that as cells mature, they take on more specialized tasks and cooperate as a system (Fellin and Carmignoto, 2004; Stipursky et al., 2011; Suzuki et al., 2011).

The dual actions of system  $x_C^-$  give it a unique potential for influencing cell fate. System  $x_C^-$  activity can be either beneficial or destructive depending on the cellular properties. If cells are susceptible to oxidative stress, increasing system  $x_C^-$  activity should be protective as it increases cystine uptake, which can contribute to increased antioxidative defense. However, if the cells express high levels of glutamatergic receptors, it is likely that they will be sensitive to glutamate induced excitotoxicity. Thus, increasing system  $x_C^-$  activity might be destructive by increasing extracellular glutamate, which can potentially over-stimulate extrasynaptic glutamatergic receptors.

In the present study, we used primary mixed neuronal and glial cell cultures derived from prenatal mouse cortex to investigate the effect of 48 hour FGF-2 treatment on neuronal survival/death. We have previously demonstrated that 24 hour FGF-2 treatment upregulated system  $x_C^-$  activity on astrocytes, but not neurons or microglia. We demonstrate here that after system  $x_C^-$  is upregulated for a prolonged period of time, neuronal death occurs due to system  $x_C^-$  mediated excitotoxicity.

## **MATERIALS AND METHODS**

### **Materials**

Timed pregnant Swiss Webster mice were obtained from Charles River Laboratories (Wilmington, DE). Serum was from Atlanta Biologicals (Lawrenceville, GA). FGF-2 was from Alomone Labs (Jerusalem, Israel).  $^{14}\text{C}$ -cystine was from PerkinElmer (Waltham, MA). All other chemicals were obtained from Sigma (St. Louis, MO).

### **Cortical cell cultures**

Mixed cortical cell cultures containing glial and neuronal cells were prepared from fetal (15-16 day gestation) mice as previously described (Lobner, 2000). Dissociated cortical cells were plated on 24-well plates coated with poly-D-lysine and laminin in Eagles' Minimal Essential Medium (MEM, Earle's salts, supplied glutamine-free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2 mM glutamine and glucose (total 21 mM). Neuron-enriched cultures were prepared exactly as above with the addition of 10  $\mu\text{M}$  cytosine arabinoside 48 hours after plating to inhibit glial replication. In these cultures <1% of cells are astrocytes (Dugan et al., 1995; Rush et al., 2010). Astrocyte-enriched cultures were prepared as described for mixed cultures except they are from cortical tissue taken from post-natal day 1-3 mice (Choi et al., 1987; Schwartz and Wilson, 1992; Rush et al., 2010). Cultures were maintained in humidified 5%  $\text{CO}_2$  incubators at 37°C. Mice were handled in accordance with a protocol approved by our institutional animal care committee and in compliance with the Public Health

service Policy on Humane Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and reduce the number of animals used.

### **Induction of neuronal death**

All experiments were performed on cultures 13 days in vitro (DIV). Cultures were exposed to different compounds for 48 hours in media as described for plating except without serum.

### **Assay of neuronal death**

#### **LDH release**

Cell death was assessed in mixed cultures by the measurement of lactate dehydrogenase (LDH) released from damaged or destroyed cells, in the extracellular fluid 48 hours after the beginning of the insult (Koh and Choi, 1987; Lobner, 2000). Blank LDH levels were subtracted from insult LDH values and results normalized to 100% neuronal death caused by 500  $\mu$ M NMDA, or 100% cell death caused by 20  $\mu$ M of the calcium ionophore A23187, added 24 hours before the assay. Control experiments have shown previously that the efflux of LDH occurring from either necrotic or apoptotic cells is proportional to the number of cells damaged or destroyed. Glial cell death (assessed by trypan blue staining) was not observed in any of the current studies.

#### **MTT assay**

Cell survival was quantified by the measurement of the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to produce a dark blue



formazan product (Lobner, 2000). MTT was added to each well 48 hours after the beginning of the insult to the cells (following removal of media for LDH assay). After 30-minute incubation, the medium was removed, and cells were dissolved in dimethyl sulfoxide. The formation of formazan was measured as the amount of reaction product by absorbance change at a wavelength of 590 nm by using a VersaMax tunable microplate reader (Molecular Devices, Sunnyvale, CA). Levels of formazan formation from cultures exposed to 500  $\mu$ M NMDA (100% neuronal death) were subtracted from insult formazan levels, and results were normalized to a sham wash.

### **<sup>14</sup>C-cystine uptake**


System  $x_C$ - mediated uptake of radiolabeled cystine was assayed as previously described with modifications (Liu et al., 2009). FGF-2 was added to the serum containing media for the indicated durations. Cultures were then washed into HEPES buffered saline solution and immediately exposed to <sup>14</sup>C-cystine (0.025 $\mu$ Ci/ml) for 20 min. Following <sup>14</sup>C-cystine exposure, cultures were washed with ice cold HEPES buffered saline solution and dissolved in 250  $\mu$ l sodium dodecyl sulfate (0.1%). An aliquot (200  $\mu$ l) was removed and added to scintillation fluid for counting. Values were normalized to <sup>14</sup>C-cystine uptake in untreated control on the same experimental plate.

### **Statistical analysis**

Differences between test groups were examined for statistical significance by means of one-way ANOVA followed by the Bonferroni correction post-hoc test, with  $p < 0.05$  being considered significant.

## **RESULTS**


As reported previously, 24 hour FGF-2 treatment of mixed neuronal and glial cultures did not cause any cell death (Fig. 4.1.). However, significant neuronal death was observed after 48 hours of FGF-2 treatment (Fig. 4.1.).



**FIGURE 4.1. FGF-2 induced toxicity occurs in mixed neuronal and glial cultures after 48 hour treatment.**

Bars show % neuronal cell death (mean  $\pm$  s.e.m.,  $n = 24$ ) quantified by measuring release of LDH, 24 and 48 hours after the beginning of treatment with 100 ng/ml FGF-2. \* indicates significant difference from control.

This neuronal death following FGF-2 treatment for 48 hours is only observed on mixed neuronal and glial cultures, but not neuronal-enriched cell cultures or glial-enriched cell cultures (Fig. 4.2.), suggesting an interaction of glia and neurons may be necessary for FGF-2 induced neuronal death to occur.




**FIGURE 4.2. FGF-2 does not induce toxicity after 48 hour treatment on either neuronal-enriched cultures or astrocyte-enriched cultures.**

A: Neuronal-enriched culture. Bars show % neuronal death (mean  $\pm$  s.e.m.,  $n = 8$ ) quantified by measuring release of LDH, 48 hours after the beginning of treatment with 100 ng/ml FGF-2. B: Astrocyte-enriched culture. Bars show % cell death (mean  $\pm$  s.e.m.,  $n = 16$ ) quantified by measuring release of LDH, 48 hours after the beginning of treatment with 100 ng/ml FGF-2.

We have shown previously that 24 hour FGF-2 treatment significantly increased system  $x_C^-$  activity selectively in astrocytes, with no effect on neuronal-enriched and microglial-enriched cultures (Liu et al., 2011). To determine whether FGF-2 upregulated system  $x_C^-$  function is still present after 48 hours we measured 20 min cystine uptake following 48 hour FGF-2 treatment of astrocyte-enriched cultures. FGF-2 treatment


doubled the cystine uptake, and the cystine uptake was mediated by system  $x_C$ - as its inhibitor (s)-4-carboxyphenylglycine (CPG) completely blocked the increase (Fig. 4.3.).



**FIGURE 4.3. FGF-2 induced increase in cystine uptake is mediated by system  $x_C$ -.**

Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 48 hours, washed into a growth factor free media, and  $^{14}\text{C}$ -cystine uptake measured for 20 min with or without the system  $x_C$ - antagonist (s)-4-carboxyphenylglycine (200  $\mu\text{M}$  CPG). Bars show % control (mean  $\pm$  s.e.m., n = 6). \* indicates significant difference from control uptake.


To assess whether system  $x_C$ - is involved in the FGF-2 induced neuronal death, we tested the effects of the system  $x_C$ - inhibitors CPG and sulfasalazine (SSZ) on neuronal death induced by 48 hour FGF-2 treatment. Cotreatment of cells with either CPG or SSZ during the 48 hour FGF-2 incubation prevented the neuronal death (Fig. 4.4.). Because SSZ interferes with the LDH release assay, we used the MTT metabolism assay to assess cell survival.



**FIGURE 4.4. FGF-2 induced neuronal death is prevented by blocking system  $x_c^-$ .**

Mixed neuronal and astrocyte cultures were exposed to FGF-2 (100 ng/ml) with or without the system  $x_c^-$  antagonists (s)-4-carboxyphenylglycine (200  $\mu$ M CPG) or sulfasalazine (300  $\mu$ M SSZ) for 48 hours. Bars show % cell survival (mean  $\pm$  s.e.m., n = 8) quantified by measuring MTT reduction, 48 hours after the beginning of the insult. \* indicates significant difference from control.

System  $x_c^-$  mediates cystine uptake and glutamate release at the same time: cystine uptake contributes to GSH synthesis that can decrease oxidative stress, therefore, it is not likely to cause cell death; However, increasing glutamate release can lead to over-activation of glutamatergic receptors to cause excitotoxicity. To test this possibility, we used various glutamatergic receptor antagonists to determine if they prevented FGF-2 induced neuronal death. We found that the AMPA receptor antagonist NBQX, but not the NMDA receptor blocker memantine, blocked the FGF-2 induced neuronal death (Fig. 4.5A.). This result is surprising because both NBQX and memantine block 48 hour direct glutamate toxicity (Fig. 4.5B.).




**FIGURE 4.5. Effects of the AMPA receptor antagonist NBQX and the NMDA receptor antagonist memantine on neuronal death induced by 48 hour exposure to FGF-2 or glutamate.**

A: FGF-2 (100 ng/ml) treatment induced toxicity is protected by blocking AMPA receptors. B: Glutamate (15  $\mu$ M) induced toxicity is protected by blocking AMPA or NMDA receptors. NBQX: 7.5  $\mu$ M 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione. MEM: 10  $\mu$ M memantine. Bars show % neuronal cell death (mean  $\pm$  s.e.m., n = 12) quantified by measuring release of LDH, 48 hours after the beginning of the insult. \* indicates significant difference from control. # indicates significant difference from FGF-2 or glutamate treated.

One possibility for the results is that FGF-2 upregulates calcium permeable AMPA receptors making the neurons susceptible to AMPA receptor mediated toxicity.

However, we did not observe any protection against neuronal death when cultures were cotreated with FGF-2 and various concentrations of the selective calcium permeable AMPA receptor antagonist 1-naphthyl acetyl spermine (NASPM) (Fig. 4.6.).



**FIGURE 4.6. FGF-2 induced toxicity is not mediated by calcium-permeable AMPA receptors.**

Mixed neuronal and glial cultures were exposed to FGF-2 (100 ng/ml) for 48 hours with or without calcium permeable AMPA receptor antagonist 1-naphthyl acetyl spermine (NASPM). Bars show % neuronal cell death (mean  $\pm$  s.e.m.,  $n = 8$ ) quantified by measuring release of LDH, 48 hours after the beginning of the insult. \* indicates significant difference from control.

## DISCUSSION

This study examined the effect of FGF-2 on neuronal cell death in mixed neuronal and glial cultures and the involvement of its selective upregulation of system  $x_C^-$  on astrocytes. System  $x_C^-$  has gained increasingly more attention because of its dual transport property. System  $x_C^-$  provides cystine to the cells, which is the rate-limiting source for cysteine, which is one of the three components of glutathione, the major antioxidant in the brain (Dringen et al., 2000; Dringen and Hirrlinger, 2003). In contrast, system  $x_C^-$  mediated glutamate release can lead to uncontrolled extracellular glutamate

and cause excitotoxicity (Fogal et al., 2007; Jackman et al., 2010). Both oxidative stress and excitotoxicity are involved in various neurodegenerative diseases and psychiatric disorders. Also, FGF-2 dysregulation is observed in acute and chronic neurological disorders (Gaughran et al., 2006; Terwisscha van Scheltinga et al., 2010; Zechel et al., 2010). Therefore, it is possible that changes in system  $x_C^-$  function may be responsible for some of the actions of FGF-2.

Our previous data showed that 24 hour FGF-2 treatment resulted in an increase in cystine uptake through system  $x_C^-$  on astrocytes, but with no effect on neuronal and microglial cystine uptake (Liu et al., 2011). FGF-2 treatment mediated increase of system  $x_C^-$  was mediated through activation of FGFR1 and required both MEK/ERK and PI3 kinase pathway activations (Liu et al., 2011). All of these cellular events happened without significant neuronal toxicity. However, after 48 hour FGF-2 treatment, significant neuronal cell death began to occur. This neuronal death was blocked by the system  $x_C^-$  antagonists CPG and SSZ.

The role of system  $x_C^-$  in cell death has been investigated in different cell types and under different conditions. Inhibition of system  $x_C^-$  has been shown to be harmful to system  $x_C^-$  expressing cells. Oxidative glutamate toxicity was first described on immature neuronal cultures, in which system  $x_C^-$  is the major route of cystine uptake (Murphy et al., 1989; 1990). Applying high concentrations of glutamate (millimolar range) to these immature neurons led to GSH depletion and eventually cell death from oxidative stress (Miyamoto et al., 1989; Murphy et al., 1989; Murphy and Baraban, 1990). Under these circumstances, increasing system  $x_C^-$  levels would likely be protective.



However, increasing system  $x_C$ - function is not always protective. It seems that increasing system  $x_C$ - function in certain population of cells can be toxic to the surrounding cells. Primary microglia cultured in physiological extracellular concentrations of cystine and glutamine have been shown to be able to release enough glutamate through system  $x_C$ - to kill surrounding neurons (Piani and Fontana, 1994) (Domercq et al., 2007). Activation of these microglia by bacterial components enhanced system  $x_C$ - mediated glutamate release, which was prevented by blocking protein synthesis (Piani and Fontana, 1994). Similarly, the increase in  $xCT$  expression in microglia induced by lipopolysaccharide treatment led to increased system  $x_C$ - mediated release of glutamate, causing excitotoxicity to cocultured oligodendrocytes (Domercq et al., 2005). This toxicity was decreased by blocking AMPA receptors with CNQX (Domercq et al., 2005). This result is similar to what we have observed on our primary mixed neuronal and glial cultures. The difference is that oligodendrocytes are normally sensitive to AMPA receptor toxicity (McDonald et al., 1998; Takahashi et al., 2003), while in cortical neurons, glutamate induced excitotoxicity is normally mediated primarily by activation of NMDA receptors (Choi et al., 1987; Choi, 1998).

Similar to microglia, selectively increasing system  $x_C$ - on astrocytes with  $IL-1\beta$  can also lead to increased glutamate release, which potentiates surrounding neuronal death induced by hypoglycemia and hypoxia (Jackman et al., 2010; 2012), both of which are well-known to kill neurons in a process that involves over-activation of glutamatergic receptors (Snider et al., 1998; Czyz et al., 2002). The neuronal death in these conditions was largely attenuated by blocking NMDA receptors with the selective NMDA receptor open channel blocker MK-801, and was also blocked by the system  $x_C$ - inhibitor CPG

(Fogal et al., 2007; Jackman et al., 2010; 2012). Our data shows that FGF-2 treatment, like IL-1 $\beta$ , selectively increases system x<sub>C</sub>- activity on astrocytes (Liu et al., 2011). But FGF-2 by itself induced neuronal cell death after system x<sub>C</sub>- activity was upregulated for 48 hours. Also, the pharmacological profile of the excitotoxicity was different from non-FGF-2 treated neurons. We showed that, while neuronal death induced by direct exposure of cultures to glutamate was blocked by either NMDA or AMPA receptor antagonists, FGF-2 induced neuronal death was only attenuated by the AMPA antagonist.

FGF-2 has been shown to be able to change neuronal expression of both NMDA and AMPA receptors, and to alter sensitivity to NMDA receptor mediated toxicity both in vitro and in vivo. A study conducted on cerebellar granule cells reported that FGF-2 treatment caused a time-dependent decrease in expression of NMDA receptor subunits GluN2A and GluN2C with a decrease of NMDA-evoked calcium influx, while GluN1 and GluN2B levels were not changed (Brandoli et al., 1998). Also, FGF-2 pretreatment protected striatal neurons from NMDA receptor mediated toxicity (Freese et al., 1992). Systematic administration of FGF-2 protected against intrastriatal injection of NMDA (Nozaki et al., 1993a; 1993b). FGF-2 treatment enhanced the rate of NMDA receptor inactivation in response to calcium influx in hippocampal neurons (Boxer et al., 1999). FGF-2 treatment decreased NMDA receptor levels in hippocampal cell cultures and elevations in intracellular calcium levels after glutamate exposure compared to non-FGF-2 treated cells (Mattson et al., 1993). FGF-2 treatment has been shown to increase AMPA receptor subunit GluR1 levels in the same cultures, without altering GluR2, GluR3, and GluR4 levels (Cheng et al., 1995). This suggested the possibility that FGF-2 increased the levels of GluR2 subunit lacking AMPA receptors, which have calcium

permeability (Bannerman et al., 2007). However, the selective antagonist of these channels, NASPM, failed to offer protection in our study. At concentrations above 5  $\mu\text{M}$ , NASPM began to induce some toxicity by itself. The  $\text{IC}_{50}$  of NASPM for calcium-permeable AMPA receptors is 0.33  $\mu\text{M}$  (Brackley et al., 1993; Koike et al., 1997). Therefore, the 5  $\mu\text{M}$  concentration that was not toxic should have been an effective concentration. Therefore, it is possible that the FGF-2 treatment induced increased glutamate release from system  $x_{\text{C-}}$  causes an AMPA receptor specific neuronal death because of attenuated NMDA receptor mediated toxicity induced by FGF-2 treatment.

FGF-2 was a potential candidate for the treatment of stroke as it was shown to reduce ischemic damage, as well as, promote recovery and regeneration in multiple in vitro and animal models (Nozaki et al., 1993b; Rosenblatt et al., 1994; Song et al., 2002; Watanabe et al., 2004). However, in human clinical trials, FGF-2 not only failed to show any beneficial effect in treated patients compared to control patients, it actually increased the mortality rate in treated patients (Clark et al., 2000; Bogousslavsky et al., 2002). The reasons for FGF-2 being beneficial in animal models but not in human trials are not yet fully understood. Given that FGF-2 can increase system  $x_{\text{C-}}$  activity, and the dual functions of system  $x_{\text{C-}}$ , it is not surprising that FGF-2 can have varying effects on cerebral ischemia.

FGF-2 administration has been shown to be beneficial in rodent studies in other disease models, such as depression (Turner et al., 2008c) and Parkinson disease (Hsuan et al., 2006). It is possible that these beneficial effects may be mediated by the FGF-2 effect on system  $x_{\text{C-}}$ , which leads to enhanced glutathione synthesis. However, again

taking into account the dual actions of system  $x_C$ -, the effects of long-term treatment with FGF-2 must be rigorously studied.

## **CONCLUSIONS**

The dual amino acid transport function allows system  $x_C$ - regulate intracellular cystine and extracellular glutamate levels at the same time. Cystine taken up is broken down immediately to cysteine, which is a substrate for glutathione synthesis and protein synthesis. While increasing cystine uptake can be protective by increasing the cells' antioxidative defense, glutamate released at the same time can potentially cause toxicity by over activating glutamatergic receptors. We show here that the net effect of long-term upregulation of system  $x_C$ - selectively on astrocytes in mixed neuronal and glial cultures by FGF-2 treatment is negative. That is, the excitotoxicity component dominates, leading to neuronal death.

## **CHAPTER V**


### **GENERAL DISCUSSION**

System  $x_C^-$  mediates cystine and glutamate exchange (Sato et al., 1999), thus it is involved in both regulating extracellular glutamate and intracellular GSH due to its dual amino acid transport function. Both abnormal glutamate transmission and chronic oxidative stress have been indicated to contribute to neurodegenerative diseases, such as amyotrophic lateral sclerosis, stroke, traumatic spinal cord/brain injury, Alzheimer's disease and Parkinson's disease (Dugan and Choi, 1994; Andersen, 2004), as well as psychiatric disorders such as addiction (Tsai et al., 1998) and schizophrenia (Pérez-Neri et al., 2006). Therefore, it seems likely that alterations in system  $x_C^-$  function may play a role in these diseases. To begin to resolve this question, a series of studies were conducted to find out how system  $x_C^-$  is involved in brain cell health in primary cortical cell cultures. We found that the environmental neurotoxin BMAA can compete with cystine at system  $x_C^-$  leading to both oxidative stress and excitotoxicity, that FGF-2 can upregulate system  $x_C^-$  selectively on astrocytes, and that the upregulation of system  $x_C^-$  by FGF-2 treatment may be responsible for AMPA receptor specific neuronal death caused by 48 hour treatment FGF-2. Following is a discussion of some of the issues that arose during these studies.

### **INTERACTION OF FGF-2 AND BMAA ON NEURONAL DEATH**

Since both BMAA and FGF-2 have actions on system  $x_C^-$ : FGF-2 upregulates system  $x_C^-$  function (Liu et al., 2011) and BMAA competes with cystine at system  $x_C^-$  (Liu et al., 2009), we examined whether FGF-2 pretreatment alters BMAA toxicity. FGF-2 pretreatment for 24 hours changed the concentration response of BMAA toxicity (Fig. 5.1). At low concentrations, BMAA toxicity was potentiated by FGF-2

pretreatment, while at high concentrations, FGF-2 pretreatment protected neurons from BMAA toxicity.



**FIGURE 5.1. Concentration response of BMAA induced neuronal death after FGF-2 pretreatment.**

Mixed neuronal and glial cultures were pretreated with 100 ng/ml FGF-2 for 24 hours before various concentrations of BMAA were added. Media was sampled for LDH assay 24 hours after the beginning of the BMAA insults. Bars show % neuronal cell death (mean  $\pm$  s.e.m.,  $n=8$ ) quantified by measuring release of LDH. \* indicates significant difference from control (no BMAA).

The mechanism to explain this result may be very complicated, since both BMAA and FGF-2 have multiple effects on cells. BMAA can decrease glutathione by decreasing cystine uptake (Liu et al., 2009), inhibiting glutathione synthesis (Esterhuizen-Londt et al., 2011), and potentially be incorporated into glutathione. With bicarbonate present, BMAA mimics glutamate and directly activates glutamatergic receptors (Weiss and Choi, 1988; Rao et al., 2006; Lobner et al., 2007). FGF-2, as a growth factor, has a wide range of effects on both neurons and glia (Beck, 1994; Eckenstein, 1994; Ghosh and Greenberg, 1995; Temple and Qian, 1995; Grothe and Wewetzer, 1996; Ford-Perriss et al., 2001; Reuss and Bohlen und Halbach, 2003; Mudò et al., 2009).

If we consider system  $x_{C-}$  as the main mediator of the effects of both compounds, the most likely explanation for the data is as follows. At low levels of BMAA, when system  $x_{C-}$  is upregulated by FGF-2 pretreatment, BMAA drives increased glutamate release from system  $x_{C-}$ , which exacerbates BMAA toxicity by over activating glutamatergic receptors. The result could also be explained by a different mechanism: FGF-2 pretreatment may potentiate low level BMAA toxicity by upregulating system  $x_{C-}$  allowing more BMAA to enter the cells and through inhibition of enzymes or incorporation into glutathione act to decrease cellular glutathione levels. However, at high levels of BMAA, excitotoxicity caused by direct activation of glutamatergic receptors by BMAA is already maximized, and no further excitotoxicity can be induced, but elevated system  $x_{C-}$  function by FGF-2 pretreatment provides cells with more cystine which strengthens antioxidative defense, thus providing protection against BMAA toxicity.

Due to the complicated actions of both BMAA and FGF-2, and the lack of direct scientific implication of their interaction occurring, no further studies were performed concerning BMAA and FGF-2 interactions.

### **CONTROVERSIES REGARDING BMAA**

In chapter two of this thesis we examined the mechanisms of BMAA toxicity and found that one novel way in which it kills neurons is through actions on system  $x_{C-}$ . It not only competitively inhibits cystine uptake leading to glutathione depletion, but also increases glutamate release, causing excitotoxicity. This is potentially a very important result because it provides a novel mechanism for BMAA toxicity, but it is only important




if BMAA does play a role in neurodegenerative diseases. In this section, we will explore some of the controversies regarding the potential role of BMAA in neurodegenerative diseases.

### **Is BMAA a potent neurotoxin?**

One major question concerning BMAA is whether it can cause neuronal death at low enough concentrations to make it a potential factor in neurodegenerative diseases. Studies in cortical cell culture have shown that very high BMAA concentrations (1 - 3 mM) are required to induce neuronal death (Ross et al., 1987; Weiss and Choi, 1988; Weiss et al., 1989b; Lobner et al., 2007). One potential mechanism by which BMAA may be involved in neurodegenerative diseases is that it is not acting as the sole cause of the disease, but may act in concert with other environmental or genetic factors. In support of this possibility it was found that BMAA, at concentrations as low as 10  $\mu$ M, potentiated amyloid- $\beta$  and 1-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>) toxicity, models of Alzheimer's and Parkinson's disease, respectively (Lobner et al., 2007).

We also looked into the possibility of BMAA causing selective toxicity of specific vulnerable populations of neurons. Mesencephalic and septal primary cultures were prepared to study the death of dopaminergic neurons and cholinergic neurons, which are associated with Parkinson's disease and Alzheimer's disease, respectively. The small percentage (0.1%-1%) of dopaminergic and cholinergic neurons present in the two cultures allowed for the analysis of death of these specific cell populations at the same time as death of the total neuronal population. That is, the total neuronal death was assessed by the LDH release assay, and then the cells were fixed and stained, with the

number of dopaminergic or cholinergic cells counted. In mesencephalic cultures there was no difference between the sensitivity of the total neuronal population and the dopaminergic neurons to BMAA toxicity (Fig. 5.2A). In contrast, in the septal cultures, the cholinergic neurons were significantly more sensitive than the total neuronal population at both the 30 and 300  $\mu\text{M}$  BMAA concentrations (Fig. 5.2B). The  $\text{LC}_{50}$  values calculated by nonlinear regression analysis were: dopaminergic neurons – 304  $\mu\text{M}$ ; total mesencephalic neurons – 241  $\mu\text{M}$ ; cholinergic neurons – 32  $\mu\text{M}$ ; total septal neurons – 586  $\mu\text{M}$ .




**FIGURE 5.2. Cholinergic, but not dopaminergic neurons are selectively sensitive to BMAA toxicity.**

BMAA concentrations of 3 μM, 30 μM, 300 μM, and 1 mM were present for 24 hours. The cell counting data shows % dopaminergic (A) or cholinergic (B) neuronal death (mean ± SEM, n = 8) quantified by counting the number of TH or ChAT-positive neurons. The LDH release data shows % total neuronal cell death (mean ± SEM, n = 8). \* indicates significant difference between the LDH release and cell counting data.

To determine the mechanism of BMAA toxicity in septal cultures we assayed the protective effects of the NMDA receptor antagonist MK-801, the AMPA/kainate receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), and the free radical scavenger trolox on both total neural death and specific cholinergic neuronal death. To match the levels of death, 500 μM BMAA was used for total septal neuronal death, and 300 μM BMAA for cholinergic neuronal death. For total septal

neuronal death, protection was provided by MK-801 and trolox, but not NBQX (Fig. 5.3A.). This is consistent with our previous results in cortical cultures where we found evidence for both NMDA receptor and free radical mediated neuronal death (Lobner et al., 2007). In contrast, the death of cholinergic neurons was not attenuated by MK-801 or trolox, but was decreased by NBQX (Fig. 5.3B.).



**FIGURE 5.3. MK801 (10 μM) and trolox (100 μM) provide protection against BMAA toxicity to total septal neurons (A), while NBQX (20 μM) provides protection of cholinergic neurons (B).**

Bars show % neuronal cell death (mean + SEM, n= 12) quantified by measuring release of LDH (A) or counting of cholinergic neurons (B). \* indicates significant difference from control.

In cortical cultures, where at least 1mM BMAA is required to induce general neuronal death (Ross et al., 1987; Weiss and Choi, 1988; Weiss et al., 1989b; Lobner et al., 2007). However, death of the small subpopulation of NADPH-diaphorase cells occurs at a BMAA concentration of 100  $\mu$ M, because these NADPH-diaphorase cells are characterized by high levels of calcium permeable AMPA receptors (Weiss et al., 1989b). Similarly, motor neurons, which are also characterized by calcium permeable AMPA receptors, have also been shown to be highly sensitive to BMAA toxicity, with death occurring at a concentration of 30  $\mu$ M (Rao et al., 2006). Furthermore, like NADPH-diaphorase cells, this death is mediated by activation of AMPA/kainate receptors (Weiss et al., 1989a; Carriedo et al., 1995). Cholinergic neurons have also been shown to possess high levels of calcium permeable AMPA receptors (Yin et al., 1994). The results indicated that neurons containing high levels of calcium permeable AMPA receptors are more sensitive to BMAA toxicity. However, the protective effect of NBQX was not complete, suggesting that other mechanisms of toxicity are also involved.

Rapid electrophysiological studies have established that the effects of BMAA on NMDA receptors are due to direct actions on the receptor (Weiss et al., 1989b; Lobner et al., 2007). BMAA has been shown to bind to AMPA receptors (Rakonczay et al., 1991; Cucchiaroni et al., 2010), and cause convulsions when injected into the lateral ventricle of rats that are blocked by AMPA antagonists (Matsuoka et al., 1993). In our lab, we found that BMAA is a substrate for system  $x_C^-$ , and through this action drives glutamate release (Liu et al., 2009). Therefore, an alternative explanation for BMAA being a direct AMPA receptor agonist is that BMAA may stimulate the release of endogenous glutamate, which activates the glutamatergic receptors. In this case, the presence or

absence of calcium permeable AMPA receptors would determine the sensitivity of the cells to the toxicity of the endogenous glutamate.

The importance of these results is that they show that specific, and functionally important, populations of neurons are sensitive to BMAA toxicity at concentrations that are much lower than the general cortical neuronal population, making it more likely that BMAA plays a role in neurodegenerative diseases where cell death of specific populations occurs.

### **Measurement of BMAA**

Another area of controversy is the detection and quantification of BMAA in tissues. There are labs that have successfully measured and quantified it in multiple types of tissues (Cox and Sacks, 2002; Murch et al., 2004a; Pablo et al., 2009), while there are also labs that have failed to detect BMAA in similar systems (Montine et al., 2005; Snyder et al., 2009). Different methods used in these studies may be responsible for the lack of detection (Crimmins and Cherian, 1997). A recent review by Steve Cohen of Waters Corp, the developer of multiple amino acid detection methods, suggested that using HILIC columns with tandem mass spectrometry, the method used by all of the investigators not detecting BMAA, may not be detecting BMAA because of the high level of ionization suppression due to much higher concentrations of other matrix components (Cohen, 2012). Another complication is that it has been shown that the majority of BMAA in tissue is protein bound (Murch et al., 2004b). This may be occurring through misincorporation into cellular proteins by BMAA being mischarged to the tRNAs (unpublished data). Therefore, the processing method of samples becomes

important in whether BMAA is detected (Crimmins and Cherian, 1997; Murch et al., 2004b).

### **BMAA in animal models**

Several studies have been conducted to examine BMAA effects in vivo. Macaques were fed 100-350 mg/kg BMAA daily for 13 weeks, after which corticomotoneuronal dysfunction, Parkinsonian features and behavioral abnormalities were observed (Spencer et al., 1987). However, the study was criticized for the high levels of BMAA that was tested (Duncan et al., 1990). Intracerebroventricular administration of 0.5 mg/day of BMAA to rats up to 60 days old caused cholinergic cell degeneration as early as 16 days after BMAA administration and general cortical neuronal damage after 40 days (Rakonczay et al., 1991). With the same BMAA administration, behavioral changes such as splay, jerking movements, and rigidity were elicited 6 days after administration (Rakonczay et al., 1991; Matsuoka et al., 1993). Although the symptoms elicited by BMAA administration are not exactly the same as observed in ALS-PDC, considering the difficulty in modeling the effects of chronic BMAA exposure, it was encouraging to observe neuronal toxicity and behavior changes following BMAA administration. However, these studies involve intracerebroventricular injection, while exposure in humans is through ingestion. There are a number of studies that failed to observe any behavioral responses following oral intake of BMAA. Force-feeding a total of 15.5 g/kg (500mg/kg or 1000 mg/kg doses) of BMAA to Cynomolgus monkeys for 11 weeks did not induce any behavior changes, nor any neurotoxicity in the cerebral cortex (Perry et al., 1989). In another study, feeding adult mice 28 mg/kg of

BMAA per day for 30 days caused no motor, cognitive or neuropathological changes (Cruz-Aguado et al., 2006). Therefore, whether chronic BMAA administration induces any behavioral or neuropathological changes is still controversial and requires more study. One problem is that humans may be exposed to BMAA for decades, which cannot be mimicked in animal models. Also, animal studies have involved administration of BMAA to young, healthy animals, which does not mimic the complex changes occurring in the aging human brain, or interactions with other environmental and genetic factors.

### **Is action on system $x_C$ - an important mechanism of BMAA toxicity?**

We showed that along with the already known action of BMAA of activating glutamatergic receptors, BMAA also acts as a substrate for system  $x_C$ - decreasing cystine uptake and increasing glutamate release. Thus, by acting at system  $x_C$ -, BMAA can cause both oxidative stress and excitotoxicity, both of which occur during neurodegenerative diseases. This makes it an attractive mechanism to explain BMAA's potential role in neurodegenerative diseases. BMAA producing cyanobacteria exist ubiquitously, and it can get into the food supply, by accumulation in fish, crabs, and oysters (Banack et al., 2007; Cox et al., 2009; Brand et al., 2010; Jonasson et al., 2010; Li et al., 2010). Therefore, it is important to study the potential threats of BMAA and understand the role of system  $x_C$ - in its mechanism of toxicity.

### **REGULATION OF SYSTEM $x_C$ - BY FGF-2**

In chapter three of this thesis, we presented data showing the novel action of FGF-2 on astrocytes: increasing system  $x_C$ - function (Liu et al., 2011). This effect was




mediated by FGFR1, and required activation of both the PI3K/Akt and MEK/ERK pathways. It has been well accepted that FGF-2 is involved in many aspects of central nervous system function and regulation (Eckenstein, 1994; Dono, 2003; Reuss and Bohlen und Halbach, 2003). This new action of FGF-2 might provide insights into some of its effects in the brain.

### **FGF-2 in the central nervous system**

FGF-2 is a well studied growth factor that has been shown to be more prevalent in the central nervous system than the peripheral organs (Ledoux et al., 1992). By interacting with four cell surface tyrosine kinase FGF receptors and acting through several intracellular pathways, FGF-2 has been shown to be involved in development (Ohkubo et al., 2004), adult neurogenesis (Mudò et al., 2009), and tissue repair (Reuss and Bohlen und Halbach, 2003). FGF-2 may be involved in acute and chronic neurodegenerative diseases such as stroke (Alzheimer and Werner, 2002) and Alzheimer's disease (Mark et al., 1997). FGF-2 expression can be changed. Processes such as injury, stress, seizures, learning and memory all have been shown to increase FGF-2 expression (Dono, 2003; Fumagalli et al., 2005). FGF-2 dysregulation has been suggested in schizophrenia (Terwisscha van Scheltinga et al., 2010), stress (Molteni et al., 2001; Frank et al., 2007), addiction (Flores and Stewart, 2000), major depression (Evans et al., 2004), as well as traumatic brain injury (Mellergård et al., 2012). Its important role in neurogenesis and tissue repair in adult makes FGF-2 an attractive candidate for treatment of various neurodegenerative disorders.

## **FGF-2 and oxidative stress**

There is substantial evidence indicating that system  $x_C^-$  is induced when cells suffer from oxidative stress or low GSH (Sato et al., 2004; Seib et al., 2011; Lewerenz et al., 2012; Bridges et al., 2012b). The effects of FGF-2 on oxidative stress are unclear. It has been shown that FGF-2 potentiates oxidative stress mediated neuronal death (Lobner et al., 2003). However, FGF-2 has also been shown to be protective against oxidative stress mediated toxicity (Yang and de Bono, 1997; Yamada et al., 2001). Regarding the possibility that the FGF-2 upregulation of system  $x_C^-$  that we observed was mediated by oxidative stress, co-treatment of the free radical scavenger trolox with FGF-2 did not prevent the increased system  $x_C^-$  mediated cystine uptake induced by FGF-2 treatment (Fig. 5.4.). We have shown previously that trolox blocks methylmercury induced increased system  $x_C^-$  activity, which we believe was mediated by decreased glutathione/oxidative increased stress (Rush et al., 2012b). Therefore, it is unlikely that the FGF-2 treatment induced increase in system  $x_C^-$  function was mediated by oxidative stress.



**FIGURE 5.4. FGF-2 induced increase in cystine uptake is not oxidative stress dependent.**


Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) with or without the free radical scavenger trolox (100  $\mu$ M) for 24 hours, washed into a growth factor free media, and <sup>14</sup>C-cystine uptake measured for 20 min. Bars show % control (mean  $\pm$  s.e.m., n = 6). \* indicates significantly different from control uptake.

### FGF-2 and glutamate

It is well accepted that there is an interaction between FGF-2 and glutamate neurotransmission. FGF-2 is required for normal generation of glutamatergic projections in vivo (Korada et al., 2002). Decreased glutamatergic neurons and glutamatergic transmissions were reported in FGF-2 deficient mice (Fadda et al., 2007). Mice carrying a mutation in *fgfr1* gene showed decreased glutamatergic transmission in frontal and temporal cortex (Shin et al., 2004). FGF-2 also promotes glial expression of glutamate transporters (Figiel et al., 2003), and reduced NMDA receptor activity in vivo (Fumagalli et al., 2004).

We also investigated whether glutamate has an effect on system  $x_c^-$  activity. We used 50  $\mu$ M bicuculline, a GABA(A) receptor blocker, and 2.5  $\mu$ M 4-AP, a potassium channel blocker, to cause the presynaptic release of neurotransmitters and selectively

activate synaptic receptors. In our primary cortical cultures, the majority of the synapses are glutamatergic synapses. Our preliminary data suggested that synaptic glutamate release can lead to increased cystine uptake within 20 min (Fig. 5.5.), and the cystine uptake was mediated through system  $x_c^-$  because it was CPG sensitive (Fig. 5.5.). The effect, while significant, was small and variable among different plates. When we continued these studies by testing the effect of various glutamatergic receptor antagonists on the effect of bicuculline/4-AP of increasing cystine uptake, the increase in cystine uptake disappeared. Also, we were unable to determine whether the increase of system  $x_c^-$  function is caused by synaptic glutamate release. Therefore, this line of study was not pursued further.



**FIGURE 5.5. Short-term synaptic glutamate release increases system  $x_c^-$  activity.**

Mixed neuronal and glial cultures were exposed to (-)-bicuculline methochloride (Bic, 50  $\mu\text{M}$ ) and 4-aminopyridine (4-AP, 2.5  $\mu\text{M}$ ) for 20 min, then  $^{14}\text{C}$ -cystine is added to the media, and  $^{14}\text{C}$ -cystine uptake is measured for 20 min. Bar show % control (mean $\pm$ s.e.m., n=24). \* indicates significantly different from control uptake.

## TOXICITY OF FGF-2 MEDIATED BY SYSTEM X<sub>C</sub>-

Despite the numerous reports of FGF-2 as a neuroprotective growth factor (Alzheimer and Werner, 2002), cytotoxic effects of FGF-2 have also been reported. FGF-2 inhibits growth of cultured breast cancer cells (Johnson et al., 1998; Wang et al., 1998), Ewing's sarcoma cells (Schweigerer et al., 1987), and human neuroblastoma cells (Russo et al., 2004). In Ewing's sarcoma tumors, the cytotoxic effect of FGF-2 is mediated through the same pathways that were associated with FGF-2 induced cell proliferation (Kim et al., 2004; Russo et al., 2004; Williamson et al., 2004; Ma et al., 2008). 48 hour treatment of FGF-2 inhibits Ewing's sarcoma growth by inducing cell death in three different cell lines (Sturla et al., 2000; Ma et al., 2008). FGF-2 also inhibits Ewing's sarcoma growth in vivo (Sturla et al., 2000). Overexpressing FGF-2 in mice reduces chondrocyte proliferation by increasing apoptosis (Sahni et al., 2001).

We also observed significant neuronal death 48 hours after FGF-2 treatment, which was associated with upregulation of system x<sub>C</sub>- activity. Blocking either system x<sub>C</sub>- or AMPA receptors eliminated the neuronal cell death, suggesting glutamate exported from astrocytic system x<sub>C</sub>- contributes to the neuronal death. However, we cannot exclude the possibility that the neuronal toxicity was due to FGF-2 sensitizing the neurons to normal glutamate release from system x<sub>C</sub>-. An AMPA receptor antagonist, NBQX, but not an NMDA receptor antagonist, MEM, blocked the FGF-2 induced neuronal death. This profile of toxicity is different from non-FGF-2 treated cells, in which low level glutamate exposure causes a similar level of neuronal death, but it is prevented by either AMPA or NMDA receptor antagonists. We could not use the more potent NMDA receptor antagonists (2R)-amino-5-phosphonovaleric acid (APV) or MK-

801 because they cause cell death by themselves, even at low concentrations, after 48 hours (data not shown). Bath incubation of glutamate is believed to activate extracellular receptors, which is likely similar to glutamate released from system  $x_C$ . Therefore, FGF-2 is in some way altering the type of excitotoxicity that occurs to the neurons. To determine what FGF-2 changes in terms of response to glutamate, detailed studies would need to be carried out examining whether the levels of NMDA and AMPA receptors were changed. This could be done by western blotting, examining the levels of NMDA and AMPA receptor subunits. Furthermore, electrophysiological studies would be needed to examine whether functional changes in receptors occurred. Fura-2 studies could also be carried out to examine whether calcium influx was changed by FGF-2 treatment. It is also possible that the changes in glutamate receptor mediated toxicity are due to changes in the intracellular signaling cascade downstream of receptor activation.

We made several attempts to measure whether there was elevated glutamate accumulating in the culture media following 48 hour FGF-2 treatment. DIV 13 astrocyte-enriched cultures were washed into fresh media, then following 48 hour exposure to FGF-2 or not (CTRL), bathing media from the cell cultures was collected and assayed for glutamate by HPLC. The media used for such long-term exposure was required to be a complex media we call MS, which contains more than 100  $\mu$ M concentrations of 8 amino acids including cystine. Astrocyte-enriched cultures were used because in mixed cultures neuronal death would occur at this time point, and the dead neurons would have released large amounts of glutamate. Since the FGF-2 effect on system  $x_C$  occurs on astrocytes, the effect should be observed in the astrocyte-enriched cultures. Two HPLC methods were tried to quantitate glutamate: phenylisothiocyanate (PITC) derivatization with

ultraviolet detection on an Agilent 1100 HPLC and fluorescence detection with ophthaldehyde pre-column derivitization on a Shimadzu LC10AD HPLC. However, because the experiments were done in a complex media, there was an interfering peak where glutamate was to be measured. Both a Hypersil-ODS reverse phase column and a Synergi Hydro-RP column were tested with the PITC derivatization with ultraviolet detection method in an attempt to separate the interfering peak from the glutamate peak. Also various mobile phases and flow rates were tested. Although the new column, and using a slower flow rate appeared to give us better separation, it significantly decreased the sensitivity for detection of glutamate (more than 10 times less sensitive). Since we are detecting glutamate in a large amount of extracellular media compared to that of the restricted space among the attached cells (with an estimated 1:1000 dilution), the glutamate concentration in the extracellular media is very low. Furthermore, it is not known whether FGF-2 treatment changes the glutamate uptake efficiency. Therefore, we were unable to determine the extracellular glutamate levels under these conditions.

We cannot exclude the possibility of FGF-2 treatment changing neuronal susceptibility to normal extracellular glutamate levels. One of the possibilities being that FGF-2 treatment changes the astrocytes' ability to release cysteine-containing molecules, which in turn, selectively decreases glutathione levels in neurons, causing them to be susceptible to any insult, including glutamate levels that does not cause death to healthy neurons. This hypothesis could be tested by measuring thiols by HPLC in the culture media of mixed neuronal and glial cultures.

## **IS SYSTEM X<sub>C</sub>- ACTIVITY TOXIC TO NEURONS?**

In this dissertation, we have shown that BMAA can contribute to neuronal death by acting at system x<sub>C</sub>-. Also, that prolonged FGF-2 treatment can upregulate system x<sub>C</sub>- and cause a system x<sub>C</sub>- function dependent neuronal toxicity. As knowledge of the function of system x<sub>C</sub>- expands, and the interest in targeting this system as a treatment for various neurodegenerative diseases and psychiatric disorders increases, it is important to understand the potential damage that system x<sub>C</sub>- activity can cause. Currently, it is clear that for cells that mainly rely on system x<sub>C</sub>- to take up cystine for the production of glutathione, blocking system x<sub>C</sub>- function can be toxic (Murphy et al., 1989). The question remains whether the glutamate exchanged out of these cells by system x<sub>C</sub>- is a threat to surrounding cells. Glioma cells have increased system x<sub>C</sub>- function, as well as decreased glutamate uptake, leading to increased extracellular glutamate which can cause toxicity to the surrounding neurons (Ye and Sontheimer, 1999; Sontheimer, 2003; 2008; Ogunrinu and Sontheimer, 2010). Both FGF-2 (Liu et al., 2011) and IL-1 $\beta$  (Fogal et al., 2007) upregulate system x<sub>C</sub>- function selectively on astrocytes. Long-term FGF-2 treatment causes a system x<sub>C</sub>- function dependent, and AMPA receptor specific, neuronal death. While IL-1 $\beta$  treatment potentiates hypoxia and glucose deprivation induced neuronal death through a system x<sub>C</sub>- activity dependent mechanism (Fogal et al., 2007; Jackman et al., 2012). Another example of increased system x<sub>C</sub>- function is activated microglia, which release enough glutamate through system x<sub>C</sub>- to cause toxicity to the surrounding neurons (Domercq et al., 2007). In all of these studies, along with the involvement of system x<sub>C</sub>-, the neurons are under stress: hypoxia, glucose deprivation, or stimulation by growth factors or cytokines. Therefore, while it is clear that enhanced



system  $x_C^-$  activity on non-neuronal cells can potentiate neuronal death when the neurons are compromised, it is uncertain whether glutamate release from system  $x_C^-$  can cause neuronal death under normal conditions.

## **QUESTIONS REGARDING SYSTEM $x_C^-$ STUDIES**

### **Molecular properties of system $x_C^-$**

Northern blot has shown three different xCT transcripts (12, 3.5 and 2.5 kb) in cultured macrophages and HT22 cells, as well as in various mouse organ tissues (Sato et al., 1999; 2001; 2004; 2005; Lewerenz et al., 2006; Taguchi et al., 2007). They may represent alternative splicing or alternative polyadenylation (Sato et al., 1999; Lewerenz et al., 2006). While all of these transcripts are inducible to a similar extent in culture (Sato et al., 1999), they have a different distribution pattern. The 3.5 and 2.5 kb transcripts were predominantly seen in macrophages, while the 12 kb RNA transcript was found in mouse brain, but not in peripheral organs such as heart, lung, liver, and kidney (Sato et al., 1999; Bassi et al., 2001; Sato et al., 2002). Human ovarian cancer cell lines (Okuno et al., 2003), hamster kidney cells (Sasaki et al., 2002), and cultured rat astrocytes (Gochenauer and Robinson, 2001) were shown to exclusively express the 12 kb transcript of xCT.

The predicted amino acid sequence from cDNA for xCT would be a protein of 502 amino acids with a relative molecular mass of 55.5 kDa (Sato et al., 1999). However, in reality, xCT with various molecular masses have been reported. The 55kDa protein is observed both in brain in vivo and in cortical neuronal stem cell cultures (Sims et al., 2012). 50 kDa xCT was detected in human glioma cells (Kim et al., 2001) and

retinal ganglion cell line membranes (Dun et al., 2006). In vitro expression of xCT in *Xenopus* oocytes (Sato et al., 1999) and HT22 cells (Burdo et al., 2006) showed a band of an approximately 40 kDa protein, which could be downregulated by siRNA (Burdo et al., 2006). This 40 kDa xCT was detected in rat brain tissue, with the expression level increasing during development and reaching the highest expression as an adult (La Bella et al., 2007). xCT was also observed in mouse hippocampus at a molecular weight of ~35 kDa, which is absent in xCT  $-/-$  mice (Pacchioni et al., 2007; De Bundel et al., 2011).

There are also studies reporting that xCT is detected at multiple molecular masses in the same tissue, with the same antibody. A study done in primary rat astrocyte cultures revealed three distinct bands for xCT: 40, 45, and 50 kDa, however, only the 40 kDa was released from the system  $x_C$ - heterodimer after reducing agent was added (Seib et al., 2011). xCT was also detected at 50 kDa and 40 kDa in mouse Muller cells, with the 50 kDa protein as the majority version. However, it was not inducible by oxidative stress, while the minority 40 kDa form, which is normally predominantly located intracellularly, was upregulated by oxidative stress and translocated to the membrane (Mysona et al., 2009). The same 40 kDa form of xCT was also found to be almost exclusively present on the cellular membrane in rat brain tissue, cultured human fibroblast, rat neurons and astrocytes (La Bella et al., 2007). xCT was detected at 35 kDa and 55 kDa in mouse brain and mouse astrocyte cultures, with the 55 kDa form prominently detected only in mouse meninges (Shih et al., 2006).

Together with these mixed results, there are also a number of system  $x_C$ - studies that did not report the band(s) mass in their paper (Bridges et al., 2004; Qiang et al., 2004; Sakakura et al., 2007). It seems that the use of different antibodies and different


tissues can lead to different results. Furthermore, increased expression does not necessarily mean increased membrane expression and increased function. Therefore, claims about potential system  $x_C$ - function by measuring xCT protein expression must be considered skeptically. In our studies, we have focused on the functional activity of system  $x_C$ - measured by  $^{14}\text{C}$ -cystine uptake.

### **Relevance and limitations of translating in vitro studies to in vivo:**

It has been suggested that when compared to in vivo, system  $x_C$ - activity is much higher in vitro (Lewerenz et al., 2012). This is believed to be because system  $x_C$ - activity can be easily induced. Even regular cell culture conditions with ambient  $\text{O}_2$  of 21% strongly induces system  $x_C$ - activity in diverse cell types, including fibroblasts, HEK cells, hippocampal HT22 cells, astrocytes, and microglial (Lewerenz et al., 2012). In freshly prepared hepatocytes and macrophages, the activity of system  $x_C$ - is barely detectable (Takada and Bannai, 1984; Watanabe and Bannai, 1987), but it is significantly upregulated after 12 hours of culturing (Watanabe and Bannai, 1987). A much higher system  $x_C$ - activity level is measured in macrophages cultured for 8 hours in the presence of LPS and diethyl maleate (Sato et al., 1995a). Various electrophilic agents and different pH have been proven to be system  $x_C$ - activity inducers (Reynolds et al., 1991; Sasaki et al., 2002). These concerns regarding cell culture studies must be kept in mind when attempting to extrapolate cell culture studies to the in vivo situation.

Our in vitro data showed that astrocytes have greater system  $x_C$ - activity than neurons (Lobner, 2009), in agreement with another lab (Jackman et al., 2012). Preliminary data from our lab indicates that neuronal conditioned media significantly

increases astrocytic system  $x_c^-$  activity within 24 hours (Fig. 5.7). The exact mechanism of how neuronal conditioned media causes this functional increase of system  $x_c^-$  in astrocytes requires further study.



**FIGURE 5.7. 24 hour exposure to neuronal-conditioned media (NCM) increases system  $x_c^-$  mediated cystine uptake in astrocytes.**

Culture media from the DIV 13 primary mouse glia-enriched cultures was replaced with NCM collected from DIV 13 neuronal-enriched cultures,  $^{14}\text{C}$ -cystine uptake for 20 min is measured 24 hours later. Bars show % control (mean  $\pm$  s.e.m.,  $n = 12-16$ ). \* indicates significantly different from control uptake.

## CONCLUSION

System  $x_C^-$  dysregulation has been implicated in various neurodegenerative diseases and psychiatric disorders. The dual function of system  $x_C^-$  awards it a distinct role in influencing cell fate. It may be protective by promoting cystine uptake and preventing oxidative stress, but it may be harmful by releasing glutamate and exacerbating excitotoxicity.

The goal of this thesis was to add to the knowledge regarding the role of system  $x_C^-$  in neuronal death. Two major advancements to the field were made. First, we discovered that the environmental neurotoxin BMAA acts as a substrate for system  $x_C^-$ . Through this action, BMAA both inhibits cystine uptake, leading to oxidative stress and drives glutamate release causing excitotoxicity. This result is important not only for understanding the mechanism of BMAA toxicity, but also provides evidence that compounds that are transported by system  $x_C^-$ , particularly if they do not lead to increased glutathione production, are potentially highly neurotoxic. Second, the results involving FGF-2 suggest that increasing system  $x_C^-$  selectively on astrocytes is potentially harmful to neurons. This finding, in concert with the well known neurotoxic action of glomas, that also have upregulated system  $x_C^-$ , suggests a general hypothesis that upregulation of system  $x_C^-$  on non-neuronal cells can be toxic to neurons.

## BIBLIOGRAPHY

- Agulhon C, Petravicz J, McMullen A, Sweger E, Minton S, Taves S, Casper K, Fiocco T, Mccarthy K (2008) What Is the Role of Astrocyte Calcium in Neurophysiology? *Neuron* 59:932–946.
- Alagarsamy S, Marino MJ, Rouse ST, Gereau RW, Heinemann SF, Conn PJ (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. *Nat Neurosci* 2:234–240.
- Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D (2004) Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. *Neuropharmacology* 46:793–806.
- Alzheimer C, Werner S (2002) Fibroblast growth factors and neuroprotection. *Adv Exp Med Biol* 513:335–351.
- Amara SG (1992) Neurotransmitter transporters. A tale of two families. *Nature* 360:420–421.
- Amen SL, Piacentine LB, Ahmad ME, Li S-J, Mantsch JR, Risinger RC, Baker DA (2011) Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. *Neuropsychopharmacology* 36:871–878.
- Ameri K, Harris AL (2008) Activating transcription factor 4. *Int J Biochem Cell Biol* 40:14–21.
- Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? *Nat Med* 10 Suppl:S18–S25.
- Anton ES, Marchionni MA, Lee KF, Rakic P (1997) Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex. *Development* 124:3501–3510.
- Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, Swanson RA (2006) Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. *Nat Neurosci* 9:119–126.
- Arrick BA, Griffio W, Cohn Z, Nathan C (1985) Hydrogen peroxide from cellular metabolism of cystine. A requirement for lysis of murine tumor cells by vernolepin, a glutathione-depleting antineoplastic. *Journal of Clinical Investigation* 76:567–574.
- Aschner M, Mullaney KJ, Wagoner D, Lash LH, Kimelberg HK (1994) Intracellular glutathione (GSH) levels modulate mercuric chloride (MC)- and methylmercuric chloride (MeHgCl)-induced amino acid release from neonatal rat primary astrocytes cultures. *Brain Research* 664:133–140.

- Asztely F, Erdemli G, Kullmann DM (1997) Extrasynaptic glutamate spillover in the hippocampus: dependence on temperature and the role of active glutamate uptake. *Neuron* 18:281–293.
- Augustin H, Grosjean Y, Chen K, Sheng Q, Featherstone DE (2007) Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo. *Journal of Neuroscience* 27:111–123.
- Ay H, Ay I, Koroshetz WJ, Finklestein SP (1999) Potential usefulness of basic fibroblast growth factor as a treatment for stroke. *Cerebrovasc Dis* 9:131–135.
- Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. *Brain Res Brain Res Rev* 25:335–358.
- Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I (2008) Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. *Neuropsychopharmacology* 33:1760–1772.
- Baker DA, McFarland K, Lake RW, Shen H, Tang X-C, Toda S, Kalivas PW (2003) Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat Neurosci* 6:743–749.
- Baker DA, Xi Z-X, Shen H, Swanson CJ, Kalivas PW (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. *Journal of Neuroscience* 22:9134–9141.
- Baker MA, Cerniglia GJ, Zaman A (1990) Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. *Anal Biochem* 190:360–365.
- Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) Glutathione dysregulation and the etiology and progression of human diseases. *Biol Chem* 390:191–214.
- Banack SA, Johnson HE, Cheng R, Cox PA (2007) Production of the neurotoxin BMAA by a marine cyanobacterium. *Mar Drugs* 5:180–196.
- Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, Kölle P, Tschöep K, Issels RD, Daniel PT, Conrad M, Bornkamm GW (2008) The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. *Oncogene* 27:1618–1628.
- Bannai S (1984) Induction of cystine and glutamate transport activity in human fibroblasts by diethyl maleate and other electrophilic agents. *The Journal of Biological Chemistry* 259:2435–2440.
- Bannai S, Kitamura E (1980) Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. *The Journal of Biological Chemistry*

255:2372–2376.

- Bannerman P, Horiuchi M, Feldman D, Hahn A, Itoh A, See J, Jia ZP, Itoh T, Pleasure D (2007) GluR2-free alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors intensify demyelination in experimental autoimmune encephalomyelitis. *Journal of Neurochemistry* 102:1064–1070.
- Barbour B, Brew H, Attwell D (1988) Electrogenic glutamate uptake in glial cells is activated by intracellular potassium. *Nature* 335:433–435.
- Barger SW, Basile AS (2001) Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. *Journal of Neurochemistry* 76:846–854.
- Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martín R, Zorzano A, Borsani G, Palacín M (2001) Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc-. *Pflugers Arch* 442:286–296.
- Beck KD (1994) Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons. *Prog Neurobiol* 44:497–516.
- Benarroch EE (2009) Astrocyte-neuron interactions: implications for epilepsy. *Neurology* 73:1323–1327.
- Benquet P, Gee CE, Gerber U (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. *Journal of Neuroscience* 22:9679–9686.
- Beutler E (1989) Nutritional and metabolic aspects of glutathione. *Annu Rev Nutr* 9:287–302.
- Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D, Rizzini BL, Pozzan T, Volterra A (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. *Nature* 391:281–285.
- Bezzi P, Gundersen V, Galbete JL, Seifert G, Steinhäuser C, Pilati E, Volterra A (2004) Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. *Nat Neurosci* 7:613–620.
- Bébé P, Stern P, Wyllie DJ, Nassar M, Schoepfer R, Colquhoun D (1995) Determination of NMDA NR1 subunit copy number in recombinant NMDA receptors. *Proc Biol Sci* 262:205–213.
- Bogdanov VB, Bogdanova OV, Koulchitsky SV, Chauvel V, Multon S, Makarchuk MY, Brennan KC, Renshaw PF, Schoenen J (2013) Behavior in the open field predicts the number of KCl-induced cortical spreading depressions in rats. *Behav Brain Res*



236:90–93.

- Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo J-MM, Chamorro A, Desmet A, European-Australian Fiblast (Trafermin) in Acute Stroke Group (2002) Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. *Cerebrovasc Dis* 14:239–251.
- Bolaños JP, Heales SJ, Land JM, Clark JB (1995) Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. *Journal of Neurochemistry* 64:1965–1972.
- Boxer AL, Moreno H, Rudy B, Ziff EB (1999) FGF-2 potentiates Ca(2+)-dependent inactivation of NMDA receptor currents in hippocampal neurons. *Journal of Neurophysiology* 82:3367–3377.
- Brackley PT, Bell DR, Choi SK, Nakanishi K, Usherwood PN (1993) Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins. *J Pharmacol Exp Ther* 266:1573–1580.
- Bradley WG, Mash DC (2009) Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. *Amyotroph Lateral Scler* 10 Suppl 2:7–20.
- Brand LE, Pablo J, Compton A, Hammerschlag N, Mash DC (2010) Cyanobacterial Blooms and the Occurrence of the neurotoxin beta-N-methylamino-L-alanine (BMAA) in South Florida Aquatic Food Webs. *Harmful Algae* 9:620–635.
- Brandoli C, Sanna A, De Bernardi MA, Follesa P, Brooker G, Mocchetti I (1998) Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. *J Neurosci* 18:7953–7961.
- Bridges CC, Hu H, Miyauchi S, Siddaramappa UN, Ganapathy ME, Ignatowicz L, Maddox DM, Smith SB, Ganapathy V (2004) Induction of cystine-glutamate transporter xc<sup>-</sup> by human immunodeficiency virus type 1 transactivator protein tat in retinal pigment epithelium. *Investigative Ophthalmology & Visual Science* 45:2906–2914.
- Bridges R, Lutgen V, Lobner D, Baker DA (2012a) Thinking Outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System xc<sup>-</sup>) to Normal and Pathological Glutamatergic Signaling. *Pharmacological reviews* 64:780–802.
- Bridges RJ, Natale NR, Patel SA (2012b) System xc<sup>-</sup> cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. *Br J Pharmacol* 165:20–34.
- Brigelius-Flohé R, Traber MG (1999) Vitamin E: function and metabolism. *FASEB J*

13:1145–1155.

- Brownson DM, Mabry TJ, Leslie SW (2002) The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. *J Ethnopharmacol* 82:159–167.
- Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H (2011) Glutamate release by primary brain tumors induces epileptic activity. *Nat Med*.
- Burdo J, Dargusch R, Schubert D (2006) Distribution of the cystine/glutamate antiporter system xc<sup>-</sup> in the brain, kidney, and duodenum. *J Histochem Cytochem* 54:549–557.
- Burnashev N, Zhou Z, Neher E, Sakmann B (1995) Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes. *The Journal of Physiology* 485 ( Pt 2):403–418.
- Butt AM (2011) ATP: a ubiquitous gliotransmitter integrating neuron-glia networks. *Semin Cell Dev Biol* 22:205–213.
- Cabungcal J-H, Preissmann D, Delsech C, Cuénod M, Do KQ, Schenk F (2007) Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. *Neurobiol Dis* 26:634–645.
- Carriedo SG, Yin HZ, Lamberta R, Weiss JH (1995) In vitro kainate injury to large, SMI-32(+) spinal neurons is Ca<sup>2+</sup> dependent. *Neuroreport* 6:945–948.
- Chang RCC, Wong AKY, Ng H-K, Hugon J (2002) Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. *Neuroreport* 13:2429–2432.
- Charleston JS, Body RL, Mottet NK, Vahter ME, Burbacher TM (1995) Autometallographic determination of inorganic mercury distribution in the cortex of the calcarine sulcus of the monkey *Macaca fascicularis* following long-term subclinical exposure to methylmercury and mercuric chloride. *Toxicology and Applied Pharmacology* 132:325–333.
- Chase LA, Peterson NL, Koerner JF (2007) The lathyrus toxin, beta-N-oxalyl-L-alpha,beta-diaminopropionic acid (ODAP), and homocysteic acid sensitize CA1 pyramidal neurons to cystine and L-2-amino-6-phosphohexanoic acid. *Toxicology and Applied Pharmacology* 219:1–9.
- Chen H-H, Liao P-F, Chan M-H (2011) mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. *J Biomed Sci* 18:19.

- Chen H-SV, Lipton SA (2006) The chemical biology of clinically tolerated NMDA receptor antagonists. *Journal of Neurochemistry* 97:1611–1626.
- Chen Y, Swanson RA (2003) Astrocytes and brain injury. *J Cereb Blood Flow Metab* 23:137–149.
- Cheng B, Furukawa K, O'Keefe JA, Goodman Y, Kihiko M, Fabian T, Mattson MP (1995) Basic fibroblast growth factor selectively increases AMPA-receptor subunit GluR1 protein level and differentially modulates Ca<sup>2+</sup> responses to AMPA and NMDA in hippocampal neurons. *Journal of Neurochemistry* 65:2525–2536.
- Chintala S, Li W, Lamoreux ML, Ito S, Wakamatsu K, Sviderskaya EV, Bennett DC, Park Y-M, Gahl WA, Huizing M, Spritz RA, Ben S, Novak EK, Tan J, Swank RT (2005) Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. *Proc Natl Acad Sci USA* 102:10964–10969.
- Choi D (1998) Antagonizing excitotoxicity: a therapeutic strategy for stroke? *Mt Sinai J Med* 65:133–138.
- Choi DW (1987) Ionic dependence of glutamate neurotoxicity. *J Neurosci* 7:369–379.
- Choi DW, Maulucci-Gedde M, Kriegstein AR (1987) Glutamate neurotoxicity in cortical cell culture. *J Neurosci* 7:357–368.
- Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. *Journal of Neuroscience* 25:7101–7110.
- Chung WJ, Sontheimer H (2009) Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. *Journal of Neurochemistry* 110:182–193.
- Clark WM, Schim JD, Kasner SE, Victor SJ (2000) Trafermin in acute ischemic stroke: results of a phase II/III randomized efficacy study. *Neurology* 54:A88.
- Clem RL, Barth A (2006) Pathway-specific trafficking of native AMPARs by in vivo experience. *Neuron* 49:663–670.
- Cohen SA (2012) Analytical techniques for the detection of  $\alpha$ -amino- $\beta$ -methylaminopropionic acid. *Analyst* 137:1991–2005.
- Cohen SA, Bidlingmeyer BA, Tarvin TL (1986) PITC derivatives in amino acid analysis. *Nature* 320:769–770.
- Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. *Annu Rev Pharmacol Toxicol* 37:205–237.
- Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ (1990) Glutamate induces

- calcium waves in cultured astrocytes: long-range glial signaling. *Science* 247:470–473.
- Costa-Mattioli M, Gobert D, Stern E, Gamache K, Colina R, Cuello C, Sossin W, Kaufman R, Pelletier J, Rosenblum K, Krnjević K, Lacaille J-C, Nader K, Sonenberg N (2007) eIF2 $\alpha$  phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. *Cell* 129:195–206.
- Cox PA, Banack SA, Murch SJ (2003) Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. *Proc Natl Acad Sci USA* 100:13380–13383.
- Cox PA, Banack SA, Murch SJ, Rasmussen U, Tien G, Bidigare RR, Metcalf JS, Morrison LF, Codd GA, Bergman B (2005) Diverse taxa of cyanobacteria produce beta-N-methylamino-L-alanine, a neurotoxic amino acid. *Proc Natl Acad Sci USA* 102:5074–5078.
- Cox PA, Richer R, Metcalf JS, Banack SA, Codd GA, Bradley WG (2009) Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. *Amyotroph Lateral Scler* 10 Suppl 2:109–117.
- Cox PA, Sacks OW (2002) Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. *Neurology* 58:956–959.
- Crimmins DL, Cherian R (1997) Increasing the sensitivity of 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate amino acid analysis: a simple solution. *Anal Biochem* 244:407–410.
- Crockett S, Clarke M, Reeves S, Sims B (2011) Cystine glutamate exchanger upregulation by retinoic acid induces neuroprotection in neural stem cells. *Neuroreport* 22:598–602.
- Cruz-Aguado R, Winkler D, Shaw CA (2006) Lack of behavioral and neuropathological effects of dietary beta-methylamino-L-alanine (BMAA) in mice. *Pharmacol Biochem Behav* 84:294–299.
- Cucchiaroni ML, Viscomi MT, Bernardi G, Molinari M, Guatteo E, Mercuri NB (2010) Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons. *Journal of Neuroscience* 30:5176–5188.
- Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Giménez-Gallego G (1991) Hypotensive activity of fibroblast growth factor. *Science* 254:1208–1210.
- Cui K, Luo X, Xu K, Ven Murthy MR (2004) Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. *Progress in neuro-psychopharmacology & biological psychiatry* 28:771–799.

- Czyz A, Baranauskas G, Kiedrowski L (2002) Instrumental role of Na<sup>+</sup> in NMDA excitotoxicity in glucose-deprived and depolarized cerebellar granule cells. *Journal of Neurochemistry* 81:379–389.
- De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, Vermoesen K, Bannai S, Sato H, Michotte Y, Smolders I, Massie A (2011) Loss of system x(c)<sup>-</sup> does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. *Journal of Neuroscience* 31:5792–5803.
- Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S, Berk M (2009) A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. *Curr Med Chem* 16:2965–2976.
- Deguchi Y, Naito T, Yuge T, Furukawa A, Yamada S, Pardridge WM, Kimura R (2000) Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. *Pharm Res* 17:63–69.
- Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. *Am J Physiol* 257:L163–L173.
- Dholakia JN, Wahba AJ (1989) Mechanism of the nucleotide exchange reaction in eukaryotic polypeptide chain initiation. Characterization of the guanine nucleotide exchange factor as a GTP-binding protein. *The Journal of Biological Chemistry* 264:546–550.
- Diamond JS, Jahr CE (1997) Transporters buffer synaptically released glutamate on a submillisecond time scale. *J Neurosci* 17:4672–4687.
- Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. *Pharmacological reviews* 51:7–61.
- Domercq M, Etxebarria E, Pérez-Samartín A, Matute C (2005) Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. *Glia* 52:36–46.
- Domercq M, Sánchez-Gómez MV, Sherwin C, Etxebarria E, Fern R, Matute C (2007) System xc<sup>-</sup> and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. *J Immunol* 178:6549–6556.
- Dono R (2003) Fibroblast growth factors as regulators of central nervous system development and function. *Am J Physiol Regul Integr Comp Physiol* 284:R867–R881.
- Dringen R, Gutterer JM, Hirrlinger J (2000) Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. *Eur J Biochem* 267:4912–4916.

- Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. *Biol Chem* 384:505–516.
- Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. *J Neurosci* 19:562–569.
- Dringen R, Wiesinger H, Hamprecht B (1993) Uptake of L-lactate by cultured rat brain neurons. *Neuroscience Letters* 163:5–7.
- Duan S, Anderson CM, Keung EC, Chen Y, Chen Y, Swanson RA (2003) P2X7 receptor-mediated release of excitatory amino acids from astrocytes. *Journal of Neuroscience* 23:1320–1328.
- Dugan LL, Bruno VM, Amagasu SM, Giffard RG (1995) Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. *J Neurosci* 15:4545–4555.
- Dugan LL, Choi DW (1994) Excitotoxicity, free radicals, and cell membrane changes. *Ann Neurol* 35 Suppl:S17–S21.
- Dun Y, Mysona B, Van Ells T, Amarnath L, Ola MS, Ganapathy V, Smith SB (2006) Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. *Cell Tissue Res* 324:189–202.
- Duncan MW, Markey SP, Weick BG, Pearson PG, Ziffer H, Hu Y, Kopin IJ (1992) 2-Amino-3-(methylamino)propanoic acid (BMAA) bioavailability in the primate. *NBA* 13:333–337.
- Duncan MW, Steele JC, Kopin IJ, Markey SP (1990) 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. *Neurology* 40:767–772.
- Duncan MW, Villacreses NE, Pearson PG, Wyatt L, Rapoport SI, Kopin IJ, Markey SP, Smith QR (1991) 2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. *J Pharmacol Exp Ther* 258:27–35.
- Duncan R, Hershey JW (1985) Regulation of initiation factors during translational repression caused by serum depletion. Covalent modification. *The Journal of Biological Chemistry* 260:5493–5497.
- Duncan RF, Hershey JW (1987) Initiation factor protein modifications and inhibition of protein synthesis. *Mol Cell Biol* 7:1293–1295.
- Eckenstein F, Woodward WR, Nishi R (1991a) Differential localization and possible functions of aFGF and bFGF in the central and peripheral nervous systems. *Annals of the New York Academy of Sciences* 638:348–360.

- Eckenstein FP (1994) Fibroblast growth factors in the nervous system. *J Neurobiol* 25:1467–1480.
- Eckenstein FP, Shipley GD, Nishi R (1991b) Acidic and basic fibroblast growth factors in the nervous system: distribution and differential alteration of levels after injury of central versus peripheral nerve. *J Neurosci* 11:412–419.
- Edvinsson L, Krause DN (2002) Cerebral blood flow and metabolism.
- Erdner DL, Dyble J, Parsons ML, Stevens RC, Hubbard KA, Wrabel ML, Moore SK, Lefebvre KA, Anderson DM, Bienfang P, Bidigare RR, Parker MS, Moeller P, Brand LE, Trainer VL (2008) Centers for Oceans and Human Health: a unified approach to the challenge of harmful algal blooms. *Environ Health* 7 Suppl 2:S2.
- Erecińska M, Silver IA (1990) Metabolism and role of glutamate in mammalian brain. *Prog Neurobiol* 35:245–296.
- Erickson AM, Nevarea Z, Gipp JJ, Mulcahy RT (2002) Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifier subunit gene. Revision of the ARE consensus sequence. *The Journal of Biological Chemistry* 277:30730–30737.
- Escartin C, Won SJ, Malgorn C, Auregan G, Berman AE, Chen P-C, Déglon N, Johnson JA, Suh SW, Swanson RA (2011) Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression. *Journal of Neuroscience* 31:7392–7401.
- Esterhuizen M, Downing TG (2008) Beta-N-methylamino-L-alanine (BMAA) in novel South African cyanobacterial isolates. *Ecotoxicol Environ Saf* 71:309–313.
- Esterhuizen-Londt M, Pflugmacher S, Downing TG (2011) The effect of  $\beta$ -N-methylamino-L-alanine (BMAA) on oxidative stress response enzymes of the macrophyte *Ceratophyllum demersum*. *Toxicon* 57:803–810.
- Estévez R, Camps M, Rojas AM, Testar X, Devés R, Hediger MA, Zorzano A, Palacín M (1998) The amino acid transport system y<sup>+</sup>L/4F2hc is a heteromultimeric complex. *FASEB J* 12:1319–1329.
- Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. *Cytokine Growth Factor Rev* 16:139–149.
- Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H, Lopez JF, Thompson RC, Meng F, Stead JD, Walsh DM, Myers RM, Bunney WE, Watson SJ, Jones EG, Akil H (2004) Dysregulation of the fibroblast growth factor system in major depression. *Proc Natl Acad Sci USA* 101:15506–15511.
- Fadda P, Bedogni F, Fresu A, Collu M, Racagni G, Riva MA (2007) Reduction of corticostriatal glutamatergic fibers in basic fibroblast growth factor deficient mice is

- associated with hyperactivity and enhanced dopaminergic transmission. *Biol Psychiatry* 62:235–242.
- Fafournoux P, Bruhat A, Jousse C (2000) Amino acid regulation of gene expression. *Biochem J* 351:1–12.
- Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase. *The Journal of Biological Chemistry* 273:18623–18632.
- Fellin T, Carmignoto G (2004) Neurone-to-astrocyte signalling in the brain represents a distinct multifunctional unit. *The Journal of Physiology* 559:3–15.
- Fellin T, Sul J-Y, D'Ascenzo M, Takano H, Pascual O, Haydon PG (2006) Bidirectional astrocyte-neuron communication: the many roles of glutamate and ATP. *Novartis Found Symp* 276:208–17–discussion217–21–233–7–275–81.
- Ferraguti F, Shigemoto R (2006) Metabotropic glutamate receptors. *Cell Tissue Res* 326:483–504.
- Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J (2003) Regulation of glial glutamate transporter expression by growth factors. *Experimental Neurology* 183:124–135.
- Flores C, Stewart J (2000) Basic fibroblast growth factor as a mediator of the effects of glutamate in the development of long-lasting sensitization to stimulant drugs: studies in the rat. *Psychopharmacology* 151:152–165.
- Fogal B, Li J, Lobner D, McCullough LD, Hewett SJ (2007) System x(c)- activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. *Journal of Neuroscience* 27:10094–10105.
- Fonnum F (1984) Glutamate: a neurotransmitter in mammalian brain. *Journal of Neurochemistry* 42:1–11.
- Ford-Perriss M, Abud H, Murphy M (2001) Fibroblast growth factors in the developing central nervous system. *Clin Exp Pharmacol Physiol* 28:493–503.
- Foucher JR, Luck D (2006) Psychosis related to neurological conditions: pro and cons of the dis- / mis-connectivity models of schizophrenia. *Dialogues Clin Neurosci* 8:17–27.
- Frank MG, Der-Avakian A, Bland ST, Watkins LR, Maier SF (2007) Stress-induced glucocorticoids suppress the antisense molecular regulation of FGF-2 expression. *Psychoneuroendocrinology* 32:376–384.
- Frautschy SA, Walicke PA, Baird A (1991) Localization of basic fibroblast growth factor



- and its mRNA after CNS injury. *Brain Research* 553:291–299.
- Freeman BA, Crapo JD (1982) Biology of disease: free radicals and tissue injury. *Lab Invest* 47:412–426.
- Freese A, Finklestein SP, DiFiglia M (1992) Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity. *Brain Research* 575:351–355.
- Fridovich I (1975) Superoxide dismutases. *Annu Rev Biochem* 44:147–159.
- Fumagalli F, Bedogni F, Maragnoli ME, Gennarelli M, Perez J, Racagni G, Riva MA (2003) Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus. *J Neurosci Res* 74:74–80.
- Fumagalli F, Bedogni F, Slotkin TA, Racagni G, Riva MA (2005) Prenatal stress elicits regionally selective changes in basal FGF-2 gene expression in adulthood and alters the adult response to acute or chronic stress. *Neurobiol Dis* 20:731–737.
- Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G, Riva MA (2004) Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. *Neuroreport* 15:2109–2112.
- Fumagalli F, Pasquale L, Racagni G, Riva MA (2006) Dynamic regulation of fibroblast growth factor 2 (FGF-2) gene expression in the rat brain following single and repeated cocaine administration. *Journal of Neurochemistry* 96:996–1004.
- Futamachi KJ, Pedley TA (1976) Glial cells and extracellular potassium: their relationship in mammalian cortex. *Brain Research* 109:311–322.
- Garruto RM, Gajdusek DC, Chen KM (1981) Amyotrophic lateral sclerosis and parkinsonism-dementia among Filipino migrants to Guam. *Ann Neurol* 10:341–350.
- Gasol E, Jiménez-Vidal M, Chillarón J, Zorzano A, Palacín M (2004) Membrane topology of system xc- light subunit reveals a re-entrant loop with substrate-restricted accessibility. *The Journal of Biological Chemistry* 279:31228–31236.
- Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M (2006) Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. *Brain Research Bulletin* 70:221–227.
- Ghosh A, Greenberg ME (1995) Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis. *Neuron* 15:89–103.
- Gochenauer GE, Robinson MB (2001) Dibutyryl-cAMP (dbcAMP) up-regulates astrocytic chloride-dependent L-[3H]glutamate transport and expression of both system xc(-) subunits. *Journal of Neurochemistry* 78:276–286.

- Gonzalez AM, Berry M, Maher PA, Logan A, Baird A (1995) A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. *Brain Research* 701:201–226.
- Gómez-Pinilla F, Dao L, Choi J, Ryba EA (2000) Diazepam induces FGF-2 mRNA in the hippocampus and striatum. *Brain Research Bulletin* 53:283–289.
- Grienberger C, Konnerth A (2012) Imaging calcium in neurons. *Neuron* 73:862–885.
- Grothe C, Wewetzer K (1996) Fibroblast growth factor and its implications for developing and regenerating neurons. *Int J Dev Biol* 40:403–410.
- Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, Wang Y-Z (2009) The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. *Cancer Chemother Pharmacol* 64:463–472.
- Hamby ME, Uliasz TF, Hewett SJ, Hewett JA (2006) Characterization of an improved procedure for the removal of microglia from confluent monolayers of primary astrocytes. *J Neurosci Methods* 150:128–137.
- Han AP, Yu C, Lu L, Fujiwara Y, Browne C, Chin G, Fleming M, Leboulch P, Orkin SH, Chen JJ (2001) Heme-regulated eIF2 $\alpha$  kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. *EMBO J* 20:6909–6918.
- Harada M (1995) Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. *Crit Rev Toxicol* 25:1–24.
- Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. *Nat Rev Neurosci* 11:682–696.
- Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat Neurosci* 5:405–414.
- Hashimoto K, Shimizu E, Komatsu N, Nakazato M, Okamura N, Watanabe H, Kumakiri C, Shinoda N, Okada S-I, Takei N, Iyo M (2003) Increased levels of serum basic fibroblast growth factor in schizophrenia. *Psychiatry Res* 120:211–218.
- Hershey JW (1989) Protein phosphorylation controls translation rates. *The Journal of Biological Chemistry* 264:20823–20826.
- Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. *Journal of Cell Science* 117:5965–5973.
- Hsuan S-L, Klintworth HM, Xia Z (2006) Basic fibroblast growth factor protects against

- rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. *Journal of Neuroscience* 26:4481–4491.
- Hu RG, Lim J, Donaldson PJ, Kalloniatis M (2008) Characterization of the cystine/glutamate transporter in the outer plexiform layer of the vertebrate retina. *Eur J Neurosci* 28:1491–1502.
- Huang YH, Sinha SR, Tanaka K, Rothstein JD, Bergles DE (2004) Astrocyte glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of hippocampal interneurons. *Journal of Neuroscience* 24:4551–4559.
- Ince PG, Codd GA (2005) Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? *Neuropathol Appl Neurobiol* 31:345–353.
- Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes & Development* 13:76–86.
- Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I (2006) Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. *The Journal of Physiology* 572:789–798.
- Jackman NA, Melchior SE, Hewett JA, Hewett SJ (2012) Non-cell autonomous influence of the astrocyte system xc- on hypoglycaemic neuronal cell death. *ASN Neuro* 4.
- Jackman NA, Uliasz TF, Hewett JA, Hewett SJ (2010) Regulation of system x(c)(-) activity and expression in astrocytes by interleukin-1 $\beta$ : implications for hypoxic neuronal injury. *Glia* 58:1806–1815.
- Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. *Neurology* 47:S161–S170.
- Johnson FO, Atchison WD (2009) The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis. *Neurotoxicology* 30:761–765.
- Johnson HE, King SR, Banack SA, Webster C, Callanaupa WJ, Cox PA (2008) Cyanobacteria (*Nostoc commune*) used as a dietary item in the Peruvian highlands produce the neurotoxic amino acid BMAA. *J Ethnopharmacol* 118:159–165.
- Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. *Nature* 325:529–531.
- Johnson MR, Valentine C, Basilico C, Mansukhani A (1998) FGF signaling activates

- STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. *Oncogene* 16:2647–2656.
- Jonas P, Racca C, Sakmann B, Seeburg PH, Monyer H (1994) Differences in Ca<sup>2+</sup> permeability of AMPA-type glutamate receptor channels in neocortical neurons caused by differential GluR-B subunit expression. *Neuron* 12:1281–1289.
- Jonasson S, Eriksson J, Berntzon L, Spácil Z, Ilag LL, Ronnevi L-O, Rasmussen U, Bergman B (2010) Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposure. *Proc Natl Acad Sci* 107:9252–9257.
- Kalra L, Ratan RR (2008) Advances in stroke regenerative medicine 2007. *Stroke* 39:273–275.
- Kamnasaran D, Muir WJ, Ferguson-Smith MA, Cox DW (2003) Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. *J Med Genet* 40:325–332.
- Kanai Y, Hediger MA (1992) Primary structure and functional characterization of a high-affinity glutamate transporter. *Nature* 360:467–471.
- Kau KS, Madayag A, Mantsch JR, Grier MD, Abdulhameed O, Baker DA (2008) Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. *Neuroscience* 155:530–537.
- Kilberg MS, Pan Y-X, Chen H, Leung-Pineda V (2005) Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. *Annu Rev Nutr* 25:59–85.
- Kilberg MS, Shan J, Su N (2009) ATF4-dependent transcription mediates signaling of amino acid limitation. *Trends Endocrinol Metab* 20:436–443.
- Kilbride J, Rush AM, Rowan MJ, Anwyl R (2001) Presynaptic group II mGluR inhibition of short-term depression in the medial perforant path of the dentate gyrus in vitro. *Journal of Neurophysiology* 85:2509–2515.
- Kim CH, Lee J, Lee J-Y, Roche KW (2008) Metabotropic glutamate receptors: phosphorylation and receptor signaling. *J Neurosci Res* 86:1–10.
- Kim JY, Kanai Y, Chairoungdua A, Cha SH, Matsuo H, Kim DK, Inatomi J, Sawa H, Ida Y, Endou H (2001) Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. *Biochim Biophys Acta* 1512:335–344.
- Kim M-S, Kim CJ, Jung HS, Seo MR, Juhn Y-S, Shin HY, Ahn HS, Thiele CJ, Chi JG (2004) Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumour cells. *J Pathol* 202:103–112.

- Kimball SR (1999) Eukaryotic initiation factor eIF2. *Int J Biochem Cell Biol* 31:25–29.
- Kisby GE, Roy DN, Spencer PS (1988) Determination of beta-N-methylamino-L-alanine (BMAA) in plant (*Cycas circinalis* L.) and animal tissue by precolumn derivatization with 9-fluorenylmethyl chloroformate (FMOC) and reversed-phase high-performance liquid chromatography. *J Neurosci Methods* 26:45–54.
- Kleijn M, Proud CG (2000) The activation of eukaryotic initiation factor (eIF)2B by growth factors in PC12 cells requires MEK/ERK signalling. *FEBS Lett* 476:262–265.
- Klejbor I, Myers JM, Hausknecht K, Corso TD, Gambino AS, Morys J, Maher PA, Hard R, Richards J, Stachowiak EK, Stachowiak MK (2006) Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. *Journal of Neurochemistry* 97:1243–1258.
- Knackstedt LA, Melendez RI, Kalivas PW (2010) Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. *Biol Psychiatry* 67:81–84.
- Koh JY, Choi DW (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. *J Neurosci Methods* 20:83–90.
- Koh JY, Gwag BJ, Lobner D, Choi DW (1995) Potentiated necrosis of cultured cortical neurons by neurotrophins. *Science* 268:573–575.
- Koike M, Iino M, Ozawa S (1997) Blocking effect of 1-naphthyl acetyl spermine on Ca(2+)-permeable AMPA receptors in cultured rat hippocampal neurons. *Neurosci Res* 29:27–36.
- Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. *Nat Med* 10:719–726.
- Korada S, Zheng W, Basilico C, Schwartz ML, Vaccarino FM (2002) Fibroblast growth factor 2 is necessary for the growth of glutamate projection neurons in the anterior neocortex. *Journal of Neuroscience* 22:863–875.
- Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J (1997) A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. *Cell* 89:693–702.
- Köles L, Leichsenring A, Rubini P, Illes P (2011) P2 receptor signaling in neurons and glial cells of the central nervous system. *Adv Pharmacol* 61:441–493.
- Kranich O, Hamprecht B, Dringen R (1996) Different preferences in the utilization of amino acids for glutathione synthesis in cultured neurons and astroglial cells

- derived from rat brain. *Neuroscience Letters* 219:211–214.
- Kreft M, Stenovec M, Rupnik M, Grilc S, Krzan M, Potokar M, Pangrsic T, Haydon PG, Zorec R (2004) Properties of Ca(2+)-dependent exocytosis in cultured astrocytes. *Glia* 46:437–445.
- Kurland LT, Mulder DW (1954) Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. *Neurology* 4:355–378.
- La Bella V, Valentino F, Piccoli T, Piccoli F (2007) Expression and developmental regulation of the cystine/glutamate exchanger (xc-) in the rat. *Neurochem Res* 32:1081–1090.
- Lau A, Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. *Pflugers Arch* 460:525–542.
- Ledoux D, Gannoun-Zaki L, Barritault D (1992) Interactions of FGFs with target cells. *Prog Growth Factor Res* 4:107–120.
- Lee J-M, Johnson JA (2004) An important role of Nrf2-ARE pathway in the cellular defense mechanism. *J Biochem Mol Biol* 37:139–143.
- Lehre KP, Danbolt NC (1998) The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. *J Neurosci* 18:8751–8757.
- Lewerenz J, Albrecht P, Tien M-LT, Henke N, Karumbayaram S, Kornblum HI, Wiedau-Pazos M, Schubert D, Maher P, Methner A (2009) Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. *Journal of Neurochemistry* 111:332–343.
- Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P (2012) The Cystine/Glutamate Antiporter System x(c)(-) in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities. *Antioxid Redox Signal*.
- Lewerenz J, Klein M, Methner A (2006) Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity. *Journal of Neurochemistry* 98:916–925.
- Lewerenz J, Maher P (2009) Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. *The Journal of Biological Chemistry* 284:1106–1115.
- Léveillé F, Gaamouch El F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A (2008)

Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. *The FASEB Journal* 22:4258–4271.

Li A, Tian Z, Li J, Yu R, Banack SA, Wang Z (2010) Detection of the neurotoxin BMAA within cyanobacteria isolated from freshwater in China. *Toxicon* 55:947–953.

Lipton SA, Chen H-S (2004) Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. *Cell Death Differ* 11:18–20.

Liu H, Wang H, Shenvi S, Hagen TM, Liu R-M (2004) Glutathione metabolism during aging and in Alzheimer disease. *Annals of the New York Academy of Sciences* 1019:346–349.

Liu X, Resch J, Rush T, Lobner D (2011) Functional upregulation of system xc- by fibroblast growth factor-2. *Neuropharmacology*.

Liu X, Rush T, Zapata J, Lobner D (2009) beta-N-methylamino-L-alanine induces oxidative stress and glutamate release through action on system Xc(-). *Experimental Neurology* 217:429–433.

Liu XQ, Rush T, Ciske J, Lobner D (2010) Selective death of cholinergic neurons induced by beta-methylamino-L-alanine. *Neuroreport* 21:55–58.

Lo M, Ling V, Wang YZ, Gout PW (2008) The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. *Br J Cancer* 99:464–472.

Lobner D (2000) Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? *J Neurosci Methods* 96:147–152.

Lobner D (2009) Mechanisms of beta-N-methylamino-L-alanine induced neurotoxicity. *Amyotroph Lateral Scler* 10 Suppl 2:56–60.

Lobner D, Ali C (2002) Mechanisms of bFGF and NT-4 potentiation of necrotic neuronal death. *Brain Research* 954:42–50.

Lobner D, Choi DW (1996) Preincubation with protein synthesis inhibitors protects cortical neurons against oxygen-glucose deprivation-induced death. *Neuroscience* 72:335–341.

Lobner D, Golner S, Hjelmhaug J (2003) Neurotrophic factor effects on oxidative stress-induced neuronal death. *Neurochem Res* 28:749–756.

Lobner D, Piana PMT, Salous AK, Peoples RW (2007) Beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. *Neurobiol Dis* 25:360–366.

Lomeli H, Mosbacher J, Melcher T, Höger T, Geiger JR, Kuner T, Monyer H, Higuchi

- M, Bach A, Seeburg PH (1994) Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. *Science* 266:1709–1713.
- López-Bayghen E, Ortega A (2011) Glial glutamate transporters: New actors in brain signaling. *IUBMB Life*.
- Lu L, Han AP, Chen JJ (2001) Translation initiation control by heme-regulated eukaryotic initiation factor 2 $\alpha$  kinase in erythroid cells under cytoplasmic stresses. *Mol Cell Biol* 21:7971–7980.
- Lu PD, Jousse C, Marciniak SJ, Zhang Y, Novoa I, Scheuner D, Kaufman RJ, Ron D, Harding HP (2004) Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. *EMBO J* 23:169–179.
- Ma C, Bower KA, Chen G, Shi X, Ke Z-J, Luo J (2008) Interaction between ERK and GSK3 $\beta$  mediates basic fibroblast growth factor-induced apoptosis in SK-N-MC neuroblastoma cells. *The Journal of Biological Chemistry* 283:9248–9256.
- Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, Grier MD, Baker DA (2007) Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. *Journal of Neuroscience* 27:13968–13976.
- Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2011) Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. *Neuro Endocrinol Lett* 32:133–140.
- Magistretti PJ, Pellerin L (1996) Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. *Cereb Cortex* 6:50–61.
- Mallei A, Shi B, Mocchetti I (2002) Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. *Molecular Pharmacology* 61:1017–1024.
- Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA (2004) Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. *Biol Psychiatry* 55:1095–1102.
- Marino MJ, Valenti O, Conn PJ (2003) Glutamate receptors and Parkinson's disease: opportunities for intervention. *Drugs Aging* 20:377–397.
- Mark RJ, Keller JN, Kruman I, Mattson MP (1997) Basic FGF attenuates amyloid  $\beta$ -peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in hippocampal neurons. *Brain Research* 756:205–214.
- Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, De Bundel D,



- Vermoesen K, Bannai S, Smolders I, Conrad M, Plesnila N, Sato H, Michotte Y (2011) Dopaminergic neurons of system x(c)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. *The FASEB Journal* 25:1359–1369.
- Massie A, Schallier A, Mertens B, Vermoesen K, Bannai S, Sato H, Smolders I, Michotte Y (2008) Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats. *Neuroreport* 19:1589–1592.
- Matrisian LM, Rautmann G, Magun BE, Breathnach R (1985) Epidermal growth factor or serum stimulation of rat fibroblasts induces an elevation in mRNA levels for lactate dehydrogenase and other glycolytic enzymes. *Nucleic Acids Research* 13:711–726.
- Matsuoka Y, Rakonczay Z, Giacobini E, Naritoku D (1993) L-beta-methylamino-alanine-induced behavioral changes in rats. *Pharmacol Biochem Behav* 44:727–734.
- Matts RL, London IM (1984) The regulation of initiation of protein synthesis by phosphorylation of eIF-2(alpha) and the role of reversing factor in the recycling of eIF-2. *The Journal of Biological Chemistry* 259:6708–6711.
- Mattson MP, Kumar KN, Wang H, Cheng B, Michaelis EK (1993) Basic FGF regulates the expression of a functional 71 kDa NMDA receptor protein that mediates calcium influx and neurotoxicity in hippocampal neurons. *J Neurosci* 13:4575–4588.
- McBean GJ (2002) Cerebral cystine uptake: a tale of two transporters. *Trends Pharmacol Sci* 23:299–302.
- McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP (1998) Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. *Nat Med* 4:291–297.
- Meeks JP, Mennerick S (2007) Astrocyte membrane responses and potassium accumulation during neuronal activity. *Hippocampus* 17:1100–1108.
- Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D (2003) NF-kappa B functions in synaptic signaling and behavior. *Nat Neurosci* 6:1072–1078.
- Meister A, Anderson ME (1983) Glutathione. *Annu Rev Biochem* 52:711–760.
- Mellergård P, Sjögren F, Hillman J (2012) The cerebral extracellular release of glycerol, glutamate, and FGF2 is increased in older patients following severe traumatic brain injury. *Journal of Neurotrauma* 29:112–118.
- Metcalf JS, Banack SA, Lindsay J, Morrison LF, Cox PA, Codd GA (2008) Co-occurrence of beta-N-methylamino-L-alanine, a neurotoxic amino acid with other cyanobacterial toxins in British waterbodies, 1990-2004. *Environ Microbiol* 10:702–708.

- Miller S, Romano C, Cotman CW (1995) Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes. *J Neurosci* 15:6103–6109.
- Miyamoto M, Murphy TH, Schnaar RL, Coyle JT (1989) Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. *J Pharmacol Exp Ther* 250:1132–1140.
- Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J (1996a) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. *Mol Cell Biol* 16:977–989.
- Mohammadi M, Dionne CA, Li W, Li N, Spivak T, Honegger AM, Jaye M, Schlessinger J (1992) Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. *Nature* 358:681–684.
- Mohammadi M, Schlessinger J, Hubbard SR (1996b) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. *Cell* 86:577–587.
- Molteni R, Fumagalli F, Magnaghi V, Roceri M, Gennarelli M, Racagni G, Melcangi RC, Riva MA (2001) Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity. *Brain Res Brain Res Rev* 37:249–258.
- Monson CS, Banack SA, Cox PA (2003) Conservation Implications of Chamorro Consumption of Flying Foxes as a Possible Cause of Amyotrophic Lateral Sclerosis&#x2013;Parkinsonism Dementia Complex in Guam. *Conserv Biol* 17:678–686.
- Montine TJ, Li K, Perl DP, Galasko D (2005) Lack of beta-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. *Neurology* 65:768–769.
- Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet* 370:319–328.
- Mosbacher J, Schoepfer R, Monyer H, Burnashev N, Seeburg PH, Ruppertsberg JP (1994) A molecular determinant for submillisecond desensitization in glutamate receptors. *Science* 266:1059–1062.
- Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, Kalivas PW (2009) N-Acetylcysteine reverses cocaine-induced metaplasticity. *Nat Neurosci* 12:182–189.
- Mudò G, Bonomo A, Di Liberto V, Frinchi M, Fuxe K, Belluardo N (2009) The FGF-2/FGFRs neurotrophic system promotes neurogenesis in the adult brain. *J Neural Transm* 116:995–1005.

- Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW (2004a) Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. *Acta Neurol Scand* 110:267–269.
- Murch SJS, Cox PAP, Banack SAS (2004b) A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. *Proc Natl Acad Sci USA* 101:12228–12231.
- Murphy TH, Baraban JM (1990) Glutamate toxicity in immature cortical neurons precedes development of glutamate receptor currents. *Brain Res Dev Brain Res* 57:146–150.
- Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. *Neuron* 2:1547–1558.
- Murphy TH, Schnaar RL, Coyle JT (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. *FASEB J* 4:1624–1633.
- Mysona B, Dun Y, Duplantier J, Ganapathy V, Smith SB (2009) Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc<sup>-</sup> in mouse retinal Müller glial cells. *Cell Tissue Res* 335:477–488.
- Niciu MJ, Kelmendi B, Sanacora G (2012) Overview of glutamatergic neurotransmission in the nervous system. *Pharmacol Biochem Behav* 100:656–664.
- Noguchi CT, Asavaritikrai P, Teng R, Jia Y (2007) Role of erythropoietin in the brain. *Crit Rev Oncol Hematol* 64:159–171.
- Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A (1984) Magnesium gates glutamate-activated channels in mouse central neurones. *Nature* 307:462–465.
- Nozaki K, Finklestein SP, Beal MF (1993a) Delayed administration of basic fibroblast growth factor protects against N-methyl-D-aspartate neurotoxicity in neonatal rats. *Eur J Pharmacol* 232:295–297.
- Nozaki K, Finklestein SP, Beal MF (1993b) Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats. *J Cereb Blood Flow Metab* 13:221–228.
- Nunn PB, Seelig M, Zagoren JC, Spencer PS (1987) Stereospecific acute neuronotoxicity of “uncommon” plant amino acids linked to human motor-system diseases. *Brain Research* 410:375–379.
- Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AHV, Halliday G (2010) Missing pieces in the Parkinson's disease puzzle. *Nat Med* 16:653–661.

- Ogunrinu TA, Sontheimer H (2010) Hypoxia increases the dependence of glioma cells on glutathione. *The Journal of Biological Chemistry* 285:37716–37724.
- Ohkubo Y, Uchida AO, Shin D, Partanen J, Vaccarino FM (2004) Fibroblast growth factor receptor 1 is required for the proliferation of hippocampal progenitor cells and for hippocampal growth in mouse. *Journal of Neuroscience* 24:6057–6069.
- Oikawa H, Nakamichi N, Kambe Y, Ogura M, YONEDA Y (2005) An increase in intracellular free calcium ions by nicotinic acetylcholine receptors in a single cultured rat cortical astrocyte. *J Neurosci Res* 79:535–544.
- Ojeda L, Gao J, Hooten KG, Wang E, Thonhoff JR, Dunn TJ, Gao T, Wu P (2011) Critical role of PI3K/Akt/GSK3 $\beta$  in motoneuron specification from human neural stem cells in response to FGF2 and EGF. *PLoS ONE* 6:e23414.
- Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ (1993) Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. *J Neurosci* 13:1441–1453.
- Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T, Bannai S (2003) Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. *Br J Cancer* 88:951–956.
- Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. *Glia* 58:831–838.
- Ovalle S, Zamanillo D, Andreu F, Farré AJ, Guitart X (2001) Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic. *Eur J Neurosci* 13:909–915.
- Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, Buck A, Mash DC (2009) Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. *Acta Neurol Scand* 120:216–225.
- Pacchioni AM, Vallone J, Melendez RI, Shih A, Murphy TH, Kalivas PW (2007) Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity. *Brain Research* 1127:26–35.
- Pacheco R, Oliva H, Martinez-Navío JM, Climent N, Ciruela F, Gatell JM, Gallart T, Mallol J, Lluís C, Franco R (2006) Glutamate released by dendritic cells as a novel modulator of T cell activation. *J Immunol* 177:6695–6704.
- Pan Z, Perez-Polo R (1993) Role of nerve growth factor in oxidant homeostasis: glutathione metabolism. *Journal of Neurochemistry* 61:1713–1721.
- Papapetropoulos S (2007) Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm.

Neurochem Int 50:998–1003.

- Parpura V, Heneka MT, Montana V, Oliek SHR, Schousboe A, Haydon PG, Stout RF, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, Verkhratsky A (2012) Glial cells in (patho)physiology. *Journal of Neurochemistry*.
- Patel SA, Warren BA, Rhoderick JF, Bridges RJ (2004) Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. *Neuropharmacology* 46:273–284.
- Patneau DK, Mayer ML (1990) Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. *J Neurosci* 10:2385–2399.
- Pauly K, Fritz K, Furey A, Lobner D (2011) Insulin-like growth factor 1 and transforming growth factor- $\beta$  stimulate cystine/glutamate exchange activity in dental pulp cells. *J Endod* 37:943–947.
- Perez JA, Clinton SM, Turner CA, Watson SJ, Akil H (2009) A new role for FGF2 as an endogenous inhibitor of anxiety. *Journal of Neuroscience* 29:6379–6387.
- Perry TL, Bergeron C, Biro AJ, Hansen S (1989) Beta-N-methylamino-L-alanine. Chronic oral administration is not neurotoxic to mice. *J Neurol Sci* 94:173–180.
- Petri S, Krampfl K, Kuhlemann K, Dengler R, Grothe C (2009) Preserved expression of fibroblast growth factor (FGF)-2 and FGF receptor 1 in brain and spinal cord of amyotrophic lateral sclerosis patients. *Histochem Cell Biol* 131:509–519.
- Petroff OAC (2002) GABA and glutamate in the human brain. *The Neuroscientist* 8:562–573.
- Pérez-Neri I, Ramírez-Bermúdez J, Montes S, Ríos C (2006) Possible Mechanisms of Neurodegeneration in Schizophrenia. *Neurochem Res* 31:1279–1294.
- Piani D, Fontana A (1994) Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. *J Immunol* 152:3578–3585.
- Pieper AA, Wu X, Han TW, Estill SJ, Dang Q, Wu LC, Reece-Fincannon S, Dudley CA, Richardson JA, Brat DJ, McKnight SL (2005) The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. *Proc Natl Acad Sci USA* 102:14052–14057.
- Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M (2011) Multiple cellular and molecular mechanisms are involved in human A $\beta$  clearance by transplanted adult astrocytes. *Glia* 59:1643–1657.
- Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple

- sclerosis. *Nat Med* 6:67–70.
- Poskanzer KE, Yuste R (2011) Astrocytic regulation of cortical UP states. *Proc Natl Acad Sci* 108:18453–18458.
- Premkumar LS, Auerbach A (1997) Stoichiometry of recombinant N-methyl-D-aspartate receptor channels inferred from single-channel current patterns. *J Gen Physiol* 110:485–502.
- Proud CG (2005) eIF2 and the control of cell physiology. *Semin Cell Dev Biol* 16:3–12.
- Pullan LM, Olney JW, Price MT, Compton RP, Hood WF, Michel J, Monahan JB (1987) Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. *Journal of Neurochemistry* 49:1301–1307.
- Qiang W, Cahill JM, Liu J, Kuang X, Liu N, Scofield VL, Voorhees JR, Reid AJ, Yan M, Lynn WS, Wong PKY (2004) Activation of transcription factor Nrf-2 and its downstream targets in response to moloney murine leukemia virus ts1-induced thiol depletion and oxidative stress in astrocytes. *Journal of Virology* 78:11926–11938.
- Qin S, Colin C, Hinnens I, Gervais A, Cheret C, Mallat M (2006a) System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. *Journal of Neuroscience* 26:3345–3356.
- Qin S, Colin C, Hinnens I, Gervais A, Cheret C, Mallat M (2006b) System Xc- and Apolipoprotein E Expressed by Microglia Have Opposite Effects on the Neurotoxicity of Amyloid- Peptide 1–40. :1–12.
- Quevedo C, Alcázar A, Salinas M (2000) Two different signal transduction pathways are implicated in the regulation of initiation factor 2B activity in insulin-like growth factor-1-stimulated neuronal cells. *The Journal of Biological Chemistry* 275:19192–19197.
- Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A (2011) Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. *BMC Psychiatry* 11:124.
- Rahman I, Biswas SK, Jimenez LA, Torres M, Forman HJ (2005) Glutathione, stress responses, and redox signaling in lung inflammation. *Antioxid Redox Signal* 7:42–59.
- Rai KS, Hattiangady B, Shetty AK (2007) Enhanced production and dendritic growth of new dentate granule cells in the middle-aged hippocampus following intracerebroventricular FGF-2 infusions. *Eur J Neurosci* 26:1765–1779.
- Rakonczay Z, Matsuoka Y, Giacobini E (1991) Effects of L-beta-N-methylamino-L-alanine (L-BMAA) on the cortical cholinergic and glutamatergic systems of the rat. *J Neurosci Res* 29:121–126.

- Rao SD, Banack SA, Cox PA, Weiss JH (2006) BMAA selectively injures motor neurons via AMPA/kainate receptor activation. *Experimental Neurology* 201:244–252.
- Ratan RR, Murphy TH, Baraban JM (1994) Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. *J Neurosci* 14:4385–4392.
- Reed DM, Brody JA (1975) Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. I. Descriptive epidemiology. *Am J Epidemiol* 101:287–301.
- Ren JM, Finklestein SP (2005) Growth factor treatment of stroke. *Curr Drug Targets CNS Neurol Disord* 4:121–125.
- Reuss B, Bohlen und Halbach von O (2003) Fibroblast growth factors and their receptors in the central nervous system. *Cell Tissue Res* 313:139–157.
- Reynolds RA, Mahoney SG, McNamara PD, Segal S (1991) The influence of pH on cystine and dibasic amino acid transport by rat renal brushborder membrane vesicles. *Biochim Biophys Acta* 1074:56–61.
- Riccio A, Ginty DD (2002) What a privilege to reside at the synapse: NMDA receptor signaling to CREB. *Nat Neurosci* 5:389–390.
- Rice ME, Russo-Menna I (1998) Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. *Neuroscience* 82:1213–1223.
- Richter KE, Mena EE (1989) L-beta-methylaminoalanine inhibits [<sup>3</sup>H]glutamate binding in the presence of bicarbonate ions. *Brain Research* 492:385–388.
- Rodriguez M, Sabate M, Rodriguez-Sabate C, Morales I (2012) The role of non-synaptic extracellular glutamate. *Brain Research Bulletin*.
- Roitbak AI, Fanardjian VV (1981) Depolarization of cortical glial cells in response to electrical stimulation of the cortical surface. *Neuroscience* 6:2529–2537.
- Ronne-Engström E, Carlson H, Liu Y, Ungerstedt U, Hillered L (1995) Influence of perfusate glucose concentration on dialysate lactate, pyruvate, aspartate, and glutamate levels under basal and hypoxic conditions: a microdialysis study in rat brain. *Journal of Neurochemistry* 65:257–262.
- Rosenblatt S, Irikura K, Caday CG, Finklestein SP, Moskowitz MA (1994) Basic fibroblast growth factor dilates rat pial arterioles. *J Cereb Blood Flow Metab* 14:70–74.
- Ross SM, Seelig M, Spencer PS (1987) Specific antagonism of excitotoxic action of “uncommon” amino acids assayed in organotypic mouse cortical cultures. *Brain Research* 425:120–127.

- Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. *Neuron* 16:675–686.
- Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW (1994) Localization of neuronal and glial glutamate transporters. *Neuron* 13:713–725.
- Rowlands AG, Panniers R, Henshaw EC (1988) The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. *The Journal of Biological Chemistry* 263:5526–5533.
- Rusakov DA, Kullmann DM (1998) Extrasynaptic glutamate diffusion in the hippocampus: ultrastructural constraints, uptake, and receptor activation. *J Neurosci* 18:3158–3170.
- Rush T, Liu X, Lobner D (2012a) Synergistic toxicity of the environmental neurotoxins methylmercury and  $\beta$ -N-methylamino-L-alanine. *Neuroreport* 23:216–219.
- Rush T, Liu X, Nowakowski AB, Petering DH, Lobner D (2012b) Glutathione-mediated neuroprotection against methylmercury neurotoxicity in cortical culture is dependent on MRP1. *Neurotoxicology*.
- Rush T, Liu XQ, Hjelmhaug J, Lobner D (2010) Mechanisms of chlorpyrifos and diazinon induced neurotoxicity in cortical culture. *Neuroscience* 166:899–906.
- Russo VC, Andaloro E, Fornaro SA, Najdovska S, Newgreen DF, Bach LA, Werther GA (2004) Fibroblast growth factor-2 over-rides insulin-like growth factor-I induced proliferation and cell survival in human neuroblastoma cells. *J Cell Physiol* 199:371–380.
- Sagara JI, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial cells. *Journal of Neurochemistry* 61:1672–1676.
- Sahni M, Raz R, Coffin JD, Levy D, Basilico C (2001) STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. *Development* 128:2119–2129.
- Sakakura Y, Sato H, Shiiya A, Tamba M, Sagara J-I, Matsuda M, Okamura N, Makino N, Bannai S (2007) Expression and function of cystine/glutamate transporter in neutrophils. *J Leukoc Biol* 81:974–982.
- Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H, Tamba M, Itoh K, Yamamoto M, Bannai S (2002) Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. *The Journal of Biological Chemistry* 277:44765–44771.



- Sasaki T, Kuga N, Namiki S, Matsuki N, Ikegaya Y (2011) Locally synchronized astrocytes. *Cerebral Cortex* 21:1889–1900.
- Sato H, Fujiwara K, Sagara J, Bannai S (1995a) Induction of cystine transport activity in mouse peritoneal macrophages by bacterial lipopolysaccharide. *Biochem J* 310 ( Pt 2):547–551.
- Sato H, Kuriyama-Matsumura K, Hashimoto T, Sasaki H, Wang H, Ishii T, Mann GE, Bannai S (2001) Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages. *The Journal of Biological Chemistry* 276:10407–10412.
- Sato H, Nomura S, Maebara K, Sato K, Tamba M, Bannai S (2004) Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. *Biochemical and Biophysical Research Communications* 325:109–116.
- Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K-I, Moriguchi T, Takahashi S, Bannai S (2005) Redox imbalance in cystine/glutamate transporter-deficient mice. *The Journal of Biological Chemistry* 280:37423–37429.
- Sato H, Takenaka Y, Fujiwara K, Yamaguchi M, Abe K, Bannai S (1995b) Increase in cystine transport activity and glutathione level in mouse peritoneal macrophages exposed to oxidized low-density lipoprotein. *Biochemical and Biophysical Research Communications* 215:154–159.
- Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. *The Journal of Biological Chemistry* 274:11455–11458.
- Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S (2000) Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc-. *Antioxid Redox Signal* 2:665–671.
- Sato H, Tamba M, Okuno S, Sato K, Keino-Masu K, Masu M, Bannai S (2002) Distribution of cystine/glutamate exchange transporter, system x(c)-, in the mouse brain. *Journal of Neuroscience* 22:8028–8033.
- Schell MJ, Molliver ME, Snyder SH (1995) D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. *Proc Natl Acad Sci USA* 92:3948–3952.
- Schlessinger J, Lax I, Lemmon M (1995) Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? *Cell* 83:357–360.
- Schneggenburger R, Zhou Z, Konnerth A, Neher E (1993) Fractional contribution of calcium to the cation current through glutamate receptor channels. *Neuron* 11:133–143.

- Schoepfer R, Monyer H, Sommer B, Wisden W, Sprengel R, Kuner T, Lomeli H, Herb A, Köhler M, Burnashev N (1994) Molecular biology of glutamate receptors. *Prog Neurobiol* 42:353–357.
- Schousboe A, Waagepetersen HS (2007) GABA: homeostatic and pharmacological aspects. *Prog Brain Res* 160:9–19.
- Schousboe A, Westergaard N, Sonnewald U, Petersen SB, Yu AC, Hertz L (1992) Regulatory role of astrocytes for neuronal biosynthesis and homeostasis of glutamate and GABA. *Prog Brain Res* 94:199–211.
- Schubert D, Piasecki D (2001) Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. *J Neurosci* 21:7455–7462.
- Schulz JB, Lindenau J, Seyfried J, Dichgans J (2000) Glutathione, oxidative stress and neurodegeneration. *Eur J Biochem* 267:4904–4911.
- Schwartz JP, Wilson DJ (1992) Preparation and characterization of type 1 astrocytes cultured from adult rat cortex, cerebellum, and striatum. *Glia* 5:75–80.
- Schweigerer L, Neufeld G, Gospodarowicz D (1987) Basic fibroblast growth factor as a growth inhibitor for cultured human tumor cells. *Journal of Clinical Investigation* 80:1516–1520.
- Seib TM, Patel SA, Bridges RJ (2011) Regulation of the system x(C)- cystine/glutamate exchanger by intracellular glutathione levels in rat astrocyte primary cultures. *Glia* 59:1387–1401.
- Seifert G, Steinhäuser C (2001) Ionotropic glutamate receptors in astrocytes. *Prog Brain Res* 132:287–299.
- Selten J-P, Cantor-Graae E (2005) Social defeat: risk factor for schizophrenia? *Br J Psychiatry* 187:101–102.
- Selten J-P, Cantor-Graae E (2007) Hypothesis: social defeat is a risk factor for schizophrenia? *Br J Psychiatry Suppl* 51:s9–s12.
- Sen R, Smale ST (2010) Selectivity of the NF- $\kappa$ B response. *Cold Spring Harb Perspect Biol* 2:a000257.
- Shibasaki T, Iuchi Y, Okada F, Kuwata K, Yamanobe T, Bannai S, Tomita Y, Sato H, Fujii J (2009) Aggravation of ischemia–reperfusion-triggered acute renal failure in xCT-deficient mice. *Archives of Biochemistry and Biophysics* 490:63–69.
- Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH (2006) Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. *Journal of Neuroscience* 26:10514–10523.

- Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. *Journal of Neuroscience* 23:3394–3406.
- Shin DM, Korada S, Raballo R, Shashikant CS, Simeone A, Taylor JR, Vaccarino F (2004) Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice. *Journal of Neuroscience* 24:2247–2258.
- Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998) Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. *Proc Natl Acad Sci USA* 95:316–321.
- Sies H (1997) Oxidative stress: oxidants and antioxidants. *Exp Physiol* 82:291–295.
- Simonian NA, Coyle JT (1996) Oxidative stress in neurodegenerative diseases. *Annu Rev Pharmacol Toxicol* 36:83–106.
- Sims B, Clarke M, Francillion L, Kindred E, Hopkins ES, Sontheimer H (2012) Hypoxic preconditioning involves system Xc<sup>-</sup> regulation in mouse neural stem cells. *Stem Cell Res* 8:285–291.
- Sims B, Clarke M, Njah W, Hopkins ES, Sontheimer H (2010) Erythropoietin-induced neuroprotection requires cystine glutamate exchanger activity. *Brain Research* 1321:88–95.
- Smith QR, Nagura H, Takada Y, Duncan MW (1992) Facilitated transport of the neurotoxin, beta-N-methylamino-L-alanine, across the blood-brain barrier. *Journal of Neurochemistry* 58:1330–1337.
- Smith T, Groom A, Zhu B, Turski L (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. *Nat Med* 6:62–66.
- Snider BJ, Lobner D, Yamada KA, Choi DW (1998) Conditioning heat stress reduces excitotoxic and apoptotic components of oxygen-glucose deprivation-induced neuronal death in vitro. *Journal of Neurochemistry* 70:120–129.
- Snyder LR, Cruz-Aguado R, Sadilek M, Galasko D, Shaw CA, Montine TJ (2009) Lack of cerebral bmaa in human cerebral cortex. *Neurology* 72:1360–1361.
- Song B-W, Vinters HV, Wu D, Pardridge WM (2002) Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. *J Pharmacol Exp Ther* 301:605–610.
- Sontheimer H (2003) Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. *Trends in Neurosciences* 26:543–549.

- Sontheimer H (2008) A role for glutamate in growth and invasion of primary brain tumors. *Journal of Neurochemistry* 105:287–295.
- Soñanez-Organis JG, Rodriguez-Armenta M, Leal-Rubio B, Peregrino-Uriarte AB, Gómez-Jiménez S, Yepiz-Plascencia G (2012) Alternative splicing generates two lactate dehydrogenase subunits differentially expressed during hypoxia via HIF-1 in the shrimp *Litopenaeus vannamei*. *Biochimie* 94:1250–1260.
- Spencer PS, Nunn PB, Hugon J, Ludolph A, Roy DN (1986) Motorneurone disease on Guam: possible role of a food neurotoxin. *Lancet* 1:965.
- Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. *Science* 237:517–522.
- Stipursky J, Romão L, Tortelli V, Neto VM, Gomes FCA (2011) Neuron-glia signaling: Implications for astrocyte differentiation and synapse formation. *Life Sciences* 89:524–531.
- Storck T, Schulte S, Hofmann K, Stoffel W (1992) Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. *Proc Natl Acad Sci USA* 89:10955–10959.
- Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA (2000) Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. *Cancer Res* 60:6160–6170.
- Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM (2011) Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell* 144:810–823.
- Taguchi K, Tamba M, Bannai S, Sato H (2007) Induction of cystine/glutamate transporter in bacterial lipopolysaccharide induced endotoxemia in mice. *J Inflamm (Lond)* 4:20.
- Takada A, Bannai S (1984) Transport of cystine in isolated rat hepatocytes in primary culture. *The Journal of Biological Chemistry* 259:2441–2445.
- Takahashi JL, Giuliani F, Power C, Imai Y, Yong VW (2003) Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. *Ann Neurol* 53:588–595.
- Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M (2001) Glutamate release promotes growth of malignant gliomas. *Nat Med* 7:1010–1015.
- Tan S, Somia N, Maher P, Schubert D (2001) Regulation of antioxidant metabolism by translation initiation factor 2alpha. *The Journal of Cell Biology* 152:997–1006.
- Tan S, Wood M, Maher P (1998) Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. *Journal*

- of *Neurochemistry* 71:95–105.
- Temple S, Qian X (1995) bFGF, neurotrophins, and the control of cortical neurogenesis. *Neuron* 15:249–252.
- Terwisscha van Scheltinga AF, Bakker SC, Kahn RS (2010) Fibroblast growth factors in schizophrenia. *Schizophrenia Bulletin* 36:1157–1166.
- Thau N, Jungnickel J, Knippenberg S, Ratzka A, Dengler R, Petri S, Grothe C (2012) Prolonged survival and milder impairment of motor function in the SOD1 ALS mouse model devoid of fibroblast growth factor 2. *Neurobiol Dis*.
- Torrents D, Estévez R, Pineda M, Fernández E, Lloberas J, Shi YB, Zorzano A, Palacín M (1998) Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. *The Journal of Biological Chemistry* 273:32437–32445.
- Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. *Am J Psychiatry* 155:726–732.
- Tsuang M (2000) Schizophrenia: genes and environment. *Biol Psychiatry* 47:210–220.
- Turner CA, Akil H, Watson SJ, Evans SJ (2006) The fibroblast growth factor system and mood disorders. *Biol Psychiatry* 59:1128–1135.
- Turner CA, Calvo N, Frost DO, Akil H, Watson SJ (2008a) The fibroblast growth factor system is downregulated following social defeat. *Neuroscience Letters* 430:147–150.
- Turner CA, Capriles N, Flagel SB, Perez JA, Clinton SM, Watson SJ, Akil H (2009) Neonatal FGF2 alters cocaine self-administration in the adult rat. *Pharmacol Biochem Behav* 92:100–104.
- Turner CA, Clinton SM, Thompson RC, Watson SJ, Akil H (2011) Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals.
- Turner CA, Flagel SB, Clinton SM, Akil H, Watson SJ (2008b) Cocaine interacts with the novelty-seeking trait to modulate FGFR1 gene expression in the rat. *Neuroscience Letters* 446:105–107.
- Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H (2008c) Antidepressant-like effects of intracerebroventricular FGF2 in rats. *Brain Research* 1224:63–68.
- Unekawa M, Tomita Y, Toriumi H, Suzuki N (2012) Suppressive effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats.

- Cephalalgia 32:518–527.
- Unterberger U, Höftberger R, Gelpi E, Flicker H, Budka H, Voigtländer T (2006) Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. *J Neuropathol Exp Neurol* 65:348–357.
- Uversky VN (2008) Alpha-synuclein misfolding and neurodegenerative diseases. *Curr Protein Pept Sci* 9:507–540.
- Vaccarino FM, Schwartz ML, Raballo R, Nilsen J, Rhee J, Zhou M, Doetschman T, Coffin JD, Wyland JJ, Hung YT (1999) Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. *Nat Neurosci* 2:246–253.
- Venance L, Stella N, Glowinski J, Giaume C (1997) Mechanism involved in initiation and propagation of receptor-induced intercellular calcium signaling in cultured rat astrocytes. *J Neurosci* 17:1981–1992.
- Ventura R, Harris KM (1999) Three-dimensional relationships between hippocampal synapses and astrocytes. *Journal of Neuroscience* 19:6897–6906.
- Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. *Proc Natl Acad Sci USA* 93:14960–14965.
- Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *The Journal of Biological Chemistry* 269:5241–5248.
- Waite K, Eickholt BJ (2010) The neurodevelopmental implications of PI3K signaling. *Curr Top Microbiol Immunol* 346:245–265.
- Wang H, Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. *Free Radic Biol Med* 27:612–616.
- Wang L, (null), Jiang H, Yin Z, Aschner M, Cai J (2008) Methylmercury Toxicity and Nrf2-dependent Detoxification in Astrocytes. *Toxicological Sciences* 107:135–143.
- Wang Q, Maloof P, Wang H, Fenig E, Stein D, Nichols G, Denny TN, Yahalom J, Wieder R (1998) Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. *Exp Cell Res* 238:177–187.
- Wang XF, Cynader MS (2000) Astrocytes provide cysteine to neurons by releasing glutathione. *Journal of Neurochemistry* 74:1434–1442.
- Wang Z, Li V, Chan GCK, Phan T, Nudelman AS, Xia Z, Storm DR (2009) Adult type 3 adenylyl cyclase-deficient mice are obese. *PLoS ONE* 4:e6979.

- Watanabe H, Bannai S (1987) Induction of cystine transport activity in mouse peritoneal macrophages. *J Exp Med* 165:628–640.
- Watanabe T, Okuda Y, Nonoguchi N, Zhao MZ, Kajimoto Y, Furutama D, Yukawa H, Shibata M-A, Otsuki Y, Kuroiwa T, Miyatake S-I (2004) Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 24:1205–1213.
- Wei OY, Huang YL, Da CD, Cheng JS (2000) Alteration of basic fibroblast growth factor expression in rat during cerebral ischemia. *Acta Pharmacol Sin* 21:296–300.
- Weiss JH, Choi DW (1988) Beta-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor. *Science* 241:973–975.
- Weiss JH, Christine CW, Choi DW (1989a) Bicarbonate dependence of glutamate receptor activation by beta-N-methylamino-L-alanine: channel recording and study with related compounds. *Neuron* 3:321–326.
- Weiss JH, Koh JY, Choi DW (1989b) Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. *Brain Research* 497:64–71.
- Wek RC, Jiang H-Y, Anthony TG (2006) Coping with stress: eIF2 kinases and translational control. *Biochemical society transactions* 34:7–11.
- Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG (1998) Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. *FEBS Lett* 421:125–130.
- Welsh GI, Proud CG (1993) Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. *Biochem J* 294 ( Pt 3):625–629.
- Williams E-J, Walsh FS, Doherty P (2003) The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. *The Journal of Cell Biology* 160:481–486.
- Williamson AJK, Dibling BC, Boyne JR, Selby P, Burchill SA (2004) Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75NTR. *The Journal of Biological Chemistry* 279:47912–47928.
- Winder DG, Conn PJ (1993) Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. *J Neurosci* 13:38–44.

- Witcher MR, Park YD, Lee MR, Sharma S, Harris KM, Kirov SA (2010) Three-dimensional relationships between perisynaptic astroglia and human hippocampal synapses. *Glia* 58:572–587.
- Xi Z-X, Ramamoorthy S, Baker DA, Shen H, Samuvel DJ, Kalivas PW (2002) Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. *J Pharmacol Exp Ther* 303:608–615.
- Xia P, Chen H-SV, Zhang D, Lipton SA (2010) Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. *The journal of Neuroscience*:1–5.
- Xiong ZJ, Storey KB (2012) Regulation of liver lactate dehydrogenase by reversible phosphorylation in response to anoxia in a freshwater turtle. *Comp Biochem Physiol B, Biochem Mol Biol* 163:221–228.
- Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, Baum ML, Bibb JA, Lombroso PJ (2009) Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. *Journal of Neuroscience* 29:9330–9343.
- Xue H, Field CJ (2011) New role of glutamate as an immunoregulator via glutamate receptors and transporters. *Front Biosci (Schol Ed)* 3:1007–1020.
- Yamada H, Yamada E, Ando A, Esumi N, Bora N, Saikia J, Sung CH, Zack DJ, Campochiaro PA (2001) Fibroblast growth factor-2 decreases hyperoxia-induced photoreceptor cell death in mice. *Am J Pathol* 159:1113–1120.
- Yang W, de Bono DP (1997) A new role for vascular endothelial growth factor and fibroblast growth factors: increasing endothelial resistance to oxidative stress. *FEBS Lett* 403:139–142.
- Ye Z-C, Sontheimer H (2002) Modulation of glial glutamate transport through cell interactions with the extracellular matrix. *Int J Dev Neurosci* 20:209–217.
- Ye ZC, Rothstein JD, Sontheimer H (1999) Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. *Journal of Neuroscience* 19:10767–10777.
- Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. *Cancer Res* 59:4383–4391.
- Yin HZ, Lindsay AD, Weiss JH (1994) Kainate injury to cultured basal forebrain cholinergic neurons is Ca<sup>2+</sup> dependent. *Neuroreport* 5:1477–1480.
- Yoshioka A, Bacskai B, Pleasure D (1996) Pathophysiology of oligodendroglial excitotoxicity. *J Neurosci Res* 46:427–437.



- Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, Manji HK (2010) Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. *J Affect Disord* 124:164–169.
- Zechel S, Werner S, Unsicker K, Bohlen und Halbach von O (2010) Expression and functions of fibroblast growth factor 2 (FGF-2) in hippocampal formation. *Neuroscientist* 16:357–373.
- Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? *Biomed Pharmacother* 62:236–249.
- Zerangue N, Kavanaugh MP (1996a) Flux coupling in a neuronal glutamate transporter. *Nature* 383:634–637.
- Zerangue N, Kavanaugh MP (1996b) Interaction of L-cysteine with a human excitatory amino acid transporter. *The Journal of Physiology* 493 ( Pt 2):419–423.
- Zhang P, McGrath BC, Reinert J, Olsen DS, Lei L, Gill S, Wek SA, Vattam KM, Wek RC, Kimball SR, Jefferson LS, Cavener DR (2002) The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice. *Mol Cell Biol* 22:6681–6688.
- Zhang Y, Tatsuno T, Carney JM, Mattson MP (1993) Basic FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron-induced degeneration. *J Cereb Blood Flow Metab* 13:378–388.